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Health Care Associated Infections (HCAIs) are a concern especially in regards to 
antibiotic resistance and effective treatments. Staphylococcus aureus is often the 
main focus for eradication and prevention procedures, however, other bacterial 
species are also problematic. These include Escherichia coli, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, and Staphylococcus epidermidis amongst 
others. Chronic infections caused by these bacteria are often biofilm related, and 
include dental caries, otitis media, osteomyelitis, burns & chronic wounds, and device 
related & prosthetic joint infections.  
Prosthetic joints and indwelling devices, such as catheters, are a prime environment 
on which biofilms can develop. This thesis aims to look at biofilms, investigating how 
they are established, the development of resistance against individual antibiotics and 
the antibiotic concentrations required to reduce biofilm load. A novel biofilm system – 
the alginate bead method will be used for these experiments, The alginate bead 
method was developed by a previous student in the Gallagher Laboratory, due to a 
need to have a reliable, robust and inexpensive technique to examine formation of 
biofilms and antibiotic resistance. There are devices and assays available, such as 
the Calgary Biofilm Device, which are extensively used for these purposes. However, 
the cost is prohibitive.  
This thesis found that the development of biofilms occurs much earlier than expected, 
with stable, fixed formation after just four hours of growth. Depending upon the 
antibiotic, resistance can develop within the first two hours of growth and thereafter 
steadily increases. By 24 hours the biofilms are fully resistant to all the tested 
antibiotics. In mixed species biofilms, the two species act synergistically protecting 
each other against the antibiotics, resulting in a much higher antibiotic concentration 
required. 
Common antibiotics used to treat staphylococcal infections are often combined to 
enhance their destructive effect and prevent the development of resistance. The 
effects of these antibiotics, when combined was explored. Biofilm resistance against 
gentamicin, one of the most common antibiotics used to treat staphylococcal 
infections develops quickly. However, when combined with other antibiotics 
gentamicin resistance is delayed.  
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As antibiotic concentrations have to be extremely high in order to have any effect on 
established biofilms, alternative methods need to be investigated. Any alternative 
approaches would be employed in conjunction with conventional therapies preventing 
stable biofilm formation and disrupting established biofilms. Such methods may 
include sugar metabolites, enzymatic disruption, D-amino acids and activation of the 
quorum sensing system. 
The main conclusion which can be taken from this work are that firstly the alginate 
bead method of a viable, suitable alternative to the Calgary Biofilm Device and 
supports biofilm formation and testing. Secondly that biofilms form and are resistant 
to antibiotics much earlier than expected, and extreme concentrations of antibiotics 
are required to have an effect. Thus the inclusion of alternative methods which disrupt 
biofilms would be beneficial to clinical practice. However, the alternative methods 
investigated within this thesis (D-amino acids and sugar metabolites) failed to show 
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Health Care Associated Infections 
 
Health Care Associated Infections (HCAIs) are defined as ‘an infection occurring in a 
patient during the process of care in a hospital or other health-care facility such as 
care homes and domestic environments where individuals are nursed, which was not 
present or incubating at the time of admission. This includes infections acquired in the 
hospital but appearing after discharge, and also occupational infections arising among 
staff of the facility’ [WHO, 2002]. They can be acquired as a result of interventions, 
devices or procedures and are the most common adverse event in healthcare facilities 
[HPA, 2012; WHO, 2011].  
HCAIs are a worldwide problem. However, the exact burden remains unclear, as 
reliable data collection is difficult, since standardized criteria, diagnostic facilities, and 
expert analysts are required. Surveillance in high-income countries (i.e. USA/UK) is 
good and control strategies are making a difference. Low- and middle-income 
countries are still working towards implementing similar systems [WHO, 2011]. 
Figures 1.1a and 1.1b display the prevalence of HCAIs in high income and low & 








Figure 1.1a: Prevalence of HCAIs in High-income Countries (most recent data used) 
[WHO, 2011].  
 
 
Figure 1.1b: Prevalence of HCAIs in Low- and Middle-Income Countries [WHO, 2011].   
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Within the UK, at the peak of the HCAI crisis, it was estimated that there were 300,000 
HCAIs annually with an estimated cost of £1 billion [NAO, 2004], 20% of these 
infections were considered preventable [Harbarth, 2003]. Consequently, due to the 
UK government prioritising infection control and pro-active reduction of HCAIs over 
the last 15 years, infection rates have decreased from 9% in 2005 to 6.4% in 2011 
[HPA, 2012; Postnote, 2005].  
HCAI incidence is highest in patients aged 1-23 months (8.2%), followed by those 
aged 65-79 (7.4%) and 50-64 years (7.3%). Intensive Care Unit patients have the 
highest levels of HCAIs (adults 23.4%, paediatric 14.7% and neonatal 13.1%). 
However, this only accounts for 9.4% of the total HCAIs reported [HPA, 2012]. The 
most 10 common HCAIs from the English Point Prevalence Survey in 2011 can be 









Types of Infections     
In the past, focus has mainly been on two HCAIs; Methicillin Resistant 
Staphylococcus aureus (MRSA) and Clostridium difficile Infection (CDI). However, 
there is now mandatory government surveillance on Methicillin-sensitive Staph. 
aureus (MSSA), Escherichia coli bacteraemias, Glycopeptide-resistant Enterococcus 
(GRE) bacteraemias and orthopaedic surgical site infections (SSI) [HPA, 2012]. Other 
voluntary schemes, overseen by the HPA, exist for different micro-organisms and 
infections and their resistance profiles [HPA, 2012]. Table 1.1 shows the most 
commonly identified microorganisms associated with HCAIs in England in 2011.  
Table 1.1: Most Commonly Identified HCAI Organisms in England [HPA, 2012]. 
Microorganism  Percentage (%) 
Enterobacteriaceae 32.4 
Staph. aureus  15.5 
C. difficile Infection 12.6 
Ps. aeruginosa 6.0 






In England, cases of MRSA and CDI have been decreasing over recent years (Figure 
1.3) due to stringent control measures which have been implemented [HPA, 2012]. 
Reporting of other bacterial infections has shown that E. coli bacteraemias have been 
increasing with third generation cephalosporin resistance recorded at 9% in 2010 
[ECDPC, 2011]. The increase in this type of infection may be due to the rigorous 
control measures and attention in place for MRSA and CDI. 
SSIs reporting was established in 1997 however, only became notifiable in 2004. In 
2010-2011 31% of these infections were observed to be caused by the 
Enterobacteriaceae, and a further 27% of infections due to Staph. aureus [HPA, 
2011]. SSIs include abdominal and cardiac surgeries, limb amputations, bone 






Figure 1.3a: MRSA Bacteraemia Cases in England 2002-2010 [HPA, 2012]. 
*Mandatory reporting of CDI in the under 65s started in 2008. 







Risk factors for HCAIs 
Risk factors for HCAIs depend upon the type of facility and the nature of the health 
care required, with more serious invasive procedures carrying a higher risk. 
Nonetheless, there are universal factors which predispose to infection including: age 
>65 years; emergency admission and to the ICU; insertion of catheters or 
endotracheal tubes; undergoing surgery; a hospital stay longer than seven days; 
trauma induced immunosuppression; neutropenia; impaired functional or coma 
status; and the presence of a potentially fatal disease [Gravel et al., 2007; Klavs et 
al., 2003; WHO, 2011].  
 
Control Strategies for Dealing with HCAIs 
Prevention of HCAIs is deemed the responsibility of all individuals and services 
providing healthcare. Cooperation and communication is required to reduce infection 
risk [WHO, 2002]. The most effective infection control programmes need to include 
surveillance, prevention activities and mandatory staff training [Godfrey et al., 2013; 
Haley et al., 1985].  
Basic controls which should be adhered to by all personnel, include appropriate 
practices of hygiene (hand washing), providing patient care using practices which 
minimize infections, notifying the control committee of HCAI cases, isolating 
suspected HCAI cases, and advising visitors on preventing infection transmission 
[WHO, 2002]. 
Identification and control of suspected HCAIs is the first line in breaking the chain of 
transmission. The source of the outbreak needs to be quickly identified, eliminated 
and preventative measures implemented to ensure there are no repeat infections 








Table 1.2: Control Measures for Management of HCAI Outbreaks [WHO, 2002]. 
Type of Transmission suspected Suggested Action 
Cross-transmission (between 
individuals)  
Patient isolation and barrier precautions 
determined by infectious agent(s)  
Hand Transmission Improvements in hand washing 
Airborne Agent Patient isolation with appropriate ventilation 
Agent present in water, waterborne 
agent 
Checking of water supply and all liquid 
containers. Use of disposable devices 
Foodborne agent Elimination of the food at risk 
 
Antibiotic Use and Resistance Surveillance 
With the advent of antibiotics in the 1940s, many severe and fatal diseases became 
curable. However, misuse and overuse led to the rapid spread of antibiotic resistance. 
Many different bacterial species are resistant to antibiotics, and in some cases to more 
than one class of antibiotic [WHO, 2002]. Within the context of HCAIs this resistance 
is a significant issue as patients are more likely to have an underlying medical 
condition, and resistance can lead to increased morbidity and death [WHO, 2002].  
The continual requirement for antibiotics within healthcare environments increases 
the likelihood of resistance developing. Resistant bacteria are easily spread between 
patients, and resistance markers between bacterial species. Every healthcare facility 
should be able to justify its antibiotic usage, as uncontrolled and inappropriate use 
amplifies this problem [WHO, 2002]. Other factors which may encourage resistance 
are under-dosing due to antibiotic shortage, empiric prescribing due to lack of 
microbiological identification and lack of suitable alternate agents [WHO, 2002]. 
For the first time, the 2011 point prevalence survey monitored Antimicrobial Usage 
(AMU) and it was found that prescription levels were 34.7% of patient admissions with 
the highest usage in paediatrics (44.7%) [HPA, 2012]. Usage was lowest in the over 
80’s suggesting that the policy of reducing antimicrobial usage to prevent CDI was 
effective [Fowler et al., 2007]. The most common antibiotics prescribed were beta-
lactams and enzyme inhibitors. Table 1.3 shows the 12 most frequently used 
antimicrobial classes in English hospitals [HPA, 2012]. 
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Table 1.3: Most Frequently Used Antimicrobial Classes in English Hospitals 
[HPA, 2012]. 
Antimicrobial Class Percentage 
Use (%) 
Combinations of penicillins, including  beta-lactamase 
inhibitors 
23.1 
Beta-lactamase resistance penicillins 7.4 
Aminoglycosides 6.8 
Macrolides 6.3 
Penicillins with extended spectrum 4.9 
Imidazole derivative 4.8 
Glycopeptide antibacterials 4.5 
Beta-lactamase sensitive penicillins 4.5 
Carbapenems 4.5 
Trimethoprim and derivatives 4.2 
Second-generation cephalosporins 3.5 
Fluoroquinolones 3.3 
Other classes 22.2 
 
As this was the first time AMU surveillance was carried out it will provide a baseline 







Figure 1.4: Percentage of Antimicrobial Usage by Diagnosis for Hospital Acquired 
Infections in England [Adapted from HPA, 2012]. 
 
Staphylococcus aureus as a HCAI 
 
Staph. aureus is one of the most prominent bacterial pathogens. Although found as a 
commensal on ~20% of the population, it causes a huge range of superficial to life 
threating infections (Table 1.4) [Cassat et al 2007]. Carriage on skin allows easy 
access to open wounds, allowing rapid colonisation and subsequent biofilm formation. 
This may explain why so many diseases are caused by Staph. aureus [Archer et al., 
2011]. 
The ability of Staph. aureus ability to form biofilms on both natural tissues and 
indwelling medical devices [Cassat et al., 2007] has elevated the species to a major 
concern especially when combined with its antibiotic resistance profile. Examples of 
biofilm related diseases are osteomyelitis, infections on indwelling devices, 
periodontitis and peri-implantitis, chronic wound infection, chronic rhinosinusitis, 





Table 1.4: Staphylococcus aureus Diseases, Pathogenesis, Transmission, 
Treatment and Prevention Controls [Adapted from Goering et al., 2008]. 
Diseases Boils, Skin and soft tissue infections, Postoperative wound 
infections,  
Scalded skin syndrome, Catheter associated infections, 
Food borne infections, Septicaemia, Endocarditis,  
Toxic shock syndrome, Osteomyelitis, Pneumonia 
Pathogenesis Virulence is multifactorial. 
Present in all strains: mucopeptide and coagulase. 
Present in some strains: cell-associated: capsule, protein A, 
fibronectin-binding protein, collagen binding proteins. 
Extracellular: enterotoxins, epidermolysis toxin, membrane 
damaging toxins (haemolysins) leucocidin, staphylokinase 
Many strains have protein A bound to the cell wall which 
interacts with host IgG antibodies reducing opsonisation and 
causing local activation of complement. 
Transmission Normal habitat humans (and animals associated with them) 
skin especially nose and perineum (carriage rates higher in 
hospital patients and staff).  
Spread by contact and air borne routes.  
Organism survives drying and is tolerant of salt and nitrites. 
Treatment/ 
Prevention 
In susceptible strains beta-lactamase-stable penicillins 
however, vast majority of hospital isolates are resistant.  
Prevention of spread by isolation and/or treatment of carriers 
in high risk areas in hospitals. 
 
Staph. aureus biofilms on indwelling devices cause millions of device infections and 
failures every year. Devices include prosthetic joints and related apparatus, stents, 
ventilators, infusion pumps, catheters, cosmetic surgical implants, stitch material and 
mechanical heart valves to name but a few. Treatment nearly always requires removal 
and replacement of the device to completely resolve the infection [Archer et al., 2011]. 
Further difficultly in treating these infections arises from the development of antibiotic 
resistance. The most common resistance of Staph. aureus is against penicillin, 
methicillin and other beta-lactams [David and Daum, 2010]. However, there is 
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resistance against other antibiotic classes, most worrying vancomycin, which is one 
of the last effective antibiotics against MRSA [Courvalin, 2006]. Without effective 
antibiotics to treat otherwise minor diseases, worsened patient outcomes could result 
in corresponding increased costs and potential fatalities [Lauderdale et al., 2010].  
Whilst MRSA is often contracted within healthcare environments by patients with pre-
disposing risk factors, there are increasing numbers of Community Associated MRSA 
(CA-MRSA) cases being reported [David and Daum, 2010]. Prevalence of CA-MRSA 
strains is not uniform geographically and has been reported at ~50% of total MRSA 
cases in parts of the USA [Popovich et al., 2008]. CA-MRSA is considered a problem 
in most high income countries [DeLeo et al., 2012]. CA-MRSA first appeared in the 
1990s and tends to present in young, otherwise healthy individuals. Most cases are 
skin and soft tissue infections but necrotizing pneumonia and severe sepsis has also 
been recorded [Naimi et al., 2003].  
However, it is notable that control and prevention measures are implemented on both 
local and national scales with mandatory reportin/.g of MRSA cases and these 
schemes have successfully decreased recorded MRSA cases (Figure 1.3a) [HPA, 
2012]. 
 
Other Hospital Acquired Infections 
 
Much attention has been paid to Staph. aureus and C. difficile in recent years 
however, there are other bacterial species which may cause HCAIs. 
Table 1.5 shows a few examples of relevant species, the diseases they cause, their 
pathogenesis, transmission routes and what treatments are commonly used [Goering 




Table 1.5: Diseases, Pathogenesis, Transmission, Treatment and Prevention of some HCAIs [Adapted from Goering et al., 2008]. 
Species Disease Pathogenesis Transmission Treatment/Prevention 
Staphylococcus 







associated with device 
related sepsis 
(catheters, prosthetic 
valves, artificial joints, 





production may be a 
virulence marker and aid 
in colonization of 
indwelling devices. 
Normal habitat skin (100%) 
spread by contact with self, 
other patients or hospital 
personal. Almost all infections 
are from hospital but may be 
endogenous. 
Often multi-resistant 
(including penicillin and 
methicillin).  
Presence within healthcare 
environments is increasing. 
Prevention of infection 





Urinary tract infections 
in otherwise healthy 
women.  
Ability to colonise 
periurethral skin and 
mucosa. 
 
Normal habitat: skin and 
genitourinary mucosa. 
Endogenous spread. 





from capsular type III), 
septicaemia and 
meningitis. 
Otitis and related 
infections in children. 
Capsule protects organism 
from phagocytosis.  
Pneumolysin may have a 
role as virulence factor. 
Viral infection may be 
precursor to pneumonia. 
~5% of population may carry 
species in small numbers. 
Normal habitat is respiratory 
tract. Transmission via droplet 
spread. 
 
Antibiotic of choice is 
penicillin but resistance is 
rapidly increasing. Tests 




Table 1.5 continued. 
Species Disease Pathogenesis Transmission Treatment 
Streptococcus 
mutans 
Dental caries but can 
cause endocarditis in 
immune compromised 
patients.  
Largely unknown but able 
to survive environmental 
fluctuations. 
Endogenous infections. Most strains susceptible to 
penicillin but resistance has 
been recorded. Good oral 
hygiene prevent caries. 
Enterococcus 
faecalis 
UTIs, endocarditis,  
Septicaemia after 
surgery and in immune 
compromised (rare). 
Plasmid mediated 
haemolysin may play a 
role. No other virulence 
factors recorded 
Normal habitat is human and 
animal gut. Most infections are 
endogenous acquired but 
cross contamination may occur 
in hospitals.  
Penicillin used in 
combination with 
aminoglycosides. 
Resistance to vancomycin 
is problematic. Patients with 
heart defects should be 
given prophylactic 
antibiotics. 
Escherichia coli UTI, diarrheal disease, 
neonatal meningitis, 
septicaemia. 
Possesses O (somatic), 
H (flagellar), F (fimbrial) 
antigens which are 
used for classification 
Endotoxin (present in all 
strains). Adhesins: pili and 
colonization factors 
associated with GI tract 
infections. Capsule 
present in some strains: 
neonatal meningitis. 
Enterotoxins associated 
with diarrheal disease 
Normal habitat is human and 
animal gut. Spread is by 
contact and through the faecal-
oral route. May be food 
associated or endogenous. 
Wide range of antibiotics 
can be used but resistance 
is variable, usage must be 
determined by susceptibility 
tests. Specific treatment of 




Table 1.5 continued. 
Species Disease Pathogenesis Transmission Treatment 
Klebsiella 
pneumoniae 
Opportunist UTI and 
respiratory infections in 
the compromised host, 
Distinction between 
colonization and 
infection can be 
difficult. 
Usually capsular. 
Endotoxin and fimbriae or 
other adhesins. Capsules 
are important for inhibiting 
phagocytosis. 
Normal habitat: human and 
animal gut, moist environment 
esp. soil and water. Infection 
can be endogenous or 
acquired by contact. 
Multiple antibiotic 
resistance, usually plasmid 
mediated. Susceptibility 
must be determined. 
Prevention depends on 





which can infect almost 
any site providing the 
conditions are 
favourable. Causes 
skin and wound 
infections. Major 
pathogen in cystic 
fibrosis and burn wards 
and can cause 
pneumonia in intubated 










(massive amounts of 
alginate produced by 
some strains).  
Pigments may have a role 
in virulence and pyoverdin 
acts as a siderophore. 
Carriage occurs naturally in a 
small percentage of normal 
healthy individuals, this 
percentage increases in 
hospital inpatients. Infection 
may be endogenous. 
Widespread in moist 
environments. Patients usually 
become infected via direct or 
indirect contact spread from 
these sites.  
Naturally resistant to many 
antibiotics and resistance 
can develop during therapy. 
Combination treatment (e.g. 
aminoglycoside and beta-
lactam) based on 
susceptibility tests is 
required. 
Prevention depends on 
good aseptic practice, 
avoiding prolonged broad 
spectrum antibiotic 




Difference in Cell Types – Persisters, Small Colony Variants and Biofilms  
 
Infection, and resolution of infection happens continuously within a system, usually 
with no lasting adverse effects. However, on occasion especially within individuals 
with a compromised immune system, infections do not resolve even after treatment 
with antibiotics. There are various phenotypes and cell states which are considered 
responsible for underpinning these chronic infections: persister cells, small colony 
variants (SCV) and biofilms.  
 
Persisters 
Persisters were first recognised in 1944 after a small percentage of a Staph. aureus 
culture were found to survive treatment with penicillin [Bigger, 1944]. Persister cells 
are described as genetically identical to susceptible bacteria however, are in a non-
growing state and thus able to tolerate antibiotics [Kint et al., 2012]. The persister cell 
type can be triggered randomly or by specific environmental conditions [Dörr et al., 
2009; Vega et al., 2012]. As the cells are genetically identical, once the selective 
pressure of the antibiotic has been removed the cells revert back to a metabolically 
active state, reseed the original population and regain sensitivity to antibiotics [Bigger, 
1944; Lewis, 2005]. This provides a basis for recurrent infections [Kint et al., 2012]. 
Persister concentrations depend upon the growth phase of the culture, amounts are 
very low in exponentially growing cultures but increase as the culture progresses 
towards stationary phase [Kint et al., 2012]. Persisters are found in both biofilms and 
planktonic cultures and make up ~1% of the population [Lewis, 2007]. The basis 
behind persisters was thought to be their dormancy; that metabolic and biosynthesis 
pathways, energy production and non-essential genes were downregulated leading 
to inactive antibiotic targets [Kint et al., 2012]. However, this passive dormancy cannot 
account entirely for the persister cell type [Allison et al., 2011] and recent studies 
suggest that there is active suppression of oxidative stresses caused by bactericidal 





Small Colony Variants (SCV) 
SCVs were first identified in 1910 as abnormal colony forms of Salmonella enterica 
serovar Typhi (then known as Eberthella typhosa) [Jacobsen, 1910; Proctor et al., 
2006]. They were subsequently discovered in Staph. aureus by Swingle [1935] and 
were thought to be a stage in the bacterial lifecycle.  
Staph. aureus SCVs are characterised by small colonies (1/10 of a wild type colony 
size), reduced respiration, reduced pigmentation & metabolic activity (including 
coagulase) and decreased haemolysis on blood-containing agar which can lead to 
complications and misdiagnosis in routine laboratory tests [Kipp et al., 2005]. Upon 
subculture the SCVs switch back to the wild type phenotype [Kahl, 2014]. 
The change from a normal colony phenotype to a SCV is likely due to a constitutive 
mechanism which generates an antibiotic tolerant subpopulation and can be 
considered a normal part of the Staph. aureus life cycle [Edwards, 2012].  
Defects in metabolism may account for SCV formation. Two main groups have been 
identified from Staph. aureus clinical isolates, those deficient in electron transport and 
those deficient in thymidine or menadione biosynthesis [Acar et al., 1995]. The 
electron transport defective SCVs cannot produce menadione or haemin and the 
addition of either of these two substances can return the bacterial strain to a wild type 
phenotype [Proctor et al., 2006]   Occasionally other SCVs have been isolated which 
are CO2 auxotrophs or for which the auxotrophism cannot be identified [Goudie and 
Goudie, 1955]. 
SCVs have been identified in a broad range of bacterial species including Staph. 
epidermidis, Staph. capitis, Ps. aeruginosa, Burkholderia cepacia, Vibrio cholera, E. 
coli, Lactobacillus acidophilus and Salmonella species [Proctor et al., 2006].  
Aggressive infections have been reported in both human and animals though it is 
more usual that a subacute, persistent, antibiotic resistant, infection is caused by 
SCVs. It has been suggested that intracellular SCVs may contribute to the difficulty in 
clearing Staph. aureus from patients leading to these recurrent infections [Proctor et 
al., 1995; Proctor et al., 2006].  
As detailed above SCVs have defects in metabolism whereas persister cells have no 
specific resistance mechanisms and are considered genetically identical to 
susceptible bacteria [Lewis, 2005; Proctor et al., 2006]. They are believed to be 
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individual cell types though they may act in the same way and produce a similar result, 
for example in antibiotic tolerance and contributing to biofilm formation and its 




The third, and most important cell state which contributes to chronic, recurrent 
infections are biofilms. Biofilms may contain both SCVs and persister cells. 
A biofilm can be defined as a microbially-derived largely sessile community with cells 
attached to a surface and each other, and embedded in a protective extracellular 
polymeric matrix [Costerton et al., 1987]. Such cells have altered growth rates, gene 
expression, metabolic activity and protein production [Archer et al., 2011; Lister and 
Horswill, 2014]. Biofilms are constructed by multiple different bacterial and fungal 
species, causing both individual and multispecies formations [Burmølle et al., 2014]. 
Biofilms can be found in virtually every situation where there is an environmental 
interface [Costerton et al., 1999].  
Aqueous channels flow though the biofilm structure, allowing transport of nutrients 
and waste materials as the biofilms can be anything from one cell layer to a substantial 
community [Costerton et al., 1995; Hogan et al., 2015]. The shape of a Gram-positive 
biofilm usually differs from that of a Gram-negative biofilm, tending to be flatter due to 
the non-motile cells which make up the biofilm. However, fluid shear forces and other 
environmental conditions can lead to the development of tower-like structures 
[Costerton et al., 1995; Mann et al., 2009].  
Differences in oxygen, nutrients and electron acceptor concentrations cause 
heterogeneous gene expression within a biofilm. Gene expression can even be 
different in neighbouring cells [Brady et al., 2007]. This has led to the identification of 
different cell states. The cells on the outer surface of a biofilm are metabolically active 
and growing aerobically, cells further in the biofilm are either growing fermentatively, 
dormant (persister or very slow growing cells) or dead [Rani et al., 2007].  
The lifecycle of a biofilm can generally be split into four phases – 1) Attachment, 2) 




Initial attachment occurs when a planktonic cell settles on a surface, if not dislodged 
the cell will bind irreversibly to the surface [Lister and Horswill, 2014]. The surface 
becomes coated in proteinaceous components which encourages further cell 
adhesion [Francois et al., 2000]. Production of extrapolysaccharide (EPS) and eDNA 
will start at this stage and begin to form the biofilm matrix [Gloag et al., 2013]. Some 
of the most important protein components are the Microbial Surface Components 
Recognising Adhesive Matrix Molecules (MSCRAMMs); these proteins have major 
roles in attaching to host factors including fibrinogen, fibronectin and collagen, 





Figure 1.5: Construction and Dispersal of a Staphylococcal Biofilm [Kiedrowski and 
Horswill, 2011]. The lifecycle of a biofilm can be split into 4 phases: 1) Attachment of 
planktonic cells to a conditioned surface, 2) Accumulation of cells to form microcolonies which, 
under optimal conditions can, 3) Develop into a mature biofilm with an exopolysaccharide 
matrix and protein-protein interactions. The final stage 4) The biofilm breaks downs leading to 







After initial attachment cells start to accumulate, forming microcolonies. Some 
sources consider this stage to be the early part of biofilm maturation, as there are no 
specific properties associated with it. However, in vivo microscopy studies on 
staphylococcal biofilms have found evidence of these small microcolonies [Stoodley 
et al., 2008]. With optimal growth conditions these microcolonies, along with further 




After the cells have accumulated, and with the exopolysaccharide (EPS) matrix 
becoming more established, protein-protein interactions complete the maturation of 
the biofilm formation. Most reports indicate that the EPS matrix is composed primarily 
of polysaccharides [Cramton et al., 1999], proteins [O’Neill et al., 2008] and 
extracellular DNA (eDNA) [Rice et al., 2007]. However, the exact composition of the 
matrix is subject to change and is species and strain dependent [Kiedrowski and 
Horswill, 2011]. 
There are two distinct biofilm forms which have been identified from clinical isolates 
of Staph. aureus and Staph. epidermidis [Knobloch et al., 2001; Rohde et al., 2005]. 
The first is mediated by the intercellular adhesion operon (icaADBC) which encodes 
the enzymes involved in the synthesis of polymeric N-acetyl-glucosamine (PNAG) 
and polysaccharide intercellular adhesin (PIA), these are considered ica-dependent 
biofilms [Cramton et al., 1999]. The second form is facilitated by the fibronectin-
binding proteins (FnBPs) which are ica–independent biofilms [Houston et al., 2011; 
O’Gara, 2007].  
 
ica-dependent Biofilms  
It has been reported that 85% of Staph. epidermidis blood culture isolates contain the 
ica genes [Ziebuhr et al., 1997]. The gene cluster (icaADBC) can be considered a 
marker to discriminate between clinically significant infecting strains or contaminating 
21 
 
isolates [Frebourg et al., 2000]. It has also been shown than PNAG/PIA has a role as 
a virulence factor for Staph. epidermidis [Vuong et al., 2004].  
The majority of Staph. aureus strains contain the icaADBC operon which is 
upregulated under in vivo conditions. However, its expression is highly regulated in 
an in vitro setting, requiring stringent conditions such as low oxygen [Fluckiger et al., 
2005]. 
The icaADBC encodes four genes: icaA, icaB, icaC, and icaD. icaA and icaD which 
collectively produce PIA which facilitates cells binding together and forming into 
biofilms [Oliveira and Cunha, 2008].  
PIA is produced from UDP-N-acetylglucosamine through the enzyme N-
acetylglucosamine transferase which is encoded by icaAD within the cellular 
membrane (Figure 1.6). This forms oligomers with between 10 and 20 sugar residues 
[Vuong et al., 2004].  When icaAD is co-expressed with icaC chains of up to 130 sugar 
residues can be synthesised [Gerke et al., 1998]. icaC also exports the growing 
oligomer to the cell surface where it is deacetylated [Vuong et al., 2004]. 
The final gene icaB produces a surface bound protein which is responsible for the 
deacetylation of the poly-N-acetylglucosamine molecule. It has been proven that non 
deacetylated poly-N-acetylglucosamine in an icaB mutant strain cannot bind to a 





Figure 1.6: Model of ica-dependent Staphylococcal Biofilm Formation [Adapted from 
Oliveria and Cunha, 2008]. IcaA and icaD, work together to produce oligomers of 10- 20 
sugar residues which are derived from UDP-N-acetylgucosamine. Only in the presence of IcaC 
can longer oligomers (of up to 130 sugar residues) be synthesised. IcaC also translocates the 
growing oligomer to the cell surface where it deacetylated by the surface bound protein icaB.  
 
ica-independent Biofilms 
Although the vast majority of clinical Staph. aureus biofilms carry the icaADBC gene 
cluster, there have been growing reports of the species producing ica-independent 
biofilms [Boles and Horswill, 2008; Fitzpatrick et al., 2005]. These biofilms are 
mediated by FnBPs, the cell wall components MSCRAMMs and teichoic acids 
[Houston et al., 2011]. Mutations in the two FnBPs (A and B), which have been 
identified to be important in biofilm development, can completely prevent biofilm 
formation [O’Neill et al., 2008]. Single mutations do not impair formation as the 
proteins are independently transcribed [Jönsson et al., 1991]. The FnPBs are large 
functional proteins binding not only to fibronectin but also elastin and fibrinogen. The 
subdomain N2N3 of FnBPA plays an essential role in binding to fibrinogen and 
promoting bacterial adhesion [Geoghegan et al., 2013; Keane et al., 2007]. This is a 
two step process, the first step is FnBPA proteins encourage attachment to a suitable 
surface (1 on Figure 1.7). The second step involves biofilm accumulation through cell 
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aggregation (2 on Figure 1.7). Whether homophilic bonds or ligand binding is 
responsible for cell-cell attachment and biofilm formation is yet to be determined as 
can be seen in Figure 1.7 (3) [Herman-Bausier et al., 2015]. 
The same process can be found in Staph. epidermidis [Rohde et al., 2005] though the 
mechanism of biofilm formation differs slightly. The proteins which have been strongly 
linked to biofilm formation are the accumulation associated protein (Aap) [Rohde et 
al., 2006] and a biofilm associated protein (BAP) homologue; Bap-homologue protein 
(Bhp) [Tormo et al., 2005]. Mutation of the bap gene destroyed the Staph. epidermidis 
strains ability to develop a biofilm, and transforming a biofilm-negative Staph. aureus 
strain with the Bap protein enabled biofilm formation [Tormo et al., 2005]. 
Once fully developed a biofilm matrix is composed of polysaccharides, proteins and 
extracellular DNA [Gloag et al/. 2013; Mann et al., 2009], though there is significant 
variation between strains. Other suggested components of the matrix include cell 
wall–associated components [Wu et al., 2003], and teichoic acids [Sadovskaya et al., 
2006]. These and other, as yet unknown, components could be contributing to the 
dynamic matrix structure, however, more investigation is needed to clarify the exact 
composition [Kiedrowski and Horswill, 2011]. 
No strict guidelines exist on what a fully established biofilm is however, the ability to 







Figure 1.7: ica-Independent Biofilm Formation in Staphylococcus aureus [Herman-
Bausier et al 2015]. FnBPA is responsible for biofilm formation in strains which do not contain 
the icaADBC gene cluster. It is the subdomain N2N3 which is the functional part of the FnBPA 
molecule responsible for fibrinogen and elastin binding and cell-cell aggregation during biofilm 
formation. A) Schematic representation of the FnBPA protein: S, secretory signal sequence; 
the A region comprising N1, N2 and N3 subdomains; R, tandem repeats of fibronectin-binding 
domains; W, proline-rich cell wall spanning region; SS, sorting signal comprising the LPXTG 
motif, membrane-spanning domain and positively charged tail. B) FnBPA encourages 
attachment to a surface (1) followed by cell accumulation and biofilm formation (2). The role 
of FnBPA in biofilm formation is thought to be to promote cell-cell attachment though either 
homophilic bonds or ligand binding (3). 
 
Detachment and Dispersal  
Once the biofilm is fully developed it provides protection and advantages over a 
planktonic cell state (detailed below) and is extremely difficult to dislodge. Shear 
forces may rarely have an effect, however, specific bacterial mechanisms need to be 
activated for the biofilm to fully disperse [Cassat et al., 2007].   
The best characterised mechanism in staphylococcal species is the accessory gene 
regulator (agr) of the quorum sensing system. Unlike in Pseudomonas aeruginosa 
[O’Loughlin et al., 2013], an active quorum sensing system in Staph. aureus inhibits 
the development and encourages the detachment and dispersal of a biofilm [Davis et 
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al., 1998; Vuong et al., 2000]. Recsei et al [1986] first described the agr gene locus 
and since then ~150 genes have been shown to be regulated by it. At least 16 of 
these are involved in virulence [Gospodarek et al., 2009; Lyon and Novick, 2004].  
As can be seen from Figure 1.8, activation of the agr system increases the production 
of extracellular proteases which affect biofilm development, indeed bacterial cells 
from a recently dispersed biofilm show very high levels of agr activity [Boles and 
Horswill, 2008]. The extracellular proteases degrade the protein adhesins which bind 
the individual cells within the biofilm matrix thereby releasing the cells back to their 
planktonic state [Boles and Horswill, 2011; Vuong et al., 2000].  
 
Figure 1.8: The Function of AutoInducing Peptide (AIP) and the agr Quorum Sensing 
System in Staphylococcus aureus [Gray et al., 2013]. The cyclic AIP activates the AgrCA 
two-component system increasing expression of virulence factors including exoproteases, 
lipase, leukocidins and hemolysins. Biofilm disassembly is also triggered. AgrB acts as a 
chaperone protein and is a multifunctional endopeptidase.  AgrD is processed by AgrB into 
AIP. AgrC is the integral membrane sensor and AgrA is the transcription factor regulator 
companion to AgrC. This molecule acts to upregulate agr and RNAIII expression. RNAIII 




Advantages of Biofilms 
 
There are a number of advantages biofilms confer over the planktonic cell phenotype. 
The major ones are resistance to antimicrobials, antiseptics & disinfectants, 
prevention of clearance by immune responses from the host and protection from 
environmental conditions [Archer et al., 2011; Mann et al., 2009]. Clearance methods 
for biofilms include use of antifouling agents, shear stress, host phagocytic 
elimination, host radical and protease defences [Archer et al., 2011].  
The polymeric matrix provides a structural and protective physical barrier against 
immune responses, environmental conditions such as desiccation and extended 
periods of reduced nutrients, and is a contributing factor to antibiotic resistance as it 
slows the inward diffusion of the antibiotics [Lewis, 2005; Hogan et al., 2015; Mann et 
al., 2009; Xu et al., 2000]. 
The low nutrient and oxygen concentrations within a biofilm leads to a semi-dormant 
cell phenotype with low metabolic activity and cell division rates which forms part of 
the basis for antibiotic resistance within biofilms [Lewis 2005]. Persister cells begin to 
dominate the population. However, once the selective pressure of the antibiotic is 
removed the persisters regain a normal phenotype and can re-ignite infection [Lewis, 
2005].  
 
Molecular Mechanisms of Biofilm Resistance 
 
Resistance of biofilms is multifactorial, with the different factors acting in concert with 
each other [Burmølle et al., 2014]. These factors include changes in the chemical 
microenvironment, reduced diffusion rates of compounds into the matrix, altered gene 
expression patterns and low or stalled growth rates [Mah and O’Toole, 2001; Van 
Acker  et al., 2014]. The biofilm matrix, as it may consist of up to 97% water, provides 
protection from desiccation and other environmental stresses [Flemming and 
Wingender, 2010]. Horizontal gene transfer rates are higher than in planktonic 
27 
 
cultures, due to the close proximity of the cells, leading to increased resistance due 
to the mobile genetic elements which can be transferred. These mobile elements can 
be shared between bacteria of the same species or between different compatible 
species [Madsen et al., 2012]. 
A class of genetic element which may be transferred in this way are efflux pumps. 
Efflux pump genes and proteins are present in all organisms [Gillis et al., 2005] with 
the genes located on the chromosome or on transferable genetic elements [Piddock, 
2006]. Efflux pumps can transport either a specific substrate or a group of structurally 
dissimilar compounds such as different classes of antibiotics (Figure 1.9). Efflux 
pumps are relevant in the health care environment as they can confer reduced 
antibiotic susceptibility and clinical levels of antibiotic resistance to multiple species 
[Hooper, 2005].  
There are five families of efflux pumps: the ATP-binding cassette (ABC) superfamily, 
the major facilitator superfamily (MFS), the multidrug and toxic-compound extrusion 
(MATE) family, the small multidrug resistance (SMR) family and the resistance 
nodulation division (RND) family [Piddock, 2006].  The classifications of the efflux 
pumps into these families are based on the number of components a pump has, the 
number of transmembrane-spanning regions the transporter protein has, the energy 
source a pump uses and the types of substrates a pump exports (Figure 1.9) [Piddock, 
2006]. 
Efflux pumps prevent antibiotics from entering the cell and also actively export 
antibiotics out of the cell. The development of antibiotic resistance may be a side 
effect of the normal physiological role of the pumps in transporting molecules 
produced by the host organism (e.g. bile) out of the cell allowing the bacteria to survive 
[Piddock, 2006]. 
Other mechanisms which may contribute to biofilm resistance are matrix 
polysaccharides which limit the penetration of antibiotics [Van Acker et al., 2014], 
presence of persister cells [Lewis, 2010] and protection against oxidative stresses 




Figure 1.9: Multidrug Resistance Efflux Pumps in Bacteria [Piddock, 2006]. There are 
five families of multidrug resistance efflux pumps in bacteria: The ATP-binding cassette (ABC) 
superfamily, the major facilitator superfamily (MFS), the multidrug and toxic-compound 
extrusion (MATE) family, the small multidrug resistance (SMR) family and the resistance 
nodulation division (RND) family. A diagrammatic representation is shown, common examples 
of the proteins which form each class and examples of transported substrates (including 





Multispecies biofilms have been described for bacterial species found in clinical and 
human situations such as the oral environment [Kolenbrander et al., 2010]. They have 
also been identified in all of non-host environments including soil, sea water, boat 
hulls and dairy production processes [Burmølle et al., 2014; Schwering et al., 2013].  
In an example of organisms of medical importance, mixed species biofilms consisting 
of Staph aureus and Candida albicans have been studied and they were found to 
exhibit enhanced virulence and resistance when co-infecting mouse models [Shirtliff 
et al., 2009]. Other examples of where mixed species biofilms of importance occur in 
healthcare facilities are in combat acquired and chronic wounds with Staph. aureus 
and Ps. aeruginosa [Dean et al., 2015], diabetic ulcers [Dowd et al., 2008], 
colonisation of urinary catheters, dental plaque [Yang et al., 2011] and cystic fibrosis 
associated infections [Elias and Banin, 2012]. 
Multispecies biofilms act together in a symbiotic way [Burmølle et al., 2014]. The 
mechanisms of biofilm protection and resistance mentioned before are often 
enhanced [Burmølle et al., 2006].  Therefore, this information should be taken into 
account when deciding treatment regimens and cleaning procedures [Burmølle et al., 





Biofilms contribute to persistent chronic infections, eradication is arduous, often 
requiring physical intervention such as surgical debridement or replacement of the 
affected device [Archer et al., 2011]. Table 1.6 details a few examples of medical 
infections caused by biofilms. This is by no means an exhaustive list. Estimates 
suggest that up to 65% of HCAIs are a direct result of biofilms [Costerton et al., 1999]. 
Removal and long term antibiotic treatment are the current first options when dealing 
with biofilms on indwelling devices however, attempts are being made to move away 
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from this as it is costly, time consuming and reduces the patient’s quality of life [Archer 
et al., 2011]. New and different therapy methods are required to treat biofilms and 
alternative approaches are currently under investigation.  
Table 1.6: Examples of Medical Infections Caused by Biofilms [Adapted from 
Costerton et al., 1999]. 
Causative Organism Infection/Disease 
Streptococcus spp. Dental caries 
Haemophilus influnezae   Otitis media 
Gram-positive cocci (Staphylococcus) Musculoskeletal infections 
Group A strep Necrotizing fasciitis 
Enteric Bacteria Biliary tract infection 
Various bacteria and fungi – often mixed Osteomyelitis 
E. coli  and other Gram-negatives Bacterial prostatitis 
Viridians group streptococci Native valve endocarditis 
P. aeruginosa and Burkholderia cepacia Cystic fibrosis pneumonia 
Pseudomonas pseudomallei Melioidosis  
Staph aureus and Staph epidermidis Sutures 
Staph aureus and Staph epidermidis Arteriovenous shunts 
Ps. aeruginosa and Gram-positive cocci Contact lens 
E. coli  and other Gram-negative rods Urinary catheter cystitis 
Variety of bacteria and fungi Peritoneal dialysis (CAPD) peritonitis 
Variety of bacteria and fungi Endotracheal tubes 
Staph epidermidis and others Central venous catheters 
Staph aureus and Staph epidermidis Mechanical heart valves 
Gram-positive cocci Vascular grafts 
Enteric Bacteria and Fungi Biliary Stent blockage 






One of the major categories of biofilm infections in hospitals is device related 
infections such as orthopaedic implants. A common practice to try to prevent 
prosthetic joint infections is the use of Antibiotic-Loaded Acrylic bone Cements 
(ALACs). Gentamicin is the most common antibiotic in use in bone cement in Europe 
because of its broad antibacterial spectrum and stability at the high temperatures 
which are required to polymerize the polymethylmethacrylate [Neut et al., 2005]. Due 
to resistance to gentamicin the bone cements may also contain another antibiotic such 
as clindamycin (Refobacin Revision®/Copal G+C®) or vancomycin (Vancogenx®) 
[Gallo et al., 2013].  
A third antibiotic, such as linezolid, daptomycin or ciprofloxacin, is sometimes mixed 
into the bone cement, though there is little evidence for increased effectiveness of 
individual or combination antibiotic treatments. Thus the antibiotics chosen are 
common ones in current practice which have proven effective [Nandi et al., 2009; 
Taggart et al., 2002]. Detailed below are the usual routes of administration, modes of 
action, effect on biofilms and resistance mechanisms of gentamicin, rifampicin, 
vancomycin, ciprofloxacin, clindamycin, linezolid and daptomycin.  
 
Gentamicin 
Gentamicin is a bactericidal member of the aminoglycoside family of antibiotics whose 
mode of action involves protein mistranslation through the incorporation of incorrect 
amino acids into peptides. A secondary effect of this is the inclusion of these 
mistranslated proteins into the cytoplasmic membrane resulting in increased 
permeability and uptake of the antibiotic into the cell [Davis et al., 1986].  
Aminoglycosides are primarily used for the treatment of staphylococci, other Gram-
positives and Gram-negative aerobic bacilli infections [Ramirez and Tolmasky, 2010]. 
When used against Gram-positives, another antibiotic (β-lactam or vancomycin) is 
often combined with a synergistic effect [Ramirez and Tolmasky, 2010]. Anaerobic 
species are naturally resistant as the uptake of aminoglycosides into the bacterial cell 
requires oxygen [Byran et al., 1979]. 
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Administration of aminoglycosides is through injection; intramuscular or in the most 
severe cases, intravenously. Oral administration is not possible due to the low 
adsorption levels. Side effects of these antibiotics are nephrotoxicity and ototoxicity 
which can limit the dose given [Ramirez and Tolmasky, 2010]. Kidney function needs 
to be monitored especially in older patients or those with impaired renal functions 
[NHS, 2010]. 
There are several recognised bacterial resistance mechanisms against 
aminoglycosides; more than one can be present in the same cell [Houghton et al., 
2010]. The mechanisms include modification of the antibiotic binding target by 
mutation of the ribosomal proteins [Galimand et al., 2005], reduced membrane 
permeability [Hancock, 1981], active export (usually Gram-negatives) [Aires et al., 
1999], sequestration of the antibiotic (usually Gram-negatives) [Magnet et al., 2003] 
and most importantly enzymatic inactivation of the antibiotic. This last mechanism is 
the most common in the clinical environment [Ramirez and Tolmasky, 2010].  
Enzymatic inactivation of aminoglycosides was first reported in 1977 [Davies and 
Courvalin, 1997] and involved two plasmid medicated enzymes. Since then many 
more aminoglycoside modifying enzymes have been recorded. These can broadly be 
spilt into three groups; the aminoglycoside N-acetyltransferases (AACs), the 
Aminoglycoside O-nucleotidyltransferases (ANTs) and the Aminoglycoside O-
phosphotransferases (APHs). All these enzymes can modify different –OH or –NH2 
groups of the 2-deoxystreptamine nucleus or sugar moieties of the antibiotic [Ramirez 
and Tolmasky, 2010]. 
The effectiveness of gentamicin on both biofilms and planktonic cultures has been 
found to be nutrient dependent [Henry-Stanley et al., 2014] which has serious 
implications in the clinical environment especially with biofilms found in hard to treat 
areas such as prosthetic joints. In fact the use of aminoglycosides for treating biofilms 
may be counter indicated as there have been reports that they promote biofilm 
formation in both Gram-negative and Gram-positive species [Hess et al., 2011; 
Hoffman et al., 2005]. Hess et al, [2011] found that biofilm biomass increased when 
using both sub-inhibitory and inhibitory concentrations of gentamicin in established 
Staph. aureus biofilms. Another aminoglycoside, tobramycin, has been found to have 
the same effect on Ps. aeruginosa and E. coli biofilms [Hoffman et al., 2005]. It is 
thought that the eDNA and extracellular matrix of the biofilm is primarily responsible 




Rifampicin is fairly unusual as it has activity against a wide range of both Gram-
positive and Gram-negative bacteria, targeting the bacterial RNA polymerase and 
inhibiting RNA synthesis [Campbell et al., 2001]. Studies have shown that rifampicin 
is extremely effective against staphylococci in various growth modes including 
biofilms, especially when combined with other antimicrobials [Kiedroski and Horswill, 
2011; Raad et al., 2007].  
The causes behind the efficiency are unknown. However, rifampicin has excellent 
pharmacokinetic properties, and is lipid soluble which improves penetration into 
multiple tissue sites [Zavasky and Sande, 1998]. Rifampicin’s bactericidal activity 
remains active under low pH conditions, and it accumulates to high concentrations in 
neutrophils which are among the first responders to infections [Lam and Mathison, 
1983]. 
Single point mutations or the accumulation of such mutations in the rpoB gene which 
encodes for DNA-dependent RNA polymerase confers a high level of resistance 
[Aubry-Damon et al., 1998]. Resistance to rifampicin develops quickly, therefore it is 
always used as part of a combination treatment and never on its own [Zimmerli et al., 
2004]. 
When used to treat biofilm based infections rifampicin has been shown to effectively 
and uniformly penetrate Staph. epidermidis and Staph. aureus biofilms, however has 
a limited effect on cell viability [Croes et al., 2010; Zheng and Stewart, 2005]. Jones 
et al [2001] confirmed this with regards to MRSA biofilms in that rifampicin had no 
significant effect on biofilm thickness over 24 hours when compared to control 
cultures, even when the antibiotic concentrations used were well over the MIC and 
minimum bactericidal concentration (MBC). However, in spite of its limited activity 
rifampicin is the most common combination drug used to treat biofilms [Jacqueline 








Vancomycin is a glycopeptide produced by Amycolatopsis orientalis, which binds to 
the peptidoglycan side chains in the cell wall, and is the treatment of choice for 
invasive staphylococcal infections [Kiedrowski and Horswill, 2011]. 
During cell wall synthesis, cross linking occurs; vancomycin prevents this leading to 
a weakened cell wall, reducing growth and eventually causing death of the cell 
[Kiedrowski and Horswill, 2011]. Long hospital stays are associated with this 
antibiotic, due to its slow bactericidal activity (significantly only acts on growing cells), 
and the need for intravenous administration [Chamber and DeLeo, 2009]. 
Vancomycin monotherapy on biofilms is not effective; though damage to the biofilm 
does occur the cells are still remain viable [Dunne et al., 1993]. However, combining 
with other antibiotics, such as tetracycline or rifampicin, leads to increased cell death 
[Monzón et al., 2002]. Vancomycin has been shown to penetrate effectively into 
biofilms [Darouiche et al., 1994] and vancomycin concentrations close to the MIC 
have been shown to prevent the initiation of biofilm formation however, when added 
to a established biofilm very little effect is seen even at over 100 times the MIC value 
[Hajdu et al., 2009; Jacqueline and Caillon, 2014; Jones et al., 2001].  
There are two major variations for vancomycin resistance, the first is complete 
resistance due to a plasmid which encodes VanA and accessory proteins. This 
decreases the cell’s binding affinity for vancomycin [Courvalin, 2006]. The second 
results in intermediate resistance and is caused by regulatory mutations that increase 
cell wall thickness and teichoic acid D-alanylation [Howden et al., 2010]. For Staph. 
aureus these are termed Vancomycin Resistant (VRSA) or Vancomycin Intermediate 
(VISA). 
Resistance to vancomycin was identified in Enterococcus species in the mid-1980s 
and has since spread rapidly. Resistance remains at a reasonably low level. However, 
it is transferrable between Gram-positive species thus, there are significant concerns 
about its emergence and the impact it would have on treating staphylococcal 






This is a second generation fluoroquinolone which is active against a wide range of 
aerobic Gram-positive and Gram-negative bacteria but with limited use against 
anaerobes [Card et al., 2015]. Ciprofloxacin’s mode of action is to target DNA 
replication and repair by binding to DNA gyrase and inhibiting its action. This induces 
double strand DNA breaks and causes cell death [Drlica and Zhao, 1997]. A second 
essential enzyme which is targeted is DNA topoisomerase IV [Drlica and Zhao, 1997]. 
As eukaryotic cells do not contain DNA gyrase, this antibiotic is selective for bacterial 
cells. 
There are three major, currently recognised, resistance mechanisms. These are 
mutations that affect the antibiotic targets, mutations that impede concentrations 
reaching effective levels within the cells, and plasmids encoding genes which protect 
the bacterial cell from the lethal effects of the quinolones [Jacoby, 2005]. 
The most commonly seen resistance mechanism are mutations of either the DNA 
gyrase or topoisomerase IV genes; generally the more resistant a strain the more 
mutations it contains [Lindren et al., 2003].  In Staph. aureus increased expression of 
norA, encoding a broad spectrum transporter keeps ciprofloxacin from reaching 
effective levels within the cell. This resistance mechanism is also active against a 
number of other antibiotics, antiseptics, and detergents [Jacoby, 2005]. Plasmid 
mediated resistance has three variations. In the first the plasmids encode for proteins 
of the pentapeptide repeat family which protect the DNA gyrase and topoisomerase 
IV. The second involves acetylation of the antibiotic and the third is plasmid encoded 
genes which produce enhanced efflux pumps for exporting the antibiotic out of the 
cells [Jacoby et al., 2014]. 
The effect of ciprofloxacin on biofilms formed by Staph. aureus, Staph. epidermidis, 
E. coli, K. pneumoniae, Ps. aeruginosa and Proteus vulgaris was investigated by El-
Feky et al [2009] who found that ciprofloxacin in combination with N-acetylcysteine 
inhibited biofilm formation by ≥60% compared to the controls. Disruption of 
established biofilms with ciprofloxacin only has also been found to be effective [El-






Clindamycin is a member of the lincosamide class of antibiotics and has a 
bacteriostatic effect on the cell through inhibition of protein synthesis [Kohanski et al., 
2010]. The mode of action involves blocking the access of peptidyl-tRNAs to the 
ribosome, subsequent blocking of the peptidyltransferase elongation reaction by 
steric inhibition and triggering dissociation of the peptidyl-tRNA, [Tenson et al., 2003]. 
Clindamycin is active against many aerobic Gram-positive cocci, Gram-positive and 
Gram-negative anaerobes and is available in both intravenous and oral formulations 
[Lewis and Jorgenson, 2005]. Distribution is good into skin and the antibiotic itself 
may be able to reduce virulence in staphylococcal species by supressing production 
of extracellular virulence factors [Stevens et al., 1988]. 
Resistance in Gram-negative species is due to mutations in the 23S rRNA encoding 
gene and alterations in efflux of the drug [Card et al., 2015], whereas resistance in 
Gram-positives is due to modification of the antibiotic binding site on the ribosome; 
this also confers resistance to macrolides, azalides, other lincoamides and group B 
streptogramins and is referred to as ‘MLSB resistance’ [Roberts et al., 1999]. This 
inducible resistance has led to uncertainly over prescribing practices. However, with 
the emerging concern of CA-MRSA, clindamycin is a decent alternative for treatment 
of various CA-MRSA diseases including skin and soft-tissue, pneumonia and 
musculoskeletal infections [Lewis and Jorgensen, 2005]. 
The effect clindamycin has on biofilms varies depending upon the species forming the 
biofilm. In Ps. aeruginosa biofilms sub-inhibitory MICs suppressed biofilm formation 
[Ichimiya et al., 1994] whereas in MRSA biofilms mean cell survival was as high as 
62% [Smith et al., 2008]. For the 12 different clinical isolates of MRSA examined by 
Smith et al [2008] clindamycin’s MIC varied from 0.125-1024 μg/ml demonstrating that 
the effectiveness of the antibiotic can be strain dependent. Of the five antibiotics 
tested by Smith et al [2009], which included clindamycin, daptomycin, linezolid, 
tigecycline and vancomycin, clindamycin was the least effective against biofilms. 
Clindamycins effect may be enhanced when used for combination treatment, for 






This bacteriostatic synthetic oxazolidinone was first approved for use in the UK in 
2001 [Ager and Gould, 2012]. Linezolid has proven activity against a broad range of 
Gram-positive aerobic bacteria including antibiotic resistant species such as MRSA, 
Vancomycin Resistance Enterococci (VRE) and Penicillin Resistance Pneumococci 
(PRP). It is also active against some Gram-positive and Gram-negative anaerobes, 
Mycobacterial species and Nocardia species [Mouton and Jansz, 2001].   
Protein synthesis is inhibited by linezolid binding to domain V of the 23S ribosomal 
RNA of the 50S subunit and to the peptidyltransferase centre of the bacterial ribosome 
[Colca et al., 2003]. Activity against biofilms has been reported in both in vivo and in 
vitro models, with better success rates linked to longer antibiotic exposure [Gander et 
al., 2001]. When combined with rifampicin in prosthetic joint infections, with implant 
removal the infection was cleared in ~70% of cases [Gomez et al., 2011]. When tested 
against 12 different clinical isolates of MRSA the MIC range was found to be between 
1 and 2 μg/ml with mean survival rates of cells from biofilms of 45% [Smith et al., 
2009]. Linezolid can inhibit initial biofilm formation of Staph. aureus and Staph. 
epidermidis when added simultaneously at concentrations close to the MIC 
[Jacqueline and Caillon, 2014].  
Resistance has been reported in E. faecium, Staph. aureus, E. faecalis, CoNS and 
viridans Streptococci though cases remain rare [Ager and Gould, 2012]. Resistance 
is due to point mutations in the 23S rRNA target site and only develops slowly as there 
are multiple copies of the 23S rRNA gene in every cell [Prystowsky et al., 2001]. 
Resistance usually occurs after prolonged linezolid treatment, although there have 
been cases of nosocomial acquisition reported in patients with no prior linezolid 
treatment [Dobbs et al., 2006]. Combination treatment with either rifampicin or fusidic 
acid could postpone the development of resistance [Millar et al., 2008]. 
Advantages of linezolid are the option of oral route of administration, good tissue 
distribution, penetration and bioavailability.  Another more unusual benefit of this 
antibiotic is the ability to suppress toxin production in Staph. aureus, thus improving 






This is a calcium-dependent bactericidal antibiotic which was developed in response 
to the increasing resistance of staphylococcal strains; it has been shown to be 
effective against most Gram-positive organisms including those with resistance to 
multiple antibiotics [Streit et al., 2004].  
Daptomycin is a 13 member amino acid cyclic lipopeptide with a decanoyl side chain 
[Steenbergen et al., 2005]. The bactericidal effect of daptomycin is thought to be 
achieved through the insertion of the lipophilic tail into the bacterial cell membrane 
causing membrane depolarization and potassium ion efflux. DNA, RNA and protein 
synthesis is rapidly terminated leading to cell death [Silverman et al., 2003]. The 
calcium required by daptomycin triggers a conformation change into an active state, 
which allows the antibiotic to penetrate deeper into the bacterial cell membrane. 
[Straus and Hancock, 2006].  
The effects of daptomycin on biofilms have reported with a MIC range of 0.06-0.25 
μg/ml and a mean cell survival rate of ~4% when tested against 12 clinical isolates of 
MRSA [Smith et al., 2009]. Other studies have also shown that compared to linezolid, 
rifampin, and vancomycin, daptomycin was the fastest at clearing the majority of the 
biofilm [Raad et al., 2007]. In fact this antibiotic may offer valuable alternatives for the 
treatment of antibiotic resistant organisms through its effective action [Petersen et al., 
2002]. 
Resistance was first reported in 2005 in patients with MRSA osteomyelitis [Hayden et 
al., 2005] and this is thought to be due to point mutations in phospholipid biosynthesis 
genes. These mutations lead to changes in membrane composition and charge which 
either directly affects the daptomycin molecule binding or causes electro-repulsion of 
the calcium-complexed daptomycin [Cameron et al., 2015]. With the increasing 
resistance to vancomycin, daptomycin is used as an alternative first line therapy 
against both log and stationary phase bacterial cells [Mascio et al., 2007]. 
Monotherapy of biofilms is effective though total killing is not achieved [Smith et al., 
2009] though, clinical success has been seen in staphylococcal bone and joint 






Combination therapy potentially has many benefits compared to individual antibiotic 
therapy specifically in the cases of severe infections. Combinations would increase 
the effectiveness of the antibiotics though synergism, increase the range of bacteria 
targeted in empirical therapy through affecting different targets, limit virulence factors 
expression, and prevent the development of antibiotic resistance. 
However, factors to be aware of when combining antibiotics are the possible 
antagonism between antibiotic classes, the detrimental effect of rapid bacteriolysis on 
the host and the fact that duel treatment might be no more beneficial than using a 
single antibiotic [Hagihara et al., 2012]. 
The most well-known system for antibiotic combination therapy for biofilms is the use 
of bone cermet. Initially lower infection rates were reported when using antibiotic 
loaded cermet compared to plain cermet [Thierse, 1978]. However, the long term 
release of gentamicin promoted the development of antibiotic resistance bacterial 
strains [van der Belt et al., 1999]. Thus the decision to add a second antibiotic to the 
cermet was made. The second antibiotic can vary including clindamycin, vancomycin 
and fusidic acid [Gallo et al., 2013; Neut et al., 2005]. As mentioned above in the 
individual antibiotic sections combinations of antibiotics for the treatment of biofilms 
can have a beneficial effect.  
Combining antibiotics improves treatment outcome though the way in which this is 
done is not clearly understood and more work needs to be conducted on this study 
especially in regards to biofilm infections. An alternative option which is currently 
being explored is combining the antibiotic with adjuvants as detailed in the next 
section.  
 
Disruption to Staphylococcal Biofilms 
 
With the difficulty of treating, and the increasing development of antibiotic resistance, 
alternative approaches need to be investigated to inhibit and disrupt biofilm formation 
Table 1.7 highlights a number of alternative approaches which have been proposed 
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to be effective. A few of these are examined in more detail below [Hogan et al., 2015; 
Kiedrowski and Horswill, 2011]. 
Table 1.7: Alternative Approaches to Inhibiting Staphylococcal Biofilms 
[Adapted from Hogan et al., 2015; Kiedrowski and Horswill, 2011]. 
Agent Target Mode of Action 
Enzymatic disruption 
Lysostaphin Cell wall Cleaves pentaglycine bridges in cell 
wall causing cell lysis  
DNase Extracellular DNA Cleavage of eDNA in the biofilm 
matrix directly or indirectly 
Dispersin B Exopolysaccharide Glycoside hydrolase enzyme which 
degrades PIA/PNAG polymer 
V8 Peptide bonds Disrupts protein mediated biofilms by 








Prevent bacterial adhesion 
Quorum Sensing Targets 
Autoinducing 
peptide (AIP) 
agr Activation of the agr system leading 




Unknown Surfactant properties promote 
dispersal of biofilms 
Bacteriophages 





bonds and inhibits 
amino acid use 
Inhibition of biofilms 
Cis-2-decanoic 
acid 





Unknown Chelator of metals especially 
magnesium 
Natural Molecules 
D-amino acids Incorporation in the 
peptidoglycan of the cell 
wall 
Inhibition of Protein Synthesis in B. 
subtilis 
Unknown in Staph. aureus 
Sugar 
metabolites 
Reactivation of metabolic systems allowing antibiotics to affect 
cells 
Immunisation 
rClfA/rCLFB Stimulates antibody production to clumping factors A and B 
(rClfA/rClfB) and the surface protein 
cna-FnBP Recombinant protein creation of fibronectin binding protein and 
collagen to prevent biofilm adhesion 
rIsdB Vaccine competes with the iron sequestering protein  
Photodynamic treatment 
Chlorin (e6) Produces free radicals and cytotoxic reactive oxygen species 
Antimicrobial peptides 
Cathelicidin Cytoplasmic membrane Disrupts biofilm formation 
 
 
Enzymatic Interference: Lysostaphin 
An enzyme upon which a fair amount of investigation has been carried out is 
lysostaphin [Hogan et al., 2015]. Lysostaphin is a 27kDa glycyl-glycine endopeptidase 
which acts by cleaving the cross-linking pentaglycine bridges in the staphylococcal 
cell wall, lysing and killing the bacteria [Wu et al., 2003; Kokai-Kun et al., 2009]. The 
enzyme is also able to destabilise biofilms by disrupting the extracellular matrix 
through the rapid lysis of the component cells leading to detachment [Wu et al., 2003]. 
It has been shown to have activity against Staph. epidermidis, MSSA, and most 
importantly MRSA [Dajcs et al., 2000; Wu et al., 2003]. Wu et al [2003] also 
investigated the effects of lysostaphin against Ps. aeruginosa with no change in the 
biofilm formation, it may be that this enzyme is purely for use with staphylococcal 
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biofilms. This property is an advantage over conventional antibiotics as it should not 
affect the host’s normal gut microbiota.  
Additionally, lysostaphin does not have any effect on human cells and little toxicity 
though repeated treatments can possibly cause an immune reaction to the protein 
[Kokai-Kun et al., 2009]. An alternative to treating the entire system can be using 
lysostaphin coated catheters which have been shown to prevent colonization of both 
Staph. aureus and to a lesser extent Staph. epidermidis. The catheters retain their 
antimicrobial properties for several days after coating [Shah et al., 2004]. 
A major concern with using enzymes to disrupt biofilms is the potential dispersal and 
seeding of bacteria to other organs and parts of the body. Nonetheless, the use of 
enzymes is promising, although, only when used in conjunction with systemic 
antibiotics [Hogan et al., 2015]. 
Other enzymes which have been shown to have activity against biofilms include 
Dispersin B, a glycoside hydrolase enzyme which degrades the surface polymer 
PIA/PNAG; DNase I which inhibits biofilm formation via the cleavage of cell surface 
nucleic acids which act as surface adhesins; and V8, a protease which severs peptide 




Bacteriophages were originally recognised in 1915 in a culture of dysentery bacilli 
[Twort, 1915] and were researched extensively until the 1940s however, with advent 
of antibiotics they were side-lined in the majority of countries [Yilmaz et al., 2013]. 
Therapy involves using lytic bacteriophages, or components thereof, to treat bacterial 
infectious diseases [Gutiérrez et al., 2015].  
Bacteriophages act on bacterial cells by attaching to the cell wall and translocating 
their DNA into the cell where it undergoes replication, subsequently producing the 
new phage particles. These are released when the cell bursts, through the actions of 
the phage proteins endolysin and holing. The new phages then infect neighbouring 
cells repeating this cycle. As the phages replicate in the system a low initial dose will 
rapidly be increased [Matsuzaki et al., 2005]. 
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Successful treatment has been reported against both Gram-positive and Gram-
negative species, including E. coli, Ps. aeruginosa, K. pneumoniae, Salmonella spp., 
E. faecium and Staph. aureus [Matsuzaki et al., 2005]. Purified phage-encoded 
peptidoglycan hydrolase (lysin) is active against Strep. pyogenes, Strep. pneumoniae, 
and Bacillus anthracis with immediate effect when used topically [Matsuzaki et al., 
2005]. 
The main advantage of bacteriophage treatment over conventional antibiotic therapy 
is that the bacteriophages are able to affect drug resistant species, as the phages 
have a completely different mode of action from antibiotics. The emergence of phage 
resistant bacteria may also be prevented by the mutation of the bacteriophage in order 
to maintain its infectivity [Matsuzaki et al., 2005]. 
Additionally, as bacteriophages are highly species specific, there is no broad 
disruption to the host microbiota, and consequently, only prokaryotic cells are 
targeted. Thus the adverse side effects and complications from antimicrobial 
treatment are drastically reduced. However, this could prove to be a disadvantage for 
a clinical setting as the specific bacterial strain causing the infection would need to be 
identified before treatment could commence [Pincus et al., 2015]. 
There are conflicting studies regarding the effectiveness of bacteriophages against 
biofilms; Yilmaz et al [2013] found that a combination of bacteriophage with antibiotic 
reduced a Staph. aureus biofilm (5000 CFU/ml for phage and antibiotic compared to 
17,165 CFU/ml for antibiotic only and 30,788 CFU/ml for phage only, 50,586 CFU/ml 
for the control group) and to a lesser extent a Ps. aeruginosa implant infection 
whereas Seth et al [2013] found that disruption though debridement was required 
before bacteriophage therapy was effective.  
The site of infection and state of the host immune system may also be relevant to the 
efficiency of bacteriophage treatment [Pincus et al., 2015]. Duration of treatment, 
route of administration, potential side effects and appropriate dose ranges would need 
to be investigated as this information is currently unknown [Hogan et al., 2015; Pincus 
et al., 2015; Yilmaz et al., 2013]. A definite decision can only be made regarding the 
effectiveness of bacteriophages against biofilm infections after this information has 




Natural Molecules: D-amino acids 
The effect of D-amino acids on biofilms was first discovered in cultures of Bacillus 
subtilis where it was found that increased incubation times in spent medium dissolved 
pellicles which had previously formed within the culture [Kolodkin-Gal et al., 2010]. 
The factor which triggered the dissolution of the biofilm was found to be D-amino acids 
which are naturally produced during late stationary phase cultures, primarily D-
tyrosine, D-leucine, D-tryptophan and D-methionine. Other D-amino acids and L-
enantiomers did not have any effect [Kolodkin-Gal et al., 2010].  
L-enantiomers are predominantly used rather than the D-enantiomers within cells 
naturally [Lam et al., 2009] therefore, incorporating D-amino acids within the cell wall 
will modulate peptidoglycan synthesis and inhibit attachment to the biofilm matrix 
proteins. This results in reduced intercellular adhesion thus having an effect on the 
stability of the biofilm [Lister and Horswill, 2014]. The morphology of cells is not altered 
by this inclusion [Lam et al., 2009]. 
D-amino acids were also shown to be effective against other bacterial species 
including Staph. aureus and Ps. aeruginosa strains [Kolodkin-Gal et al., 2010]. The 
three amino acids which have the greatest effect on Staph. aureus are D-tyrosine, D-
phenylalanine and D-proline. A mixture of these three was apparently more effective 
than using them individually [Hochbaum et al., 2011]. 
Ramón-Peréz et al [2014] has demonstrated that clinical and commensal strains of 
Staph. epidermidis are affected by D-amino acids, though the sensitivity/resistance 
differs depending on the strain. The amino acids used were D-Met, D-Phe, D-Ala, D-
Pro, D-Tyr and D-Leu, with D-Met and D-Ala having the greatest effects unlike in 
Staph. aureus. 
A possible way to utilise this information could be to coat medical devices, such as 
catheters, with D-amino acids to prevent initial biofilm formation as it has been 
suggested that the D-amino acids have to be present from the initial stages of biofilm 
formation in order to have an effect [Ramón-Peréz et al 2014]. 
The viability of D-amino acids use to disrupt/inhibit bacterial biofilms is debatable as 
the inhibitory effect of the compounds is strain dependent, and there have been some 
recently published papers which have contradicted the effectiveness of D-amino acids 
on biofilm dispersion [Leiman et al., 2013; Sarkar and Pires, 2015]. 
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The first paper raising doubts about the D-amino acids was Leiman et al [2013] who 
found that the inhibitory effects of D-amino acids on B. subtilis biofilms reported by 
Kolodkin-Gal et al [2010] was caused by a strain-specific mutation. This mutation was 
in the dtd gene. This gene encodes D-tyrosyl-tRNA deacylase and is responsible for 
preventing the misincorporation of D-amino acids into proteins. When this mutation 
was repaired the strain’s biofilm became resistant to the effects of the D-amino acids 
[Leiman et al., 2013]. 
Sarkar and Pires [2015] found that the D-amino acids do not have any effect on the 
inhibition of biofilm formation in Staph. aureus. The original paper by Hochbaum et al 
[2011] used Staph. aureus SC01 which was shown to be sensitive to D-amino acids. 
However, when Sarkar and Pries [2015] used this strain and the published D-amino 
acid concentrations no effects on the biofilms was observed. Even with a 100-fold 
increase in the D-amino acid concentrations no inhibition was seen [Sankar and Pires, 
2015]. Repeating the experiment with B. subtilis and Staph. epidermidis yielded the 
same results suggesting that in fact D-amino acids have no effect on biofilm formation 
and dispersal.  
 
Natural Molecules: Sugar Metabolites 
The influence of sugar metabolites was first reported by Allison et al [2011] who 
discovered that after adding specific carbon metabolites to persister cells, the cells 
revert back into a state against which antibiotics, specifically aminoglycosides, are 
once again effective. 
The way in which this works is that the metabolites are taken up by proton-motive 
force (PMF) into the cell which then also takes up the aminoglycosides. The sugar 
metabolites are taken up by the bacterial cell and enter glycolysis resulting in the 
production of NADH. The NADH is oxidised by electron transport chain enzymes 
which contribute to PMF. The revival of PMF enables aminoglycoside uptake into the 
cell leading to cell death. This effect is only seen with the aminoglycosides and not 
with the other classes of antibiotics tested (β-lactams and quinolones) [Allison et al., 
2011].  
The experiment was conducted on both Gram-negative (E. coli), and Gram-positive 
(Staph. aureus) bacteria and the effect was found in both species. Interestingly in 
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Staph. aureus, only fructose induces the reversion to aminoglycoside sensitivity 
whereas in E. coli, the relevant sugars are mannitol, glucose and pyruvate [Allison et 
al., 2011]. 
Sugar metabolites have also been reported to block adhesion, reduce bacterial load 
(by 38% compared to the control) and inhibit biofilm formation by Staph. aureus on 
endotracheal tubes. Once again fructose was used [Durmus et al., 2012]. 
In Ps. aeruginosa pulmonary infections caused by both mucoid and non-mucoid 
strains, a combination of three sugars, mannose, fructose, and galactose was found 
to have a synergistic effect when combined with conventional antibiotics such as β-
lactams and quinolones. Bucior et al [2013] demonstrated that a mixture of these 
sugars and antibiotics blocked bacterial adhesion and diminished bacterial induced 
cell damage in a murine model of acute pneumonia. 
Side effects would seem to be minimal as the bacterial cells do not revert to a 
metabolically active and thus pathogenic type [Allison et al., 2011; Bucior et al., 2013] 
and the sugars used are naturally found within the body. Adhesion to indwelling 
medical devices could also be reduced, thereby preventing biofilm formation [Durmus 
et al., 2012]. 
Therefore, it seems as the use of sugars, either individually as with Staph. aureus, or 
in combination as with Ps. aeruginosa, could provide an inexpensive simple therapy, 
which could prove a valuable adjunctive to conventional treatment.  
 
Quorum Sensing Targets: Autoinducing Peptides (AIP) 
Regulation of staphylococcal biofilm formation and dispersal occurs through the agr 
quorum sensing system (Figure 1.8) which is activated in response to the extracellular 
concentration of an AutoInducing Peptide (AIP) [Boles and Horswill, 2011; Kiedrowski 
and Horswill, 2011]. 
AIP is a cyclic thiolactone-containing peptide which varies slightly in composition 
depending on the strain which produces it. At low concentrations AIP binds to the 
membrane bound receptor domain of the AgrC histidine kinase activating the AgrCA 
two-component system [Hogan et al., 2015]. Once activated the global gene 
expression is adjusted increasing virulence factor expression and biofilm disassembly 
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[Kiedrowski and Horswill, 2011; Thoendel et al., 2011]. The virulence factors include 
proteases and phenol-soluble modulins (PSMs) which are small pore forming toxins 
[Boles and Horswill, 2011]. Within cells that make up biofilms, agr expression is 
repressed naturally whereas in newly dispersed cells agr activity levels are high [Boles 
and Horswill, 2008]. 
It has been shown that addition of exogenous AIP leads to complete disassembly of 
a biofilm within 20 hours and reversion to a planktonic state with a restoration in 
antibiotic sensitivity [Lauderdale et al., 2009]. However, the activation of the agr 
system with resulting increased expression of virulence factors may trigger the 
conversion of the staphylococcal strain into a more invasive pathogen, with 
associated tissue damage and reactive host immune response. This would be a major 
concern. A combination treatment of agr activation and antibiotic could alleviate this 
concern by eliminating the planktonic cells [Kiedrowski and Horswill, 2011].  
Other concerns include the AIP composition as different staphylococcal species’ 
recognise structurally unique AIPs [Thoendel et al., 2011]. A universal agr activator 
would have to be carefully selected in order to be effective against the majority of 
staphylococcal biofilms. The impact on the host’s innate and adaptive immune system 
function would also have to be considered [Hogan et al., 2015]. 
 
Current Biofilm Models  
 
In order to study biofilm formation, dispersal, antibiotic resistance and effects of 
disruptive molecules, an easy, reproducible and reliable model is required. However, 
the complexity of a biofilm makes reproduction of one, in a laboratory situation, a 
challenge. There are various models which have been developed, these are either 
open (continuous culture) or closed (batch culture) [McBain, 2009]. 
The agar plate is considered an example of a closed system biofilm model. This model 
reproduces some of the biofilm properties such as high cell density and gradients 
within the biofilm; it is useful but simplistic. Other closed systems are 24 well cell 
culture plates into which a disc has been placed; in this way a variety of bacteria and 
48 
 
materials can be investigated [McBain, 2009], and the Calgary Biofilm Device [Ceri et 
al., 1999], this will be discussed in detail further on. 
Open system biofilm models include suspended substratum reactors (SSRs) where 
the biofilms are grown inside fermentation vessels at the solid-liquid interface on 
colonisable materials which can be removed from the vessel at required sampling 
times [McBain, 2009]. SSRs are used to examine dental microbiology [Bradshaw et 
al., 1996], colonic microbiology [McFarlarlane and McFarlarlane, 2006], and to 
investigate gene expression [Whiteley et al., 2001]. 
Rotating reactors for control of shear stress, The Robbins device and flow cells, drip 
fed biofilms, and perfused biofilm fermenters are other examples of open system 
biofilm models and are comprehensively detailed in McBain [2009]. 
The advantages of all these systems are production of high population density 
biofilms, large biomass yields and controlled fluid dynamics, however, the one 
disadvantage they all have in common is that only a few samples can be processed 
or investigated at any one time [Harrison et al., 2010]. The Calgary Biofilm Device and 
MBEC (minimum biofilm eradication concentration) assay was developed to enable 
large numbers of samples to be processed[Ceri et al., 1999]. 
 
The Calgary Biofilm Device  
The rationale behind the development of this device was that the standard Minimum 
Inhibitory Concentration (MIC) testing was designed for planktonic cultures and acute 
infections [Andrews, 2001] and was not effective against chronic or device related 
infections [Ceri et al., 1999]. As biofilms cause a significant number of clinical 
infections an assay was required which could provide relevant and effective antibiotic 
dose recommendations. This is the Minimum Biofilm Eradication Concentration 
(MBEC) [Ceri et al., 2001]. The Calgary biofilm device utilises such an assay and 
involves a standard 96 well plate with a lid which has plastic removable pegs (Figure 







Figure 1.10: Photograph of a Calgary Biofilm Device Plate [Parker et al., 2014]. A 
standard 96 well plate is used as the base and can be filled with medium, antibiotics, 
antiseptics or biocides. The lid contains pegs which slot into the base well and upon which the 
biofilms can form.  
Once formed, washed and transferred these biofilms can then be exposed to 
antibiotics, antiseptics and biocides [Allan et al., 2011]. Studies have been conducted 
for various Gram-positive and Gram-negative bacterial species [Olson et al., 2002]. 
Large numbers of different antibiotics (types and concentrations) can be investigated 
at any one time [Ceri et al., 1999]. A comprehensive protocol has been published by 
Harrison et al., [2010] detailing the method and the parameters and controls required 




Figure 1.11: Formation and Challenge of Biofilms using the Calgary Biofilm Device 
[Adapted from Herrmann et al., 2010]. The formation and challenge of a biofilm on the 
Calgary Biofilm Device involves introducing the pegs into a planktonic culture (A) and 
incubating during which time the biofilm forms (B/C).  After washing, the biofilms are 
transferred to fresh medium and challenged with antibiotics (D) and washed again (E). 
Removal of the biofilm from the peg by sonication (F) followed by serial diluting (G) and plating 
to determine the CFU/ml count (H) and biofilm sensitivity. 
 
However, with all the benefits of the Calgary Biofilm Device there are significant 
disadvantages namely, the difficulty in achieving reproducible results. In fact, only 
minor deviations from the protocol such as using a rotating rather than a tilting 
platform during incubation of the biofilms can majorly affect results [Dall, 2013]. 
Another disadvantage is the removal of the biofilm from the pegs by sonication 
[Harrison et al., 2010]. Sonication is superior to other removal methods such as 
scraping [Bjerkan et al., 2009], but has its own drawbacks, specifically incomplete 
removal of biofilms, and possible damage to cells especially Gram-negative and 
anaerobic bacterial species [Monsen et al., 2009]. 
A significant factor to contemplate when considering using the Calgary Biofilm Device 
is the cost. Variations of the original 96 well plate lid with pegs and base are available. 
These are a trough base or hydroxyapatite coated pegs which facilitate biofilm growth 
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by fastidious microorganisms. The cost of these range from $672.50 to $985 (for 25) 
[Innovotech]. A sonicator would also have to be acquired further increasing the cost 
of this procedure.  
 
The Alginate Bead Method  
In order to develop a cost effective alternative to the Calgary Biofilm Device, a 
previous student in the Gallagher laboratory developed the alginate bead method 
[Dall, 2013]. This method involves using sodium alginate solidified with 2M CaCl2 and 
formed into a bead (Figure 1.12). 
 
Figure 1.12: An Alginate Bead [Dall, 2013]. The beads are formed with 210 μl 4% Sodium 
Alginate within a 96 well plate producing the characteristic oval shape and size. The bead is 
approximately 5.4 mm by 2.7 mm with a surface area of 160.31 mm2. 
It is on this surface that the biofilm forms; once the experiment/antibiotic challenge 
has been completed, the bead is dissolved ensuring that the entire biofilm is 
recovered. Full details of this method can be found in Chapters 2 and 3.  
 
Statement of Need 
Investigating biofilms and the resulting antibiotic resistance is important in light of the 
increasing bacterial resistance these days especially in health care environments.  
Determining an effective antibiotic range for biofilm infections is essential in order to 
treat patients successfully. Even though the Calgary Biofilm Device is well 
characterised and useful there are still drawbacks to it. The primary ones are the cost 
of the equipment and the difficulty in reproducibility. It is hoped that the alginate bead 
method developed by members of the Gallagher lab and fully characterised in this 
study will provide a cost-effective and simple alternative.  
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Aims of This Work 
 
To Investigate: 
 The alginate bead biofilm method and compare it to the established Calgary 
Biofilm Model. 
 The differences in antibiotic resistance between planktonic and biofilm 
Staphylococcus aureus cultures. 
 The development of resistance and consequently the amount of antibiotic 
required to reduce biofilm load of Staphylococcus aureus biofilms. 
 The effects of different antibiotic combinations on Staphylococcus aureus 
biofilms and whether synergy or antagonism between the antibiotics develop. 
 The development of biofilms and resulting antibiotic resistance of different 
heath care associated bacterial species.  
 The development of mixed species biofilms and their effect on antibiotic 
resistance. 
 Disruption of biofilms with natural molecules (sugars metabolites/ D-amino 
acids). 
Chapter 5 relates to bacterial binding proteins and different expression systems and 






























Strains, Plasmids and Oligonucleotides 
Table 2.1: Bacterial and Yeast Strains. 
Strain Details  Source 
Escherichia coli strains for protein expression 
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Lab Stock  
DH5α F– Φ80 lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Lab Stock 
Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1 λ- 
Lab Stock 
Rosetta-gami 2 Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII 
phoR araD139 ahpC galE galK rpsL 
(DE3) F′[lac+ lacIq pro] gor522::Tn10 trxB 
pRARE2 (CamR, StrR, TetR) 
Loake Lab 






Muts, Arg+ Barlow Lab 
Pichia pastoris 
G1107C 
Positive Control for P. pastoris expression Barlow Lab 
Bacterial strains for biofilms 
Staphylococcus 
aureus  
ATCC# 29213 Lab Stock 
Streptococcus mutans 
 
NCTC#10923 Lab Stock 
Klebsiella pneumoniae Clinical Isolate Lab Stock 
Staphylococcus 
saprophyticus 





Clinical Isolate Lab Stock 
Pseudomonas 
aeruginosa B 
Constitutive AlgL producer - mucoid Lab Stock 
Pseudomonas 
aeruginosa G 
Clinical Isolate from patient with 
bronchiectasis 
Govan Lab 
Escherichia coli  ATCC#25922 Lab Stock 
Escherichia coli K12 K12, MG1655 Lab stock 
Streptococcus 
pneumoniae 
Clinical sample Glaxo 
Verona, 
Italy 
Enterococcus faecalis Clinical Isolate from heart valve Lab Stock 
 
Table 2.2: Plasmids. 
Plasmid Relevant Features Source 
pPICZαB Vector containing 
inducible promoter AOX1 
for secretable protein 
expression 
Barlow Lab 
pCPGRP Contains CPGRP gene in 
pPICZαB. Optimised for 
Pichia pastoris 
Gene Art, Invitrogen 
pNirFP-C Allows fusions to the 
NirFP C-terminus 
Evrogen 
pCPGRP-NIR pPICZαB containing 
fusion of CPGRP and 
NirFP 
This Study 
pCPGRP1 (Optimised for 
bacterial growth) 
Contains CPGRP gene in 
pBAD/HisA.  
Gene Art, Invitrogen 
pSP-D Contains SP-D gene in 
pBAD/HisA. Optimised for 
bacterial growth 




Table 2.3: Oligonucleotides. 
 Name Sequence (5’-3’) Relevance 
A 5’AOX Pichia 
sequencing primer 
GACTGGTCCAATTGACAAGC Used to sequence 
construct 
B 3’AOX Pichia 
sequencing primer 
GCAAATGGCATTCTGACATCC  Used to sequence 
construct 
C α-factor Pichia 
sequencing 
CTACTATTGCCAGCATTGCTGC Used to sequence 
construct 
D NIR Plasmid 
forward 
GTGGGAGGTCTATATAAGCA Used to sequence 
construct 
E NIR Plasmid 
reverse 
GGGAGGTTTTTTAAAGCAAG Used to sequence 
construct 
F NIR sequence 
Middle Reverse 
AGATGAGGCAGCCGTTCTGG Used to sequence 
construct 
G CPGRP sequence 
middle reverse 
AATGTTCCAACCTCTACCCT Used to sequence 
construct 
H CPGRP Reverse GGT CCC ACT ACA GAG CTT 
AAT CTA GAA 
Used to sequence 
construct 
I Pichia Primer for 
NIR Forward 
AGAAGGGGTATCTCTCGAGA Used to sequence 
construct 
J NirFP Forward CACCATCATCATGGTACCATGG
GAGAAGGATAGCGAGCTGATC 
For insertion of 
NirFP into pCPGRP 





For insertion of 
NirFP into pCPGRP 
L CPGRP Forward GCACAAATAACGGGTTATTG Used to sequence 
construct 
M CPGRP Reverse CAACTTGAACTGAGGAACAG Used to sequence 
construct 
N SP-D Forward GGGCTAACAGGAGGAATTAAC
C 
Used to sequence 
construct 




Bacterial Growth and Storage Conditions 
 
Bacterial and yeast strains were stored long term at -80°C, taken from a 5 ml overnight 
culture and mixed at a ratio of 1:1 with 20% glycerol. The cultures were revived by 
streaking onto appropriate agar, with antibiotic if required. Short term storage on an 
appropriate agar plate stored at 4°C for no more than 10 days.  
Unless otherwise stated, overnight cultures were prepared by inoculating 5 ml of 
appropriate medium, with antibiotics if required, with a single colony from a plate. 




TAE (Tris-acetate-EDTA): 242 g Tris base (FW121.14), dissolve in 750 ml dH2O. Add 
57.1 ml glacial acetic acid and 100 ml 0.5M EDTA. Adjust to final volume of 1l. Store 
at room temperature. Working concentration of 1xTAE. 
Biofilm solutions were: 
Gelating agent: to make a 2M CaCl2 solution mix 29.4 g into 100 ml dH2O 
and autoclave to sterilise. 
To make the alginate beads mix 4 g of sodium alginate into 100 ml dH2O and 
autoclave to sterilise. 
Dissolving buffer: To make a 10x stock solution dissolve 5.3 g NaCO3 and 5.2 
g citric acid in 100 ml dH2O and filter sterilise. 
Universal neutraliser: Dissolve 1 g histidine, 1 g cysteine, and 2 g reduced 
glutathione in 20 ml dH2O. Filter sterilise and store at -20°C in 1 ml aliquots. This is 





Biofilm Set up 
Preparation of alginate beads: Using a 96 well plate pipette 20 μl 2M CaCl2 into each 
well, 210 μl 4% sodium alginate followed by 20 μl 2M CaCl2. The sodium alginate 
must be pipetted slowly due to its viscous consistency.  Replace the lid and incubate 
for 4 hours at 60°C to set the beads. Store at 4°C for up to a week. 
Growing the biofilms: Using a 48 well plate and an overnight culture, 600 μl LB 
containing 1/10 000 overnight culture, diluted in fresh medium (~104 CFU/ml), was 
pipetted into the wells. Alginate beads, after been washed in sterile water using flamed 
wire and forceps were added to the wells. The plate was incubated at 37°C, 150 rpm 
for the required time. Triplicate beads are used for each condition. 
After incubation the beads were transferred, using flamed forceps, into 600 µl dH2O 
in a 48 well plate for washing. They were then placed into fresh medium with antibiotic 
if required by the experiment. Incubate at 37°C for the determined challenge time. At 
the required sampling time the beads were removed and rinsed in 600 µl dH2O in a 
48 well plate before being dissolved in 2 ml dissolving solution in a 15 ml falcon tube 
(with universal neutraliser if required). The beads were crushed with a sterile loop 
handle. Controls of beads in LB and plain LB were always included to show no 
contamination. If there was any growth on these plates the experiments were 
repeated. 
An example plate is shown: Testing of antibiotic against biofilm growth time. The 
beads were incubated for the shown time, after which the beads were washed and 
placed into fresh medium with the antibiotic at the appropriate concentration added to 
wells 1-3 for 2 hours challenge. The beads were then washed and dissolved. Control 
beads (wells 4-6) were not supplied with antibiotics. 


























For some experiments the beads were not washed and placed into fresh medium 
between incubation and antibiotic challenge. Instead the antibiotic was added directly 
into the wells.  
Planktonic cultures were set up in the same manner, antibiotic was added directly to 
the wells and samples were taken and diluted as with the biofilm cultures.  
Counting the organisms: In order to assess the level of growth on the beads, they 
were placed in 2 ml of dissolving solution, with universal neutraliser as required, in a 
15 ml falcon tube crushed with the bottom of a sterilised metal loop and rotated until 
dissolved. After vortexing for 10 seconds, a sample was taken and 10 fold diluted, 6-
8 times, with PBS in a 96 well plate. Using the Miles Misra method the cultures were 
spotted onto plates (20 µl spots) and incubated at 37°C overnight or until colonies 
grew. The plates were not incubated for more than 48 hours. 
To calculate the CFU/ml bacterial load of each bead N = (C.V)/D was used. Where C 
is the number of colonies, spots were counted if they contained between 2 and 30 
colonies. V is 250 (to account for the 2 ml dissolving solution) and D is the dilution 
factor. For planktonic culture CFU calculations V is 50.  
For the graphs, CFU/ml was plotted against growth time, challenge time, antibiotic 
concentration or bead condition depending upon the experiment. Error lines of 
standard deviation were used. The detection limit of the assay is ≤50CFU/ml and is 
plotted as a black dashed line on the graphs.  
 
Sonicating Probe and Water Bath 
For dislodging the biofilms from the beads using the sonicating probe (Ultrasonic 
Processer) the following protocol was used. The beads, after washing were placed in 
a short plastic container in 2 ml dissolving solution. The container was placed on ice 
while sonication was carried out. The sterile probe was inserted into the solution and 
the bead sonicated for the required time. The probe was sterilised by wiping with 70% 
ethanol. The solution was vortexed before a sample was taken. From that point the 
samples were treated in the same manner as described above.  
When using the sonicating water bath (Decon F5 Minor, Ultrasonic Ltd) the beads 
were placed in a 48 well plate containing 600 μl dissolving solution, after the 
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experiment had been concluded. The plates were sealed with Parafilm to prevent 
leakage and/or contamination. The well plate was placed in the water bath under the 
water line but not completely submerged. After the required sonicating time the bead 
and surrounding liquid was transferred to a 15 ml falcon containing 1.4 ml solution. 
This was vortexed and sampled. The sample was treated as described above.  
 
Determination of Minimum Inhibitory Concentration (MIC) 
The antibiotic concentrations required were determined either by growth on an agar 
plate or in liquid medium. For either determination a range of concentrations were 
used based around a commonly used or manufacturers recommended concentration. 
LB agar was used which had been melted and cooled before the antibiotic was added. 
The plates were poured and allowed to set before been streaked with the test 
organism. The plates were incubated overnight at 37°C. The inhibitory concentration 
was determined by growth or no growth on the plates.  
For determining the MIC in liquid culture, a 48 well plate was used (triplicate wells per 
concentration). 600 μl of a diluted overnight culture in fresh LB (~104 CFU/ml) was 
pipetted into the wells and the plate incubated for 3 hours at 37°C, with shaking 
(150rpm). After three hours growth the different antibiotic amounts were added to the 
wells. The plates were incubated for a further 2 hours before samples were taken, 
serially diluted and plated onto LB plates which were incubated overnight (37°C). The 




Yeast Peptone Dextrose (YPD): 10 g yeast extract, 20 g peptone, 20 g dextrose (D-
glucose) and 20 g agar if required for solid medium. Dissolve in 1 litre dH2O. Final pH 
6.5± 0.2 at 25°C. Autoclave to sterilise.  
Yeast Peptone Dextrose Sorbitol (YPDS): 10 g yeast extract, 20 g peptone, 20 g 
dextrose (D-glucose), 182.2 g sorbitol and 20 g agar if required for solid medium. 
Dissolve in 1 litre dH2O. Final pH 6.5±0.2 at 25°C. Autoclave to sterilise. 
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Luria Bertani (LB): 10 g Tryptone, 10 g NaCl, 5 g yeast extract, 15 g agar if required 
for solid medium. Dissolve in 1 litre dH2O. Autoclave to sterilise.  
Low salt LB: 10 g Tryptone, 5 g NaCl, 5g Yeast extract, 15 g agar if required for solid 
medium. Dissolve in 1 litre dH2O. Autoclave to sterilise. For use with Zeocin to culture 
E. coli containing pPICzαB, pCPGRP or pCPGRP-NirFP.  
Stationary Phase Medium: LB inoculated with Staph. aureus and grown at 37°C, 
200rpm overnight. Spin down and remove cell pellet. Filter sterilise supernatant and 
use as normal. Prepare fresh before every use. 
Mueller-Hinton (MH) Broth 2 (cation-adjusted): Commercial mix containing 17.5 g 
casein acid hydrolysate, 3 g Beef Extract, 1.5 g Starch. Dissolve in 1 litre dH2O. Final 
pH 7.3 ± 0.2 at 25°C. Autoclave to sterilise according to the manufacturer’s 
instructions. 
Buffered Glycerol/Methanol complex medium (BMGY/BMMY). For P. pastoris 
expression. 
 1% yeast extract 
 2% peptone 
 100 mM potassium phosphate 
 1.34% Yeast Nitrogen Base (YNB) 
 4x10-5% biotin 
 1% glycerol or 0.5% methanol (use methanol when expressing) 
Dissolve 10 g yeast extract and 20 g peptone in 700ml dH2O. Autoclave and cool to 
room temperature. Add 100 ml 1M potassium phosphate, 100ml 10xYNB, 2ml 500x 
biotin and 100 ml 10x glycerol or 10x methanol. Store at 4°C, shelf life 2 months. More 
details can be found in the Pichia pastoris Expression Kit User manual by Invitrogen 
[2010b]. 
 
Chemicals, Enzymes and Antibiotics 
 
Unless otherwise stated, all chemicals and antibiotics were purchased from Sigma-
Aldrich Co. Zeocin was purchased from InvivoGen, ciprofloxacin and daptomycin from 
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LKT Laboratories Inc. Clindamycin and linezolid were bought from the Cayman 
Chemical Company. SYBR safe DNA gel stain was purchased from Invitrogen. 
Restriction enzymes, T4 DNA ligase, high fidelity DNA polymerase and molecular 
weight markers were purchased from New England Biolabs (NEB).  
Dinucleoside triphosphates (dNTPs) were purchased from Roche. All kits including 
plasmid mini prep, midi prep, gel purification and PCR purification kits were from 
Qiagen and used as per manufacturer’s instructions. For extraction of yeast DNA a 
Wizard Genomic DNA Purification Kit (Promega) was used. Agarose for DNA gels 
and acrylamide for SDS PAGE gels was purchased from Severn Biotech Ltd. 
 
Molecular Weight Markers 
For agarose gel electrophoresis 100 bp and 1 kb DNA ladders were used. For the 
SDS-PAGE gels a prestained protein marker, broad range (7-175 kDa) was used. 
 
D-Amino Acids 
D-Phenylalanine, D-Proline and D-Tyrosine were purchased from Sigma-Aldrich. 
They were dissolved in dH2O to 0.1M stock. D-Tyrosine requires NaOH to fully 
dissolve. Store stock at 4°C.  
 
Enzymes 
For insertion of CPGRP into pPICZαB EcoRI and XbalI were used  
KpnI and SacII used for the digestion of pCPGRP and NirFP for ligation.  
SalI to digest pCPGRP-NirFP for chromosomal insertion into P. pastoris 







Table 2.4: Antibiotics. 
Antibiotic Solvent Stock 
concentration 
Working concentration 
Carbenicillin dH2O 50 mg/ml 100 g/ml 
Ciprofloxacin Dilute HCl 10 mg/ml * 
Clindamycin EtOH 0.5 mg/ml * 
Daptomycin  dH2O 1 mg/ml * (supplement with 50 g/ml 
CaCl2) 
Gentamicin dH2O 10 mg/ml * 
Kanamycin dH2O 50 mg/ml 50 g/ml 
Linezolid EtOH 1 mg/ml * 
Rifampicin MeOH 17 mg/ml * 
Vancomycin dH2O 10 mg/ml * 
Zeocin  dH2O 100 mg/ml 25 g/ml for E. coli (low salt 
LB) 
100 μg/ml P. pastoris 
(YPD) 
*The working concentrations of these antibiotics are dependent upon the bacterial strain used. Specific 
concentrations used are stated with the results. 
Dissolved in solvent and filter sterilised through a 0.22 m filter.  
Preparation of DNA 
 
Kits were purchased from Qiagen and used according to the manufactures 
instructions. Plasmid mini-preps from the E. coli strains were prepared from 5ml 
overnight cultures in LB broth, with antibiotics as required. DNA was stored at -20°C 
until required.  PCR clean up and gel extraction kits were used as required and 
according to the manufacturer’s instructions. 
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DNA was extracted from P. pastoris using the Wizard Genomic DNA Purification Kit 
from Promega according to the manufactures instructions.  
To confirm correct insertion of constructs a DNA sample to was prepared to between 
500-600 ng in 30 μl dH2O (20ng/μl) and sent with suitable primers to Dundee 
Sequencing Services at the University of Dundee.  
 
Nucleic Acid Manipulation 
 
Polymerase Chain Reaction 
For PCR amplification of DNA fragments, a standard reaction was as follows 
                                                  Volume per reaction 
5x PCR buffer        5μl 
dNTPs (200μM)             0.5μl 
Forward primer (0.5μM)    1μl 
Reverse primer (0.5μM)    1μl 
DNA       1μl 
dH2O             16.5μl 
Final volume    25μl 
When using Phusion (NEB) high fidelity polymerase, the following programme was 
used (with modifications depending upon the melting temperature of the primers) 
Initial denaturation  98°C  1min 
Denaturation   98°C  10sec 
Annealing   62°C  20sec  30 cycles 
Extension   72°C  15sec   
Final extension  72°C  5 min 
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To confirm transformation success colony PCR was carried out. A small amount of 
bacterial colony was added to 100μl of dH2O, and vortexed. 1μl of this mixture was 
added to the PCR mixtures.  
To visualise DNA, agarose gels were used. The agarose was dissolved in 1xTAE 
buffer with SYBR Safe added at a concentration of 1:10 000. Gels were run at 80-
110V (depending on gel size) and imaged using an Epi Chemi II Darkroom (UVP 
Laboratory Products). For the P. pastoris experiments a 0.8% gel was used and for 
all other experiments a 1% gel was used. 
 
Restriction Digestion 
The following standard mixture was used for restriction digestions 
Enzyme  0.5 μl 
Buffer      2 μl 
DNA    10 μl 
dH2O   8.5 μl 
Final volume   20 μl 
Reactions were incubated at the temperature and time recommended by NEB. High 
fidelity enzymes were used when possible. Reactions were either heat denatured or 





A ratio of 1:5 (vector: insert) was used as standard, however 1:7 ratio mixtures were 
occasionally set up the maximise chances of ligation. Reactions were incubated at 
room temperature for 2 hours or 16°C overnight.  The T4 Ligase buffer was aliquoted 




The following standard mixture was used for ligations 
T4 DNA Ligase  0.5 μl 
Buffer       1 μl 
Vector DNA      2 μl 
Insert DNA    10 μl 
dH2O    6.5 μl 




To make electrocompetent bacterial cells: 1000 ml LB broth was inoculated with a 
1/100 dilution of an overnight culture and grown to OD600nm of 0.4 before transferring 
to ice for 30 minutes. Cells were pelleted at 12 000 rpm and washed three times in 
200 ml ice-cold 10% glycerol. Cold conditions were maintained throughout. After the 
last wash the pellet was re-suspended 1:1 in 10% ice cold glycerol and aliquoted into 
50 μl volumes before snap-freezing in an ethanol and dry ice bath. Cells were stored 
at -80°C until required.  
For electroporation the cells were thawed on ice, DNA was added and left to incubate 
for 15 minutes on ice before been transferred to a chilled electroporation cuvette 
(Molecular BioProducts). The cells were shocked using a Bio-Rad Gene Pulser at 
1.5V. 450 μl LB broth was added to the cells and incubation at 37°C, 150 rpm for 1 
hour was carried out before 100 μl was plated. The remaining culture was pelleted 
and re-suspended in 100 μl LB broth, this was also plated, onto LB agar containing 
the appropriate antibiotic. 
To make chemically competent bacterial cells, 100 ml of LB was inoculated with a 
1/100 dilution of an overnight and grown to OD600nm of 0.4 and centrifuged at 12 000 
for 1 minute. The pellet was re-suspended in ice-cold 0.1M CaCl2 and incubated on 
ice for 30 minutes. Cells were pelleted and re-suspended in 100 μl 0.1M CaCl2. 5-10 
μg of DNA was added and mixture was incubated on ice for 30 minutes. Cells were 
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heat-shocked in a 37°C water bath for 5 minutes. 900 μl of LB was added before 
incubation for 1 hour at 37°C. Plated as above. 
In order to transform P. pastoris the cells were made electrocompetent though the 
use of sorbitol. An overnight culture was grown and used to inoculate 500ml of fresh 
YPD. Cells were grown overnight to an OD600 of 1.3-1.5. In order to measure this 
accurately, if the culture sample was over OD600 1, it was diluted. This was done for 
all OD readings. 
Cells were pelleted at 1500 g for 5 minutes at 4°C and washed with 500 ml ice cold 
dH2O. They were centrifuged again and re-suspended in 250 ml ice cold dH2O 
followed by two more spins to re-suspend in 20 ml and 1 ml ice cold 1M sorbitol for a 
final volume of ~1.5 ml. The cells were mixed with 5-20 μg linearised DNA and 
shocked at 2.5V (Bio-Rad Gene Pulser) to transform. 1 ml ice cold 1M sorbitol was 
added and the solution was transferred to a 15 ml falcon tube. Incubate without 
shaking for 2 hours. Plate 50-200 μl aliquots onto YPDS plates containing 100 μg/ml 
zeocin. Incubate at 30°C for 2-3 days until colonies appear. Screen for insertion. Full 
details of all Pichia pastoris methods can be found in the Pichia Expression Kit User 
manual [Invitrogen, 2010b] and the pPICZα A, B, and C User Manual by [Invitrogen, 
2010c]. 
 
Expression from Pichia pastoris 
 
The standard protocol was used initially however, as that did not yield any protein the 
method was altered in an attempt to express/detect expression. 
This is the protocol taken from the User manual [Invitrogen, 2010b]. Baffled flasks 
should contain no more that 30% culture of the total flask volume to ensure adequate 
aeration. Cultures used were KM71wt (control), pCPGRP and pCPGRP-NIR. From a 
single colony inoculate 25 ml BMGY, grow at 30°C until OD600 2-6. Once the correct 
OD was reached the cells were harvested (1500xg, 5 minutes) and resuspended in 
BMMY to induce expression. 100% methanol was added to a final concentration of 
0.5% (v/v) every 24 hours to maintain expression. 1 ml samples were taken and spun 
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down at 14000 rpm for 2 minutes, both the supernatants and the pellets were retained 
and stored at -80°C. Samples were analysed by SDS-PAGE gels and Western Blots.  
This protocol was supplied by the lab which supplied the strains. Inoculate 5 ml BMGY 
with a single colony and grow at 30°C for 24hrs. Add 95 ml BMGY and grow for a 
further 60 hours. Harvest cells and resuspend in 25 ml BMMY, incubate at a reduced 
temperature of 18°C for 5 days. Add 125 ml methanol once on the second and third 
days, then twice on the fourth day (morning and evening). Harvest on the fifth day.  In 
later cultures sorbitol was added with the methanol to encourage expression 
Larger culture volumes were set up with 50 ml samples taken to purify on Ni-NTA 
Magnetic Agarose Beads using the poly-His tag on the plasmid.  
 
Expression from Escherichia coli 
 
CPGRP and SP-D were cloned into pBAD/His A to test for expression in different E. 
coli strains. Once transformed, expression was as follows. A colony was used to 
inoculate 5 ml LB (with 50 μg/ml ampicillin) and grown overnight at 37°C until OD600 
= 1-2. Inoculate 10 ml LB (containing antibiotic) and grow until OD600 = 0.5. Remove 
1 ml as a 0 hour sample. Add arabinose to induce expression and sample at set times. 
Centrifuge, remove supernatant and store pelleted samples at -20°C until required.  
Refer to the pBAD/His A manual [Invitrogen, 2010a] for more information. 
 
Purification on Ni-NTA Magnetic Agarose Beads (Qiagen) 
Wash Buffers 
Wash 1: 0.606 g Tris, 1.75 g NaCl, 0.1 ml Tween, 0.034 g imidazole, 20 µl β-
mercaptoethanol. Dissolve in 50 ml dH2O and filter sterilise. 
Wash 2: 0.606 g Tris, 0.3 g NaCl, 0.1 ml Tween, 0.034 g imidazole, 20 µl β-
mercaptoethanol. Dissolve in 50 ml dH2O and filter sterilise. 
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Elution Buffer: 0.606 g Tris, 0.3 g NaCl, 0.1 ml Tween, 1.7 g imidazole, 20 µl β-
mercaptoethanol. Dissolve in 50 ml dH2O and filter sterilise. 
Add samples to beads and rotate overnight at 4°C in a falcon tube. Using a magnetic 
rack draw off supernatant, resuspend beads in wash or elution buffers. Use 50-100 µl 
bead resin to 5 ml sample, 400 µl for the washes and no less than 50 µl for the elution. 
Buffers should be made fresh for every use. Used beads can be stored in 30% EtOH 
at 4°C until regenerated.  
 
Centricon Plus-70 (10K) Centrifugal Filter Devices 
 
The Centricon Plus-70 (10K) Centrifugal Devices were purchased from Millipore. 
Duplicate supernatants from expression using the Barlow Protocol were used to give 
50ml to spin down. Before the supernatant was passed through the columns it was 
filter sterilised (0.45 μm) to remove any remaining cell debris. A swinging bucket 
centrifuge was required and the columns were pre-rinsed using 70 ml dH2O. The 
supernatant was spun down using 3500 xg for 30 minutes to give ~400 μl. Aliquot and 
freeze at -80°C until required. Further information can be found at 
http://kirschner.med.harvard.edu/files/protocols/Millipore_centricon70.pdf. 
 
Lysis of Pichia pastoris Cell Pellet 
 
Buffer: 0.44g NaCl,  
40µl β-mercaptoethanol, 
50µl leupeptin,  
50µl peptatin,                From a 5mg/ml stock 
50µl AEBSF 
Dissolve in 50 ml TrisHCl, pH 7.8  




1. Add 1 volume ice cold lysis buffer and 3 volume zirconia beads to the cell 
pellet 
2. Vortex the cells for 5x1 min intervals with 1 minute on ice between each vortex 
3. Add 3 volumes of ice cold buffer and vortex briefly. Centrifuge for 20 minutes 
at 4000rpm to collect cell debris and zirconia beads.  
4. Transfer the supernatant to Eppendorf tubes and centrifuge at 14000 rpm for 
20 minutes 
5. Pool supernatant for further use. 
 
SDS-PAGE gels and Western Blots 
 
Acrylamide gels were prepared as set out in Laemmli [1970]. Gels were prepared with 
a final concentration of 5% w/v (stacking) and 10% w/v (separating) bis-acrylamide. 
The gels were prepared to the following recipe. APS and TEMED were the last 
ingredients to be added to the mixture to prevent premature setting. 
 
Separating gel (10%) – makes 2 gels 
dH2O    2.8 ml 
40% bis-acrylamide    2 ml 
Separating buffer    3 ml 
10%SDS    80 l 
10%APS   80 l 






Stacking gel (5%) – makes 2 gels  
dH2O    2.5 ml 
40% bis-acrylamide  0.4 ml 
    Separating buffer      1 ml 
    10%SDS       40 l 
    10%APS       40 l 
    TEMED       4 l 
Solutions Required: 
Separating buffer (1.5M Tris HCl at pH 8.8): 90.8 g Tris in 450 ml dH2O. Adjust pH 
using HCl and bring volume up to 500 ml. 
Stacking Buffer (0.5M Tris HCl at pH 6.6): 30.5 g Tris in 450 ml dH2O. Adjust pH to 
6.8 and bring volume up to 500 ml. 
APS: Ammonium persulfate. Make up a 100 mg/ml solution. Store at 4°C for no more 
than 14 days. 
5x Running Buffer: 30 g Tris, 144 g Glycine, 10 g SDS in 2 l dH2O 
Coomassie Brilliant Blue Stain: 25 ml methanol, 35 ml acetic acid in 500 ml dH2O. 
Pinch of Coomassie Brilliant Blue. 
Coomassie Blue Destain: 100 ml methanol, 140 ml acetic acid in 2 l dH2O. 
Western blot transfer buffer: 3 g Tris, 200 ml methanol, 14.4 g glycine in 1 l dH2O. 
Blocking Solution: 5 g Marvel skimmed milk powder and 0.25 ml Tween20 in 100 ml 
1xPBS. 
PBS-Tween: 250 μl Tween20 added to 500 ml 1x PBS. 
Antibody: His-probe (H-3): sc-8036 HRP, Santa Cruz Biotechnology. 1:500 dilution in 
blocking solution.  





Pelleted samples were re-suspended in 1xSDS-PAGE loading buffer before boiling 
for 10 minutes. 1xSDS-PAGE loading buffer was added to the supernatant samples 
before boiling for 10 minutes. Electrophoresis was carried out in 1x Running Buffer. 
Gels were run at 120-180 V depending on level of separation until the loading dye 
was at the bottom of the glass plates. Proteins were transferred from SDS-PAGE gels 
onto nitrocellulose membrane (GE Healthcare) using a semi-wet transfer system 
(BioRad). 
The gel was placed on three pieces of blotting paper pre-soaked in Western Blot 
Transfer buffer. The nitrocellulose membrane was equilibrated by dipping in transfer 
buffer and placed onto of the gel. A further three layers of pre-soaked blotting paper 
was placed on top of the membrane and the stack rolled flat to remove any air 
bubbles. Run at 200 mA (10 V) for ~90 minutes. 
Post transfer, membranes were incubated for one hour in blocking solution to prevent 
non-specific binding. After this, membranes were washed in PBS-Tween (4x5 
minutes) and incubated with the antibody solution (1:500 dilution) for 2 hours. Wash 
again in PBS-Tween (4x5 minutes). 
Western blots were developed with ECL chemiluminescene kit (Millipore). Equal 
amounts of the reagents were mixed together and poured over the entire surface of 
the nitrocellulose membrane. This was left for no more than three minutes, based on 
the manufacturer’s instructions. The blot was imaged with no light, long exposure 




















Chapter 3:  
Investigating the Alginate Bead Method as an 
Alternative to the Calgary Biofilm Device and 








The Calgary Biofilm Device and MBEC Method 
The Calgary Biofilm Device [Ceri et al., 1999] was developed in response to the need 
to have an accurate measurement of the concentration of antibiotic required to 
significantly affect a biofilm. Before this, the Minimum Inhibitory Concentration (MIC) 
was the standard measurement used for treatment of infections.  
However, this measurement is obtained by determining the concentration of antibiotic 
effective against actively growing planktonic cultures and is used as the 
recommended dosage in the treatment of many acute infections [Andrews, 2001]. 
As has been detailed in Chapter 1, biofilms are communities of cells attached to a 
surface and each other, and embedded in a protective extracellular polymeric matrix 
(Costerton et al., 1987; Lister and Horswill, 2014]. Biofilms have many protective 
properties including prevention of clearance by the host immune response, protection 
against harsh environmental conditions and most importantly, resistance to antibiotics 
[Archer et al., 2011].  
Due to these properties antibiotic MIC values, when used for the treatment of chronic 
and device related infections, often have little to no value, resulting in treatment failure 
[Costerton et al., 1995]. 
There are various other models and techniques which replicate biofilms to some 
extent, the most significant of which is the modified Robbins device (MRD) which has 
being used for investigating biofilm physiology and antibiotic and disinfectant 
susceptibility. The main disadvantages of this device are the small number of samples 
that can be processed at any one time, the nutrient gradient which develops along the 
length of the device, and its unsuitability for rapid testing in a clinical environment [Ceri 
et al., 1999; Hall-Stoodley et al., 1999]. 
These are the reasons the Calgary Biofilm Device was developed and why it is used 




Chapter 1 details the Calgary Biofilm Device and MBEC Assay but the procedure is 
summarised here. The Calgary Biofilm Device consists of a lid with 96 pegs (Figure 
1.10) which fits into a standard 96 well plate. A bacterial inoculum is introduced to the 
pegs which are then incubated on a rocking table at 35°C for the required time to 
allow the biofilms to form. The lid can then be transferred to other bases containing 
antibiotics, antiseptics or disinfectants for set times to challenge the biofilms [Allan et 
al., 2011]. The pegs are washed before and after exposure to the challenge medium 
to remove any non-adherent cells and residual antibiotics [Harrison et al., 2010].  
The biofilms are then removed from the pegs either individually by breaking them from 
the lid and sonicating, or from all the pegs at once though sonication. The viability of 
the biofilms is determined either by plate counts or by reading the turbidity at 650nm 
after a period of growth in a plate reader. 
There are many advantages to the Calgary Biofilm Device, the main one is the ability 
to process multiple samples at any one time. However, there are also disadvantages 
including the difficulty in reproducibility and the cost of the device [Dall, 2013; Harrison 
et al., 2010]. 
A cost effective alternative which is based on the submerged substratum model has 
been developed by a previous student in the Gallagher laboratory [Dall, 2013]. This 
method consists of sodium alginate beads (Figure 1.12) on which the biofilms form, 
and which can subsequently be dissolved to recover viable bacteria. Formation of 
stable biofilms have been confirmed on the beads though cryo-scanning electron 
microscopy (Figure 3.1). The results from the electron microscopy show that within 2 
hours ~10% of the alginate bead surface was colonised with Staph. aureus biofilms 








Figure 3.1: Cryo-SEM Images of Stable Biofilms on Alginate Beads [Dall, 2013]. The 
images were taken perpendicular to the alginate bead and show EPS secreted by and 
encasing the Staph. aureus colonies. The image on the right is in 3-D.  
 
The Alginate Bead Method 
The beads are formed by solidifying sodium alginate with 2M CaCl2 though pipetting 
20 μl 2M CaCl2 into each well of a 96 well plate, adding 210 μl of sterile 4% sodium 
alginate (w/v), followed by 20 μl 2M CaCl2, under aseptic conditions. The plate is 
covered and incubated for 4 hours at 60°C to set the beads. These beads can be 
stored at 4°C for up to a week. The basic shape of the bead is determined by the 96 
well plate in which it is formed (Figure 1.12). The beads have an average surface area 
of 160.31 mm2 [Dall, 2013].  
For the following experiments, the beads were removed from the 96 well plate using 
a sterile wire and flamed forceps, individually washed in dH2O (using a 48 well plate) 
and placed in a 48 well plate. Overnight bacterial cultures were diluted in fresh 
medium to ~104 CFU/ml and 600 μl was pipetted into the wells containing the beads. 
The plates were incubated at 37°C, with shaking (150 rpm) for the required time to 
allow the biofilms to form. Triplicate beads were used for each different condition and 
controls to test for sterility were always included.  
There are both advantages and disadvantages with this method. The major 
advantages are the low cost and easy procedures. Most of the reagents and 
equipment required are cheap, and present in many laboratories or easily obtainable. 
A disadvantage would be that the process is labour intensive. However, levels of 
reliability and reproducibly are high.  
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Comparisons are made between the two methods in terms of recovery of biofilms, 
medium used and dissolving solutions.  
 
Rationale behind Antibiotic Choices Tested against Staphylococcus aureus 
Biofilms 
The antibiotics used for the following experiments are detailed in Chapter 1 and are 
based on those in use in current clinical practice for the treatment of prosthetic joint 
infections [Nandi et al., 2009; Zilberman and Elsner, 2008]. A previous student in the 
Gallagher laboratory had investigated them in regards to orthopaedic infections 
specifically antibiotic loaded acrylic bone cements [Dall, 2013].  
 
Aims of this Chapter 
 
 To determine whether the alginate beads influence biofilm formation and the 
length of time it takes for biofilms to develop. 
 To compare the Calgary Biofilm Device method to the alginate bead method 
using different biofilm recovery techniques, media, and bead dissolving 
solutions.  
 To examine the different gentamicin concentrations required to affect 
planktonic cultures and biofilms of the same age. 
 To investigate the development of gentamicin resistance over 24 hours of 
Staphylococcus aureus biofilms. 
 To examine how Staphylococcus aureus biofilms are affected by commonly 
used antibiotics used to treat staphylococcal infections.  
 To explore what the effects are when gentamicin is combined with other 






Stable Formation of Biofilms Occurs Within Four Hours 
 
The use of alginate beads for the formation of biofilms has already been demonstrated 
[Dall, 2013]. However, like most publications which report on biofilm related 
investigations, Dall [2013] examined biofilms which had been grown for 24 hours or 
more. The initial formation (within a few hours of incubation) of biofilms needs to be 
examined in terms of how quickly the bacterial cells attach and how long after 
incubation the biofilm becomes firmly established.  
The biofilms were developed using overnight cultures diluted to ~104 CFU/ml to 
inoculate triplicate alginate beads for each time point in 48 well plates. The well plates 
were incubated at 37°C, with shaking (150rpm) for the required time (0.5, 1, 2, 3, and 
4 hours). After removal under aseptic conditions, the beads were washed and 
dissolved in 2ml dissolving buffer. This solution was sampled, serially diluted and 
plated. The CFU/ml counts were calculated as previously described. Controls of 
beads in LB and plain LB were always included. If any contamination was present in 
these, the experiments were repeated. 
It can be seen from Figure 3.2 that Staph. aureus biofilms form quickly on the alginate 
beads and that attachment is established by four hours growth, as judged by the fact 
the organisms remained attached during the wash stages.  
A preliminary experiment to this was to determine how adherent the biofilm was, 
whether the bacteria were loosely attached or whether attachment was firm. To this 
end three sets of triplicate beads were incubated for two hours in ~104CFU/ml diluted 
overnight culture. The beads were then washed once, twice or three times. The 
CFU/ml count of the beads after 1, 2 or 3 washes was approximately the same 
indicating that the cells firmly attached and starting to form a biofilm (Data not shown). 
As this demonstrates that the alginate beads are a suitable base for biofilm formation, 












Figure 3.2: Stable Formation of Biofilms by 4 hours. Mean CFU/ml counts are plotted 
against time of growth with error bars of standard deviation. Cultures were set up from diluted 
overnight cultures (~104 CFU/ml) with triplicate beads sampled at 0.5, 1, 2, 3 and 4 hours. 
Beads were washed, dissolved, serially diluted and plated as described in Materials and 








Investigating the Alginate Bead Method as an Alternative to the Calgary 
Biofilm Device 
 
One of the perceived points of variation in the Calgary Method is the recovery step. 
When the biofilms are sonicated off the pegs it is unlikely that the entire biofilm is 
removed. Indeed Dall [2013] had considerable difficulty regarding the reproducibility 
of this step. This was one of the reasons why the alginate bead method was 
developed.  
As the beads are crushed and dissolved in the alginate bead method, the entire biofilm 
is recovered; however, the crushing and dissolving is a labour intensive process and 
fairly time consuming. Thus, it was decided that sonication would be experimented 
with to examine how it differed in removal of the biofilm from the bead compared to 
the original crushing method.  
Beads were incubated for 24 hours with diluted overnight cultures (~104 CFU/ml) at 
37°C, 150 rpm, (as described in Materials and Methods), before being washed and 
transferred into short plastic universals in 2 ml dissolving solution. Triplicate beads 
were used for each condition. Initially, an Ultrasonic Processor (Thermo Scientific) 
was used for different times to sonicate the beads. During sonication the universal 
was placed on ice to reduce the heating effect of the machine. After sonication the 
solution was sampled, serially diluted and plated using the Miles Misra method (20 μl 
spots). Spots were counted if they contained between 2 and 30 colonies. 
The CFU/ml was calculated using N= (C.V)/D, where C is the number of colonies, V 
is 250 and D is the dilution factor. Error bars indicate standard deviation from the 
mean of the triplicate beads. Figure 3.3 shows the effect of high intensity sonication 
on the biofilms. 
When examining the graph (Figure 3.3) the bacteria did dislodge but at higher 
sonication times there was reduced recovery. This type of sonicator is commonly used 
to lyse cells which could account for the reduced bacterial counts. The bead structure 
was affected by the sonication with condition 2 beads (1.5 min sonication) dissolving 
by about 80%. Condition 3 beads (1 min sonication) dissolved by about 50% and for 









Figure 3.3: The Effect of High Intensity Sonication on 24 hour old Staphylococcus 
aureus Biofilms.  Mean CFU/ml counts are plotted against different bead conditions with error 
bars of standard deviation. Triplicate beads were incubated for each time points for 24 hours 
at 37°C, 150 rpm. Beads were washed and transferred into 2 ml dissolving solution. Condition 
1: normal method of crushing and dissolving, Condition 2: 1.5 min sonication at 1kHz, 
Condition 3: 1 min sonication at 1kHz and Condition 4: 30 sec sonication at 1kHz. After 
treatment the bead solutions were sampled, serially diluted and plated as described in 






Ceri et al [1999] sonicated the pegs using an Aquasonic machine for 5 minutes on 
high. The specifications of that machine are 120V, 60Hz, 4 Amps, whereas the lowest 
setting on the Ultrasonic Processor is 1 kHz; so there is a huge increase in the amount 
of power applied to the cells. A lower powered machine was therefore explored to 
allow a more accurate comparison of the Calgary Biofilm Device and alginate bead 
methods. 
Additionally, using the Ultrasonic Processor is time consuming as only one sample 
can be treated at any one time. The use of a sonicating water bath (Decon F5 Minor, 
Ultrasonic Ltd, 240V/40kHz) would solve this issue.  
When using the sonicating water bath, the biofilms were grown for 24hrs at 37°C, 150 
rpm before being washed and transferred into a standard 48 well plate containing 600 
μl dissolving solution which was then placed into the water bath. Triplicate beads were 
removed at 5, 10, 15, 20, 25, and 30 minutes (Figure 3.3). The beads and surrounding 
solutions were transferred to 1.4 ml dissolving solution, sampled, serially diluted and 





















Figure 3.4: The Effect of Different Times in a Sonicating Water Bath on 24 Hour Old 
Staphylococcus aureus Biofilms. Mean CFU/ml counts are plotted against different bead 
conditions with error bars of standard deviation. Triplicate beads were incubated for each time 
point for 24 hours at 37°C, 150 rpm. Beads were washed and transferred into 600 μl dissolving 
solution in a 48 well plate which was then placed in the sonicating water bath for 5 (1), 10 (2), 
15 (3), 20 (4), 25 (5), or 30 (6) minutes at 40kHz. For condition 7, the beads were treated in 
the normal way. After sonication, the beads and surrounding solution were transferred to 1.4 
ml dissolving liquid. This solution was sampled, serially diluted and plated as described in 






Figure 3.4 illustrates that with the lower powered machine, the different sonication 
times do not seem to affect whether the entire biofilm is recovered, with 5 minutes 
sonication (condition 1)  as effective as the normal method of crushing and completely 
dissolving the bead (condition 7). The beads remained intact, however, longer 
sonication times softened their structure. It appears that 5 minutes sonication is an 
acceptable alternative to the original method of crushing. 
The use of the water bath is a viable alternative to crushing and dissolving the beads 
reducing the time and labour required to recover the biofilms. The experiments which 
produced Figures 3.3 and 3.4 used pure dissolving solution as the liquid in which the 
biofilms are recovered. However, this solution is fairly acidic and investigations were 
carried out to examine whether this solution has an effect on cell viability.  
Figure 3.5 shows the effect of different mixtures of recovery liquid for both the original 
method (crushing and dissolving) and for 5 minutes sonication. Two different bacterial 
species were used for these experiments, Staph. aureus (A) and Ps. aeruginosa B 
(B). This Ps. aeruginosa strain is extremely mucoid and a constitutive alginate 
producer; it was included to examine whether this property has any effect on the bead 
composition.  
The beads were incubated at 37°C, 150 rpm for 24 hours in diluted overnight cultures 
(~10-4 CFU/ml) before being washed and placed into the recovery solution. For 
conditions 1-3 the normal method of crushing and dissolving the bead was carried 
out. For conditions 4-6 the beads were sonicated for 5 minutes as previously 
described. For conditions 1 and 4 2 ml dissolving buffer was used, conditions 2 and 5 
used 1ml dissolving buffer and 1 ml medium and conditions 3 and 6 used 2 ml 
medium. LB, which had been used in all previous experiments was used, as was 
cation-adjusted Mueller-Hinton (MH) broth (Figure 3.5). The choice of this medium 
was based on recommendations by the Clinical Laboratory Standards Institute (CLSI) 





Figure 3.5: Comparison of Recovery Solutions and Medium for Staphylococcus aureus 
(A) and Pseudomonas aeruginosa (B) Biofilms. Mean CFU/ml counts are plotted against 
different bead conditions with error bars of standard deviation. Triplicate beads were incubated 
for each time points for 24 hours at 37°C, 150 rpm. Beads were washed and transferred into 
either 2ml liquid and treated in the normal manner (conditions 1-3) or 600 μl liquid in a 48 well 
plate and sonicated for 5 minutes (Conditions 4-6). Conditions 1 and 4: 2 ml dissolving solution, 
Conditions 2 and 5: 1 ml dissolving solution, 1ml medium. Conditions 3 and 6: 2 ml medium. 
After sonication the beads and surrounding solution were transferred to 1.4ml dissolving liquid. 
This solution was sampled, serially diluted and plated as described in Materials and Methods.  
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From Figure 3.5 A, it can be seen that there is no great difference between the two 
medium types. However, the fact that the CFU/ml for condition 3 is slightly higher than 
the CFU/ml for condition 1 is a bit of an anomaly. There is next to no difference 
between the different recovery solutions for Staph. aureus (Figure 3.5 A).  
Regarding Figure 3.5 B the dissolving solution used for recovery (conditions 1 and 4) 
has a lower recovery of CFU/ml than the other conditions. This could be due to the 
acidic nature of the dissolving solution having an effect on cell viability. It seems that 
a 1:1 mixture of dissolving solution and medium is the best recovery solution. The fact 
that sonication was also able to remove the Ps. aeruginosa biofilms from the alginate 
beads show that even an alginate producing bacterial strain is able to form biofilms 
and be removed from the alginate beads.  
As it has now been established that the alginate beads are a suitable alternative to 
use to examine biofilm formation, the development of antibiotic resistance can be 
investigated.  
 
Inhibition of Staphylococcus aureus Biofilms by Gentamicin  
 
Gentamicin is a member of the aminoglycoside class of antibiotics which are 
commonly used in the treatment of staphylococcal infections [Ramirez and Tolmasky, 
2010]. One of gentamicin’s main uses is in the bone cement used for prosthetic joint 
surgeries. A major component of prosthetic joint infections is based biofilm based with 
long term sub-clinical infections as the most common presentation [Stoodley et al., 
2011]. Resolution of infection often requires surgical intervention and prolonged 
antibiotic treatment which severely reduces a patient’s quality of life. In a step to 
prevent infections, Antibiotic-Loaded Acrylic bone Cements (ALACs) are used, these 
contain gentamicin because of its broad antibacterial spectrum and stability at high 






The Differences in Gentamicin Concentrations which Affect Planktonic Cultures 
and Biofilms 
The ineffectualness of an antibiotic MIC on biofilm infections is well documented 
[Andrews, 2001; Ceri et al., 1999]. A direct comparison between the antibiotic 
concentrations required to affect either a planktonic culture or a biofilm is shown in 
Figure 3.6. 
In order to investigate this, overnight cultures were diluted to ~104CFU/ml in fresh LB 
and 600 μl were pipetted into a 48 well plate. Triplicate wells were set up for each 
different concentration. The 48 well plate was incubated at 37°C, 150 rpm. After 3 
hours incubation the designated gentamicin concentrations were added to the wells 
and the plate was incubated for a further two hours. After the challenge the wells were 
sampled, serially diluted and plated.  
The same diluted overnight culture was used to inoculate the alginate beads. 
Triplicate beads were set up for each antibiotic concentration. The beads were 
incubated for 3 hours before being washed and transferred into fresh LB broth with 
the appropriate antibiotic concentration for the 2 hour challenge. Once challenged, 
the beads were washed, crushed, dissolved and sampled as described in the 
Materials and Methods.   
There is a significant difference between the antibiotic concentrations required to kill 
a three hour old planktonic culture compared to a 3 hour old biofilm. Examining Figure 
3.6, it requires 125 μg/ml gentamicin to kill a 3 hour old planktonic culture whereas it 
requires 225 μg/ml to kill a 3 hour old biofilm culture suggesting that the biofilm affords 
protection against the antibiotic action.  
150 μg/ml gentamicin was over the concentration required to eliminate an actively 
growing planktonic culture (Figure 3.6). When this concentration was applied to 
biofilm growth over time, resistance developed after 4 hours. After 24 hours the 
gentamicin is having little effect on the biofilm as seen from the increase in CFU/ml 









Figure 3.6: Gentamicin Concentrations Required to Inhibit 3 hour old Planktonic 
Cultures or 3 hour old Biofilms. Mean CFU/ml counts are plotted against antibiotic 
concentrations with error bars of standard deviation. A) 600 μl diluted overnight cultures were 
incubated for 3 hours at 37°C, 150 rpm before being challenged with different gentamicin 
concentrations for 2 hours. Wells were sampled, serially diluted and plated B) The biofilms 
were incubated for 3 hours at 37°C, 150 rpm before being challenged with different gentamicin 
concentrations for 2 hours. Beads were washed, dissolved, serially diluted and plated as 









The Development of Biofilm Resistance over 24 hours with Different Gentamicin 
Concentrations 
In order, to explore how quickly the Staph. aureus biofilms developed resistance, 
growth curves were carried out with the biofilms challenged by gentamicin. Two 
different gentamicin concentrations were used (Figure 3.7). 
The concentration of gentamicin required to affect and inhibit Staph. aureus biofilm 
growth was determined either by growth at 37°C overnight on agar plates (data not 
shown) or by the concentration required to kill an actively growing planktonic culture 
(Figure 3.6). This latter concentration is considered the MIC and would be the 
standard concentration recommended by a hospital laboratory for the treatment of a 
clinical infection. 
Determination of the MIC is described in the Materials and Methods. The inoculum 
used to develop the biofilms was diluted overnight cultures and averaged ~104 
CFU/ml. 
The alginate beads were incubated at 37°C, 150 rpm for the required growth time 
(0.5, 1, 2, 3, 4, 6, 8 or 24 hours). The beads were removed and washed before being 
placed in fresh medium with the required antibiotic concentration for the 2 hour 
challenge. After this time the beads were washed, dissolved, serially diluted and 












Figure 3.7: Development of Resistance in a Biofilm over 24 hours against 15 μg/ml (A) 
and 150 μg/ml (B) Gentamicin.  Mean CFU/ml counts are plotted against time of growth with 
error bars of standard deviation. Cultures were set up from diluted overnight cultures with 
triplicate beads incubated for the indicated time points as described in Materials and Methods. 
The beads were challenged with either 15 μg/ml (A) or 150 μg/ml (B) gentamicin for 2 hours 
before being washed, dissolved, serially diluted and plated. No antibiotics were added to the 




When cultivating Staph. aureus overnight on an LB agar plate containing 15μg/ml 
gentamicin, there was complete inhibition of growth. However, as can be seen from 
Figure 3.7 A, when the bacteria are actively growing on the alginate beads and 
forming the biofilms, there is low level resistance immediately and after 4 hours 
incubation the gentamicin concentration has a negligible effect on the bacteria. 
The development of resistance with the higher gentamicin concentration of 150 μg/ml 
only occurs between 4 and 6 hours growth. However, resistance increases sharply 
and by 24 hours the CFU/ml counts between the antibiotic challenged beads and the 
control are similar. 
As has been stated before an alginate bead has a surface area of 160.31 mm2 or 
160x106 μm. If a Staph. aureus cell is ~1 μm then 1.6x107 cells are needed for 
complete coverage. However, cells would not form evenly on the bead surface and 
they would naturally clump together (Figure 3.1).  Thus it could be theorised that from 
~104/105 cells biofilms would be forming and developing resistance to the antibiotics.  
When comparing this number with Figure 3.7 A resistance starts to develop from 103 
cells with full resistance at ~107 cells supporting the argument that a biofilm has 
formed. In Figure 3.7 B resistance once again develops by ~107 cells. 
As in a clinical situation, a biofilm infection would only present after an extended 
period of sub-clinical symptoms; a 24 hour biofilm model is more appropriate to use 
to investigate the effective antibiotic concentrations required. 
 
Increasing Gentamicin Concentrations are Required to Affect a 24 hour old 
Biofilm 
As a biofilm develops and establishes itself there is a corresponding rise in the 
antibiotic concentrations required to have a significant effect. The ability to resist 
antibiotic, antiseptic and disinfectant treatments is considered a sign of a mature 
biofilm [Kiedrowski and Horswill, 2011]. In terms of experimental biofilm models this 
is usually deemed to be 24 hours. Therefore, determining antibiotic concentrations 
which affect biofilms at this time is essential.   
Triplicate beads, for each gentamicin concentration, were incubated at 37°C, with 
shaking (150 rpm) for 24 hours. For Figure 3.8 (medium change), the beads were 
washed and placed into fresh medium containing the appropriate gentamicin 
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concentration for the 2 hour challenge. After this time the beads were washed, 
dissolved, serially diluted and plated. Following incubation overnight, the colonies 
were counted and the CFU/ml calculated as described before.  
Without medium change, after 24 hours incubation the beads were not transferred 
into fresh medium, instead the antibiotic was added directly into the wells and the 
plate was incubated for the 2 hour challenge. The decision was made to not change 
the medium as in an infection situation the static biofilm would only have access to 
limited nutrients.  
Figure 3.8: Increasing Gentamicin Concentrations are Required to affect a 24 hour old 
Biofilm (with/out medium change) and Planktonic Cultures. For the medium change: the 
beads were incubated for 24 hours before been washed and transferred into fresh LB with the 
appropriate gentamicin concentration. No Medium Change: The beads were incubated for 24 
hours. The appropriate gentamicin concentration was added directly into the wells. Gentamicin 
concentrations 1: 0 μg/ml, 2: 15 μg/ml, 3: 150 μg/ml, 4: 256 μg/ml and 5: 1024 μg/ml.  After 
the 2 hour challenge, the beads were washed, dissolved, serially diluted and plated as 
described in Materials and Methods. For the planktonic cultures: 600 μl diluted overnight 
culture was incubated for 24 hrs before been challenged with gentamicin. Wells were sampled, 
serially diluted and plated.  CFU/ml counts are plotted against gentamicin concentrations with 




Figure 3.8 (medium change) shows that only the higher concentrations of gentamicin 
had a significant effect on the biofilm load. However, even the highest concentration 
of 1024 μg/ml did not completely eliminate the biofilm, instead only reducing the 
biofilm load by 3 log orders. The CFU/ml counts detected would still cover the majority 
of the bead’s surface suggesting that biofilms are present and are providing resistance 
to the antibiotics. 
A reduced effect is seen in Figure 3.8 (no medium change), with even the highest 
concentration only decreasing the biofilm load by 1.5 logs. This is most likely due to 
the addition of fresh medium reactivating the cells systems and allowing the 
gentamicin to reach its target. The surrounding planktonic culture in Figure 3.8 (no 
medium change), may also provide a protective effect in that the gentamicin would 
first affect the free floating bacterial cells before moving onto the biofilm at a lower 
concentration. The planktonic cultures included on this graph were taken from the 
same overnight culture which was used to inoculate the beads. The resistance profile 
for the planktonic culture falls between the two biofilm cultures (with/out medium 
change), with the highest concentration reducing the bacterial load by 3 log orders. It 
would seem logical that after 24 hours the cells are well into stationary phase and 
more or less metabolically inactive and thus the antibiotic would not have a strong 
effect. 
 
Development of Resistance of Staphylococcus aureus Biofilms to Other 
Antibiotics over 24 hours 
 
Having observed that the gentamicin resistance develops quickly and by 24 hours has 
a negligible effect on biofilms, the next logical step would be to compare if and how 
antibiotic resistance develops for other antibiotic classes. The antibiotics were 
selected based on a previous student’s work on orthopaedic infections and antibiotic 
loaded acrylic bone cements [Dall, 2013]. The method followed is the same as that 




Figure 3.9a: Development of Antibiotic Resistance of Staphylococcus aureus Biofilms over 24 hours for 
Rifampicin (A), Vancomycin (B), Ciprofloxacin (C) and Clindamycin (D). 
Mean CFU/ml counts are plotted 
against time of growth with error 
bars of standard deviation. The 
biofilms were incubated for the 
indicated times before being 
challenged with antibiotics for 2 
hours. Beads were washed, 
dissolved, serially diluted and 
plated as described in the Materials 
and Methods. No antibiotics were 
added to the control.  The dashed 
line indicates the detection limit of 
the assay (≤50 CFU/ml). 
A) 6 μg/ml Rifampicin,  
B) 15 μg/ml Vancomycin,  
C) 10 μg/ml Ciprofloxacin,  







Figure 3.9: Development of Antibiotic Resistance of Staphylococcus aureus Biofilms 
over 24 hours for Linezolid (E) and Daptomycin (F). Mean CFU/ml counts are plotted 
against time of growth with error bars of standard deviation. The biofilms were incubated for 
the indicated times before being challenged with antibiotics for 2 hours. Beads were washed, 
dissolved, serially diluted and plated as described in the Materials and Methods. No antibiotics 
were added for the control. E) 4 μg/ml linezolid, F) 0.5 μg/ml daptomycin (supplemented with 






From Figure 3.9 it can be seen that resistance against the antibiotics, with the 
exception of daptomycin, takes at least 3 hours to develop (Figure 3.9b, F).  
Resistance to daptomycin developed after only 1 hour’s growth. Rifampicin resistance 
developed between six and eight hours of growth (Figure 3.9a, A). This is the longest 
time observed for any of the antibiotics. However, once the resistance developed 
there was a steep increase in CFU/ml counts. Linezolid resistance develops by three 
hours with a gradual increase in CFU/ml counts. Both vancomycin and clindamycin 
resistance develops by four hours whereas ciprofloxacin resistance appears by six 
hours.  
 
Effects of Gentamicin with other Antibiotics on Staphylococcus aureus 
Biofilms over 24 hours 
 
As it is usual, within the clinical environment, to treat biofilm infections with a 
combination of antibiotics in order to improve bacterial target range and to prevent 
development of resistance, combination experiments were carried out. These 
experiments investigated synergism and antagonism between gentamicin and the 
above antibiotics (Figure 3.10 A-F). The antibiotic concentrations used were those 
which inhibited growth overnight on LB agar plates. 
The beads were incubated at 37°C, 150 rpm for the required time (0.5, 1, 2, 3, 4, 6, 8 
and 24 hours). The beads were then washed and transferred into fresh medium 
containing either gentamicin, the second antibiotic, both antibiotics, or no antibiotics 
(control). After 2 hours challenge, the beads were washed, dissolved, and the solution 
was serially diluted and plated as described in the Materials and Methods. CFU/ml 




Figure 3.10a: The Effect of Gentamicin and Rifampicin (A) or Gentamicin and 
Vancomycin (B) on Staphylococcus aureus Biofilms over 24 hours. CFU/ml counts are 
plotted against time of growth with error bars or standard deviation. Cultures were set up from 
overnight cultures and grown for the indicated times as described in Materials and Methods. 
Beads were washed and placed into fresh medium containing either 15 μg/ml gentamicin, the 
second antibiotic (A: 6 μg/ml rifampicin or B: 15 μg/ml vancomycin) or both antibiotics. No 
antibiotics were added to the control wells. Beads were washed, dissolved, serially diluted and 
plated after the 2 hour long challenge. The dashed line indicates the detection limit of the 
assay (≤50 CFU/ml) 
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Gentamicin resistance develops immediately; however, it takes over 6 hours for the 
biofilm to display resistance to rifampicin as seen in Figure 3.10 A. When the 
antibiotics are combined the effect was the same as that of rifampicin only. Rifampicin 
acts by inhibiting nucleic acid synthesis, whereas gentamicin causes incorrect reading 
of mRNA, leading to the synthesis of non-functional proteins [Campbell et al., 2001]. 
The process on which gentamicin acts is downstream to the process which rifampicin 
affects. Therefore, until rifampicin resistance develops, the gentamicin doesn’t have 
a target and so resistance cannot develop.  
For Figure 3.10 B, gentamicin and vancomycin combined, gentamicin resistance was 
observed by 0.5 hours and showed a steady increase, whereas vancomycin 
resistance developed sharply between 3 and 4 hours. When gentamicin and 
vancomycin are combined resistance develops in the same pattern as for vancomycin 
alone, beginning between 3 and 4 hours. Vancomycin acts by inhibiting cell wall 
synthesis and peptidoglycan formation and resistance is believed to be due to 
reduced permeability of the antibiotic via thickening of the cell wall [Howden et al., 
2010]. 
In Figure 3.10 C, the pattern of gentamicin resistance is the same as previously 
described for Figure 3.10 B. Ciprofloxacin resistance develops between 4 and 6 hours 
with cell numbers leaping up to 106CFU/ml. When ciprofloxacin was combined with 
gentamicin resistance developed, as seen for ciprofloxacin alone, delaying resistance 
to gentamicin. Ciprofloxacin has a bactericidal action and acts by inhibiting DNA 
gyrase [Drlica and Zhao, 1997]. Resistance is most commonly due to mutations in 
DNA gyrase; the more mutations a cell produces the higher its resistance levels 





Figure 3.10b: The Effect of Gentamicin and Ciprofloxacin (C) or Gentamicin and 
Clindamycin (D) on Staphylococcus aureus Biofilms over 24 hours. CFU/ml counts are 
plotted against time of growth with error bars of standard deviation. Cultures were set up from 
overnight cultures and grown for the indicated times as described in Materials and Methods. 
Beads were washed and placed into fresh medium containing either 15 μg/ml gentamicin, the 
second antibiotic (C: 10 μg/ml ciprofloxacin or D: 0.1 μg/ml clindamycin) or both antibiotics. 
No antibiotics were added to the control wells. Beads were washed, dissolved, serially diluted 
and plated after the 2 hour long challenge. The dashed line indicates the detection limit of the 




For Figure 3.10 D, gentamicin resistance developed as described previously. 
Clindamycin resistance developed by six hours (Figure 3.9 C). Clindamycin acts in a 
bacteriostatic manner though interference with protein synthesis by binding the 50S 
ribosomal subunit [Kohanski et al., 2010]. Resistance is due to modifications of the 
antibiotic target site on the ribosome. This also confers resistance to other classes of 
antibiotics such as macrolides, azalides, lincoamides and group B streptogramins 
[Roberts et al., 1999]. As can be seen clindamycin delayed development of resistance 
to gentamicin by 4 hours when the antibiotics are combined. 
In Figure 3.10 E, gentamicin resistance develops as previously described whilst 
linezolid resistance developed by three hours as did resistance to the combined 
antibiotics (Figure 3.10 E). The pattern of the latter two conditions is similar suggesting 
that the effect of linezolid is dormant but that the combination does not enhance the 
overall negative effect on the cells. Linezolid has a bacteriostatic action, inhibiting 
protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S 
ribosomal subunit [Mouton and Jansz, 2001]. Resistance is caused by mutations in 
the antibiotic target site and should develop slowly as there are multiple copies of the 
23S rRNA gene within the cells [Prystowsky et al., 2001]. 
Examining Figure 3.10 F, gentamicin resistance develops in a similar manner as with 
the other antibiotics. Daptomycin resistance develops earlier than any of the other 
antibiotics with resistance shown after 2 hours growth. Interestingly, there is evidence 
for an additive effect between gentamicin and daptomycin as resistance against the 
combined antibiotics appeared to develop after resistance to each individual 
antibiotic. Daptomycin is bactericidal and requires calcium to act effectively. Its 
structure contains a 13 member cyclic lipopeptide with a decanoyl side chain. The 
antibiotic action is thought to be due to the insertion of the lipophilic tail into bacterial 
cell membranes which causes membrane depolarization and potassium ion efflux 
leading to cell death [Silverman et al., 2003]. Resistance has only recently been 
reported and is believed to be a result of point mutations in the phospholipid 




Figure 3.10c: The Effect of Gentamicin and Linezolid (E) or Gentamicin and Daptomycin 
(F) on Staphylococcus aureus Biofilms over 24 hours. CFU/ml counts are plotted against 
time of growth with error bars of standard deviation. Cultures were set up from overnight 
cultures and grown for the indicated times as described in Materials and Methods. Beads were 
washed and placed into fresh medium containing either 15 μg/ml gentamicin, the second 
antibiotic (E: 4 μg/ml linezolid or F: 0.5 μg/ml daptomycin), or both antibiotics. No antibiotics 
were added to the control wells. Beads were washed, dissolved, serially diluted and plated 






Stable Formation of Biofilms occurs by Four Hours’ Growth 
The alginate beads were found to be a suitable base on which the biofilms can form 
and it has been shown that the biofilms are firmly attached to the beads after just 4 
hours’ growth (Figure 3.2). By 24 hours the biofilms are fully attached and displaying 
significant antibiotic resistance, which is considered one of the hallmarks of a mature 
biofilm [Kiedrowski and Horswill, 2011]. This chapter focused on Staph. aureus and 
the commonly utilized clinical antibiotics used to treat staphylococcal infections. 
Chapter 4 covers other bacterial species and shows that other species are also able 
to form biofilms effectively, thus making the alginate bead method a viable alternative 
to the Calgary Biofilm Device. 
 
Comparison of the Alginate bead method to the Calgary Biofilm Device  
In comparison to the Calgary Biofilm Device, the alginate bead method is reliable, 
robust and much cheaper. The equipment and reagents required are low cost and 
commonly available. The one major disadvantage is that it is labour intensive and rate 
limiting by the number of samples which can be processed at any one time. However, 
with certain aspects of the method, such as the serial dilution and spot plating there 
is the potential for automation. 
The development of biofilms on the alginate beads is supported by the previous 
microscopy work by Dall [2013] and the number of bacterial cells required for total 
surface area coverage. The paper by Ceri et al [1999] demonstrates that development 
of biofilms on the plastic pegs also occurs quickly with ~106 CFU/ml after 10 hours 
incubation (for P. aeruginosa, E. coli and Staph. aureus). Thus the beads can be 
considered a suitable base for biofilm formation.  
The best recovery solutions for the biofilms seem be a 1:1 mixture of dissolving 
solution and medium (Figure 3.5). Both LB and Muller-Hinton broth were used for the 
experiments detailed in this chapter, in the papers by Ceri et al [199] and Harrison et 
al [2010] Muller-Hinton broth was used. It was found that changing the medium did 
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not seem to have an effect on the biofilm formation or recovery and thus could be 
tailored to the bacterial species required for the experiments. 
Either the original method to recover the biofilms (crushing and dissolving) or low 
power sonication (Figures 3.4) which more closely mirrors the Calgary method could 
be used. The sonicating water bath (Defon F5 Minor, Ultrasonic Ltd) used is a closer 
match for the Aquasonic machine used by Ceri et al [1999] rather than the higher 
powered probe sonicator (Thermo Scientific) which is more commonly used to lyse 
cells. The probe sonicator can only process one sample at a time whereas the 
sonicating water bath is able to process sample batches.  
The main advantages of sonication over the original method are the reduced amount 
of time required and that more samples can be processed at any one time. However, 
there are negative aspects to sonication, namely possible damage to bacterial cells. 
Sonication damages bacterial cells especially Gram-negative species; this is most 
likely due the thinner peptidoglycan cell wall cell that Gram-negative species have 
compared to Gram-positive species [Monsen et al., 2009]. 
 
Inhibition of Staphylococcus aureus Biofilms by Gentamicin 
 
It is interesting to observe the differences in gentamicin concentrations required to 
eradicate at different stages of bacterial growth. Figure 3.7 A, shows that biofilms 
display immediate resistance to 15 μg/ml gentamicin. In contrast, when this strain is 
plated onto solid medium (LB) and grown overnight, there is complete inhibition of 
growth at this concentration. Why does the agar plate not show any growth? It could 
be the fact, that the cells have to initiate growth to form colonies on a plate and are 
therefore; susceptible to the continuous gentamicin exposure. Whereas, in the biofilm 
situation the cells are already actively growing before the addition of gentamicin and 
innate cell and biofilm resistance mechanisms can react to the antibiotic. 
Gentamicin acts by incorporating incorrect amino acids into peptides causing protein 
mistranslation, the antibiotic also increases membrane permeability allowing further 
antibiotic uptake into the cell through the inclusion of these incorrect proteins into the 
cytoplasmic membrane [Davis et al., 1986]. 
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Comparisons of the concentrations required to kill young (3 hours old) actively 
growing biofilms and planktonic cultures (Figure 3.6) show that nearly double the 
gentamicin concentration is required to kill the biofilm (225 μg/ml) compared to the 
planktonic culture (125 μg/ml). This is probably due to the innate resistance afforded 
by the structure of the biofilm matrix [Mah and O’Toole, 2001; Van Acker et al., 2014].  
For a 24 hour old biofilm a much higher concentration of gentamicin (1024 μg/ml) was 
required to reduce the biofilm load and even then only by 3 log orders (Figure 3.8). 
Moreover, when the same antibiotic concentration was added directly to the 24hr old 
biofilms (pipetted directly into the wells) the antibiotic effect decreased; the biofilm 
load was only reduced by 1.5 logs (Figure 3.8).  
Allison et al [2011] have shown that aminoglycoside sensitivity can be restored by 
supplying persister cells and biofilms with sugar metabolites. The sugar metabolites 
are taken up by the bacterial cell and enter glycolysis resulting in the production of 
NADH. The NADH is oxidised by electron transport chain enzymes which contribute 
to generation of PMF. The revival of PMF enables aminoglycoside uptake into the cell 
leading to cell death. It is possible that some of the components within the LB also act 
in this way, this would account for the differences in biofilm load reductions between 
Figures 3.8a and 3.8b. 
Further work needs to be conducted on this subject to compare the differences in 
antibiotic effectiveness with and without medium change with other antibiotic classes 
and medium types. Figure 3.8 (no medium change) is a more realistic scenario as any 
biofilm associated infection would be sessile without access to many fresh nutrients.  
van de Belt et al [2001] demonstrated that Staph. aureus is able to form biofilms on 
six different gentamicin loaded polymethylmethacrylate bone cements. After 6 hours 
growth, when compared to the unloaded cement controls, there was no obvious 
difference in biofilm formation. Only after longer exposure times was there any major 
effect observed. Biofilm reduction occurred after 24 hours but only lasted for a further 
48 hours for one of the brands (CMW3) before increasing again. It should be noted 
that the antibiotic effectiveness did not correlate with the kinetics for antibiotic release 
from the cement [van de Belt et al., 2001].  
There have been reports that aminoglycosides (gentamicin and tobramycin) can 
promote biofilm formation in both Gram-positive species (Staph. aureus) and Gram-
negative species (Ps. aeruginosa/ E. coli) which is the exact opposite of their purpose 
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[Hess et al., 2011; Hoffman et al., 2005]. This raises the question of whether 
gentamicin is a suitable antibiotic for use in a clinical environment especially in 
regards to bone cement, prosthetic joint infections and other biofilm based infections.  
 
Development of Resistance of Staphylococcus aureus Biofilms to Other 
Antibiotics over 24 hours 
The development of resistance of the other antibiotics over 24 hours all follow roughly 
the same pattern, although resistance does develop after different time periods 
(Figure 3.9). In comparison to gentamicin, the other antibiotics act at a much lower 
concentrations (Figures 3.7 and 3.9). This could be due to their different modes of 
action. However, clindamycin and linezolid also affect protein synthesis though they 
act on different targets within the cell. These two antibiotics are also bacteriostatic 
rather than bactericidal [Agar and Gould 2012; Kohanski et al., 2010]. The gentamicin 
concentration required to have an effect on a young actively growing biofilm is 10x 
that which kills on an agar plate. Whereas, the same concentration which kills on a 
plate has an effect on the young actively growing biofilms for the other antibiotics, with 
resistance developing as the biofilm develops. After 24 hours growth the antibiotics 
have very little effect with the CFU/ml count matching that of the untreated control 
(Figure 3.9).  
The modes of action of each of the antibiotics examined differed. The most effective 
antibiotic is rifampicin (Figure 3.9a, A) which is a bactericidal antibiotic that inhibits 
RNA synthesis by targeting RNA polymerase [Campbell et al., 2001]. Resistance is 
due to mutations in the gene encoding the DNA-dependent RNA polymerase [Aubry-
Damon et al., 1998]. The resistance demonstrated in Figure 3.9a A, may be a due to 
a combination of the biofilm matrix’s protective structure [Hogan et al., 2015] and any 
mutations which the bacteria develop. However, it is unlikely that the majority of the 
bacteria present within the biofilm would have mutated to become resistant during the 
experimental period, so a greater weight should be placed on the matrix as the main 
mechanism of resistance. The reduced metabolic activity of the cells within the biofilm 
[Lewis, 2005] may also contribute to the resistance as it has been shown that 
rifampicin can penetrate biofilms without killing the cells [Zhang and Stewart, 2002]. 
The antibiotic for which resistance developed most rapidly was daptomycin (Figure 
3.9b, F). This bactericidal antibiotic showed the least activity against biofilms which is 
106 
 
in contrast to the report from Smith et al [2009]. Daptomycin was found to eliminate 
96% of biofilm-associated bacteria in 12 different Staph. aureus isolates, at a MIC of 
between 0.06-0.25 μg/ml, which was lower than the concentration used for this study 
(0.5 μg/ml). Mascio et al., [2007] also demonstrated that daptomycin is active against 
log phase, stationary phase and metabolically inert Gram-positive bacteria.  
Resistance to the two bacteriostatic antibiotics clindamycin and linezolid occurred by 
four (Figure 3.9a, D) and three hours respectively (Figure 3.9b, E). These antibiotics 
inhibit protein synthesis by affecting the 50S bacterial ribosomal subunit [Colca et al., 
2003; Kohanski et al., 2010]; whether the antibiotic is bactericidal or bacteriostatic 
does not seem to affect when the resistance developed. There are contrasting reports 
about the effectiveness of linezolid against biofilms. For example, in the study by Raad 
et al [2007] results from biofilms treated with linezolid were equal to those of the 
negative control. However, Curtin et al [2003] demonstrated that linezolid was the 
most effective monotherapy for clearing biofilms from polyurethane coupons in an in 
vitro model system for Staph. epidermidis catheter related biofilm infections. Linezolid 
appears to be most effective when combined with rifampicin, this mixture cleared 
~70% of infections from prosthetic joint infections [Gómez et al., 2011]. 
Ciprofloxacin resistance developed between 4 and 6 hours (Figure 3.8a C). 
Ciprofloxacin is normally used for staphylococcal and Pseudomonas infections but is 
not effective at treating biofilms [Adire et al., 2015]. Diffusion of ciprofloxacin into 
biofilms is dependent on its charge and that of the biofilm. At neutral pH, ciprofloxacin 
is positively charged and can effectively penetrate into a biofilm with enhanced activity 
[Adire et al., 2015; Hernándex-Borrell and Montero, 2003]. Resistance to ciprofloxacin 
may be due to mutations in the DNA gyrase or topoisomerase IV genes [Lindren et 
al., 2003]. Increased expression of transporters which prevent the antibiotic from 
reaching critical concentrations within the cell is also a recognised resistance 
mechanism [Jacoby, 2005]. The third mechanism is plasmid mediated and produces 
enhanced efflux pumps [Jacoby et al., 2014]. 
Vancomycin resistance developed between 3 and 4 hours growth (Figure 3.9a, B). 
Vancomycin has a slow mode of action causing bacterial death by preventing cross 
linking in the cell wall during synthesis, this results in a weakened wall, slow growth 
and death [Kiedrowski and Horswill, 2011]. There are two recognised levels of 
resistance to vancomycin. Intermediate resistance is due to mutations which increase 
the cell wall thickness [Howden et al., 2010] and full level resistance is due to a mobile 
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genetic element which encodes for proteins that decrease the binding affinity for 
vancomycin [Courvalin, 2006]. 
Even though, all the antibiotics have specific resistance mechanisms which can be 
acquired or selected for under the pressure of antibiotic treatment. It is unlikely that 
all the resistance mechanisms were present or able to be developed from the one 
strain after less than 24 hours selective pressure. Thus, the more reasonable 
explanation for the antibiotic resistance is the biofilm itself. Biofilm resistance is based 
on heterogeneous gene & protein expression, reduced metabolic activity (including 
persisters), reduction in penetration of the antibiotics and the presence of EPS, 
extracellular proteins and eDNA in the biofilm matrix [Archer et al., 2011; Lewis, 2005; 
Mann et al., 2009; Xu et al., 2000]. 
 
Effects of Gentamicin with other Antibiotics on Staphylococcus aureus 
Biofilms over 24 hours 
The use of gentamicin is common in the clinical environment for the treatment of 
staphylococcal infections in prosthetic joints. Bone cements were introduced in 1970 
[Buchholz and Engelbrecht, 1970, Neut et al., 2005], and are used to produce a 
localised area of high concentration antibiotics around an implant to prevent 
infections. Gentamicin is used because of its broad antibacterial spectrum and 
stability at the high temperatures required to set the bone cement [Neut et al., 2005]. 
Initial results were promising with lower infection rates reported despite the lack of 
understanding around the release mechanisms and control of the antibiotics from the 
cement [Wahlig and Dingeldein, 1980]. The increasing levels of gentamicin 
resistance, recorded at ~41%, have promoted the development of bone cements 
infused with gentamicin and a second antibiotic [Neut et al., 2005]. 
Interestingly, all combinations of antibiotics resulted in delayed emergence of 
gentamicin resistance. At a gentamicin concentration of 15 μg/ml resistance emerged 
within half an hour of biofilm formation (Figure 3.7), however, when combined with 
another antibiotic, gentamicin resistance did not emerge until 3-8 hours after biofilm 
formation (Figure 3.10).  
The only antibiotic to show enhanced inhibitory activity with gentamicin was 
daptomycin (Figure 3.10c F). The biofilm resistance was delayed by roughly one hour 
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when the two antibiotics were combined. Tsuji and Rybak [2005] have shown that a 
mixture of gentamicin and daptomycin significantly reduces bacterial cell numbers in 
Staph. aureus endocarditis. However, LaPlante and Woodmansee [2009] 
demonstrated that daptomycin alone proved more effective in a rabbit model of 
infective endocarditis than in combination with either gentamicin or rifampicin. 
Clinically daptomycin is often combined with rifampicin. This mixture has been 
reported to reduce biofilm biomass but is unable to completely clear the implant-
associated infection in animal models [John et al., 2009]. Further work is required to 
clarify the effectiveness of combinations of daptomycin with gentamicin or rifampicin.  
For three of the other antibiotics, rifampicin, vancomycin and linezolid (Figure 3.10a 
A, 3.10a B and 3.10c E), there is no observed difference when they are combined 
with gentamicin compared to when they are tested as an individual substance other 
than a delay in gentamicin resistance. In fact, it has been shown linezolid, in 
combination with fusidic acid, gentamicin or rifampicin displayed no synergy but did 
prevent the emergence of resistant mutants [Grohs et al., 2003]. This is only the case 
for a short period as gentamicin resistance did still emerge. Nonetheless, as 
previously discussed the resistance is more than likely due to the biofilm composition 
and should not be regarded as true genetic based resistance. Once cells are released 
from biofilms they revert back to an antibiotic sensitive planktonic state.  
When gentamicin is combined with clindamycin (Figure 3.10b D), there seems to be 
a slight antagonistic effect, this contrasts with the paper published by Neut et al [2005]. 
Neut et al [2005] states that there is an additional antimicrobial effect when gentamicin 
and clindamycin are combined. However, the antibiotics were already present before 
the start of bacterial growth and biofilm formation, compared to Figure 3.10 D, which 
allowed the biofilm to form and then challenged with antibiotics. Thus, the comparison 
which can be made is limited by the differences in methodology. Since the difference 
is small, additional experiments are necessary to confirm that the observation is 
reproducible.    
Further investigation is necessary to examine the effects of the gentamicin in 
combination with these antibiotics. The addition of a third antibiotic would also provide 











Chapter 4:  















Many bacterial species form biofilms causing numerous HCAIs and contamination in 
healthcare environments with significant increases in length of hospital stays & costs 
and decreases in patients’ quality of life. 
The bacterial species investigated in this chapter are Staphylococcus epidermidis, 
Staphylococcus saprophyticus, Streptococcus mutans, Streptococcus pneumoniae, 
Escherichia coli (2 strains), Enterococcus faecalis, Klebsiella pneumoniae and 
Pseudomonas aeruginosa (2 strains). All these species are active in the healthcare 
environment with some causing more serious infections than others (Table 1.5). 
Notable biofilms infections include catheter, prosthetic valves, artificial joints and other 
device related sepsis by Staph. epidermidis, dental caries by Strep. mutans, and 
respiratory infections (ventilator associated) by K. pneumoniae and Ps. aeruginosa. 
Ps. aeruginosa is also a significant problem in cystic fibrosis patients and on burn 
wards due to the compromised immunity of the patients [Goering et al., 2008].    
Biofilms are considerably harder to treat than planktonic cultures due to the nature of 
the matrix, the reduced metabolic functions of the cells, and the presence of different 
cells types such as persisters. Even with prolonged treatment, once the selective 
antibiotic pressure has been removed the infection can reactivate unless the 
underlying biofilm has been eradicated [Fux et al., 2005].  
Occasionally, in the clinical setting an infection can be caused by more than one 
species. A multispecies biofilm may provide protection for one or both species and 
antibiotic resistance levels are often higher than in biofilms formed by the individual 
species. Resistance mechanisms can also be transferred between bacterial species 
in this situation. 
As treatment of biofilms is a hugely complicated issue, new and novel ways of treating 
and disrupting biofilms are constantly being investigated. One of these methods which 
has recently been published is the use of sugar metabolites to reactive the metabolic 
systems of persister cells and biofilms, subsequently restoring function to the specific 
antibiotic targets [Allison et al., 2011]. A second approach uses D-amino acids which 
modulate peptidoglycan synthesis and inhibit attachment of biofilm matrix proteins 
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thereby, preventing and disrupting biofilm formation [Hochbaum et al., 2011; 
Kolodkin-Gal et al., 2010]. 
 
Aims of this Chapter 
 
To examine: 
 How different health care associated bacterial species form biofilms using the 
alginate bead method. 
 The development of antibiotic resistance over 24 hours in these biofilms. 
 The antibiotic concentrations required to reduce the biofilm load after 3 and 24 
hours growth. 
 How a mixed species biofilm develops and its antibiotic resistance in 
comparison to the component species.  
 How natural molecules, such as sugar metabolites and D-amino acids, affect 





Development of Biofilms 
 
As virtually all bacteria can form biofilms under the correct conditions, a selection of 
different bacterial species was chosen to further validate the alginate bead method 
and investigate antibiotic resistance. The majority of the species examined were 
clinical isolates (Table 2.1).  
The biofilms (Figures 4.1 A and 4.2 A) were developed using overnight cultures grown 
in LB, at 37°C with shaking (200 rpm) which were diluted 1/10 000. This culture was 
used to inoculate triplicate alginate beads (prepared as described in Materials and 
Methods) for each time point in 48 well plates. The plates were incubated at 37°C, 
150rpm for the required time. After their removal under aseptic conditions the beads 
were individually washed briefly in dH2O (using a 48 well plate) and transferred to 
15ml falcon tubes. The tubes contained 2ml dissolving buffer in which the beads were 
crushed using the base of a flamed metal loop and dissolved. The tubes were rotated 
until the beads were fully dissolved (~15 minutes). This solution was vortexed for 10 
seconds before a sample was taken, which was serially diluted, and plated using the 
Miles Misra method (20 μl spots). Spots were counted if they contained between 2 
and 30 colonies. 
The planktonic cultures (Figures 4.1 B and 4.2 B) were set up from the same diluted 
overnight culture as the biofilms. 600 μl was pipetted into 48 well plates. Triplicate 
wells were used for each time point. After the required time, the wells were sampled. 
These samples were serially diluted and plated in the same way as the biofilm 
samples.  
The CFU/ml was calculated using N= (C.V)/D, where C is the number of colonies. For 
the biofilm samples V is 250 (to adjust for the 2ml dissolving solution) whereas for the 
planktonic samples V is 50. D is the dilution factor. The graphs show mean CFU/ml 






Figure 4.1: Development of Biofilms on Alginate Beads (A) and Planktonic Growth (B) 
by Various Gram-positive Organisms. Cultures were set up from overnight cultures as 
described in Materials and Methods, with triplicate beads or wells and sampled at the indicated 
time points. Beads were washed, dissolved, serially diluted and plated for CFU/ml counts. 
Mean CFU/ml counts are plotted against time of growth with error bars of standard deviation. 
The dashed line indicates the detection limit of the assay (≤ 50CFU/ml). 
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Figure 4.2: Development of Biofilms on Alginate Beads (A) and Planktonic Culture (B) 
by Various Gram-negative Organisms. Cultures were set up from overnight cultures as 
described in the Materials and Methods, with triplicate beads or wells and sampled at the 
indicated time points. Beads were washed, dissolved, serially diluted and plated for CFU/ml 
counts. Mean CFU/ml counts are plotted against time of growth with error bars of standard 
deviation. The dashed line indicates the detection limit of the assay (≤ 50CFU/ml). 
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As can be seen from Figures 4.1 A, and 4.2 A, the development of biofilms of the 
different bacterial species follows the same basic growth pattern with the biofilm firmly 
attached by 4 hours and fully established by 24 hours. This can be confirmed by the 
emergence of resistance as seen in Figure 4.3. It should be noted, that the alginate 
composition of the beads does not appear to have an inhibitory effect on biofilm 
development. Moreover, the assay seemed robust even with the use of a mucoid 
alginate producing strain of Ps. aeruginosa B (Figure 4.2 A). 
Some species did appear to form the biofilm more slowly than others but this perhaps 
could be accounted for by the differences in individual replication times for the 
particular species. Initial attachment to beads appeared rapid and is probably non-
specific for the first couple of hours. After this time, there was a steady increase in 
colonisation, with both replication and further planktonic attachment contributing to 
the biofilm. The planktonic growth of the organisms from the same overnight culture 
and diluted inoculum is provided for control purposes.  
As all the bacterial species selected were able to form biofilms the next step involved 
determining their antibiotic resistance and the profiles for how antibiotic resistance 
developed over 24 hours.  
 
 
Development of Resistance over 24 hours 
 
In order to determine how quickly biofilms develop resistance, growth curves were 
carried out with the biofilms challenged by either gentamicin or vancomycin. The 
inoculum used to develop the biofilms was grown overnight in LB at 37°C with shaking 
(200 rpm) and diluted in fresh LB to ~104 CFU/ml. 600 μl of this culture was pipetted 
into a 48 well plate wells.  
Triplicate beads for each time point were added to the well plate and incubated at 
37°C, with shaking (150 rpm) for the required growth time (0.5, 1, 2, 3, 4, 6, 8 or 24 
hours). The beads were removed under aseptic conditions and rinsed individually in 
dH2O, before being placed in fresh medium with the required antibiotic concentration 
for the 2 hour long challenge. The beads were once again washed, dissolved (see 
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Materials and Methods) and CFU/ml counts were determined by plating. CFU/ml 
counts were calculated as previously stated.  
The antibiotic concentration used was initially reflected by the level required to kill an 
actively growing planktonic culture (MIC as described in Materials and Methods). 
Table 4.1 summarises the antibiotic and concentration used for each species. 
Gentamicin was the first antibiotic choice however, some species were resistant. 
Vancomycin was selected if this was the case. Figure 4.3 (a, b and c) show the 
development of resistance for each species.   
 
Table 4.1: Antibiotics and Planktonic MIC Concentrations Used for Each 
Bacterial Species. 
Bacterial Strain Antibiotic Concentration (ug/ml) 
Staph. epidermidis Gentamicin 50 
Staph. saprophyticus Vancomycin 50 
Strep. mutans Vancomycin 50 
Strep. pneumoniae Gentamicin 75 
E. coli Gentamicin 90 
E. coli K12 Gentamicin 50 
E. faecalis Vancomycin 75 
K. pneumoniae Gentamicin 75 
Ps. aeruginosa G Gentamicin 75 
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Figure 4.3a: Development of Antibiotic Resistance of Biofilms of Staphylococcus epidermidis (A), 
Staphylococcus saprophyticus (B), Streptococcus mutans (C) and Streptococcus pneumoniae (D) over 24 
hours. 
Mean CFU/ml counts are 
plotted against time of growth 
with error bars of standard 
deviation. The biofilms were 
incubated for the indicated 
times before being 
challenged with antibiotics for 
2 hrs. Beads were then 
washed, dissolved, serially 
diluted and plated as detailed 
in Materials and Methods. No 
antibiotics were added to the 
control. Triplicate beads were 
set up for each time point. 
The dashed line indicates the 
detection point of the assay 
(≤50 CFU/ml). 
A) Staphylococcus 
epidermidis (50 μg/ml 
gentamicin), 
B) Staphylococcus 
saprophyticus (50 μg/ml 
vancomycin), 
 C) Streptococcus mutans 
(50 ug/ml vancomycin), and 
 D) Streptococcus 




Figure 4.3b: Development of Antibiotic Resistance of Biofilms of Escherichia coli (E), Escherichia coli K12 (F), 
Enterococcus faecalis (G) and Klebsiella pneumoniae (H) over 24 hours.
Mean CFU/ml counts are 
plotted against time of growth 
with error bars of standard 
deviation. The biofilms were 
incubated for the indicated 
times before being 
challenged with antibiotics for 
2 hrs. Beads were washed, 
dissolved, serially diluted and 
plated as detailed in Materials 
and Methods. No antibiotics 
were added to the control. 
Triplicate beads were set up 
for each time point. The 
dashed line indicates the 
detection point of the assay 
(≤50 CFU/ml). 
E) Escherichia coli (90 μg/ml    
gentamicin),  
F) Escherichia coli K12 (50 
μg/ml gentamicin),  
G) Enterococcus faecalis (75 
μg/ml vancomycin),  







Figure 4.3c: Development of Antibiotic Resistance of Biofilms of Pseudomonas 
aeruginosa G over 24 hours. Mean CFU/ml counts are plotted against time of growth with 
error bars of standard deviation. The biofilms were incubated for the indicated times before 
being challenged with antibiotics for 2 hrs. Beads were washed, dissolved, serially diluted and 
plated as detailed in Materials and Methods. Triplicate beads were set up for each time point.  
No antibiotics were added to the control. Pseudomonas aeruginosa was challenged with 75 
μg/ml gentamicin. The dashed line indicates the detection point of the assay (≤50 CFU/ml). 
 
Of the Gram-positive bacterial species, resistance became evident between 4 and 6 
hours, with the exception of E. faecalis which displayed resistance after 2 hours of 
biofilm formation (Figure 4.3b, G). It is interesting to note that there is a wide range of 
cell densities at which resistance develops. E. faecalis and Strep. mutans developed 
resistance at 102 CFU/ml, though Strep. mutans took longer to reach this point. Staph. 
saprophyticus resistance developed at 103 CFU/ml but Staph. epidermidis and Strep. 
pneumoniae resistance only developed once the cell density was above 104 CFU/ml. 
K. pneumoniae and Ps. aeruginosa exhibited resistance after 1 hour growth, whereas, 
the two E. coli strains only developed resistance after 4 (Figure 4.3b, E) and 6 hours 
(Figure 4.3b, F). As with the Gram-positive organisms the cell density ranges from 
102 CFU/ml (K. pneumoniae) and 103 CFU/ml (Ps. aeruginosa) to 106 CFU/ml (E. coli) 





Differences in Levels of Resistance of 3 and 24 hour old Biofilms 
 
In a clinical situation, the ultimate goal is to eradicate the biofilm completely. However, 
this may not be possible. Therefore, significantly reducing the biofilm load is 
considered the next logical step. In order to determine the antibiotic concentrations 
required for this, each bacterial species biofilm was grown for 3 or 24 hours (Figure 
4.4) and challenged for 2 hours with increasing antibiotic concentrations.  
Triplicate beads were incubated for each antibiotic concentration in 600μl diluted 
overnight culture (~104 CFU/ml) for 37°C, 150 rpm for 3 or 24 hours. Beads were then 
removed and washed before being placed in 600 μl fresh LB with the different 
antibiotic concentrations for the 2 hour long challenge. The beads were once again 
washed, dissolved and the resulting solution sampled, diluted and plated. CFU/ml 
counts were calculated as before. Graphs show CFU/ml counts plotted against 
antibiotic concentrations with error bars of standard deviation.  
 
Resistance Levels of 3 hour old Biofilms 
As the biofilms are still developing at three hours, it is logical to assume that the 
antibiotics will still have a significant effect, and this is especially evident with Staph. 
epidermidis and Strep. mutans (Figure 4.4a, A and C).  E. faecalis shows significant 
resistance with only the highest vancomycin concentration (96 μg/ml) having a 
detrimental effect on the biofilm. This correlates with the early development of 
resistance in Figure 4.3b (G), and as resistance to vancomycin was first identified in 
Enterococcus species [Cetinkaya et al., 2003] therefore, it is reasonable that 
resistance might develop quickly. 
Of the Gram-negative species, biofilm resistance was observed until the higher 
antibiotic concentrations, though for K. pneumoniae the biofilm was not completely 
eradicated. Gram-negative resistance to gentamicin relies mainly on active transport 
of the antibiotic out of the cell [Aires et al., 1999] and sequestrating the antibiotic 
[Magent et al., 2003]. As the gentamicin concentration rises it can overwhelm these 
systems having a detrimental effect on the cells and biofilms. 
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Figure 4.4a: Antibiotic Concentrations required to reduce Biofilm Load after 3 or 24 hours growth of 
Staphylococcus epidermidis (A), Staphylococcus saprophyticus (B), Streptococcus mutans (C) and Streptococcus 
pneumoniae (D).  
 
Mean CFU/ml counts are 
plotted against antibiotic 
concentrations with error 
bars of standard 
deviation. Triplicate 
beads were set up for 
each condition. The 
biofilms were incubated 
for 3 or 24 hours before 
being challenged with 
antibiotics for 2 hrs. 
Beads were washed, 
dissolved, serially diluted 
and plated as detailed in 
Materials and Methods. 
The dashed line indicates 
the detection limit of the 
assay (≤50 CFU/ml). 




 C) Streptococcus 
mutans, and 





Figure 4.4b: Antibiotic Concentrations required to reduce Biofilm Load after 3 or 24 hours growth of Escherichia 
coli (E), Escherichia coli K12 (F), Enterococcus faecalis (G) and Klebsiella pneumoniae (H).
Mean CFU/ml counts 
are plotted against 
antibiotic 
concentrations with 
error bars of standard 
deviation. Triplicate 
beads were set up for 
each condition. The 
biofilms were incubated 
for 3 or 24 hours before 
being challenged with 
antibiotics for 2 hrs. 
Beads were washed, 
dissolved, serially 
diluted and plated as 
detailed in Materials 
and Methods. The 
dashed line indicates 
the detection limit of the 
assay (≤50 CFU/ml). 
E) Escherichia coli, 








Figure 4.4c: Antibiotic Concentrations required to reduce Biofilm Load after 3 or 24 
hours growth of Pseudomonas aeruginosa G. Mean CFU/ml counts are plotted against 
antibiotic concentrations with error bars of standard deviation. Triplicate beads were set up for 
each condition. The biofilms were incubated for 3 or 24 hours before being challenged with 
antibiotics for 2 hrs. Beads were washed, dissolved, serially diluted and plated as detailed in 




Resistance Levels of 24 hour old Biofilms 
Within a clinical environment, a biofilm infection will be firmly established before a 
patient shows signs of clinical infection [Costerton et al., 1999; Lindsay and von Holy, 
2006]. Thus it is important that the antibiotic resistance levels of older biofilms are 
examined to determine what concentration of antibiotic is required to reduce the 
bacterial load. 
As has been discussed in Chapter 3 for older Staph. aureus biofilms (>24 hours old) 
a substantial increase in antibiotic concentration is required to have any effect on the 
biofilms. The same result is seen with the other bacterial species, in some cases over 
10x the antibiotic amount that was effective on a 3 hour old biofilm, only has a minimal 
effect on a 24 hr old biofilm.  
The species which has the lowest tolerance for the higher antibiotic concentrations is 
E. coli, with both strains biofilms being destroyed at relatively low antibiotic 
concentrations compared to the other species. It could be, as mentioned above, that 
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the cell’s defence mechanisms against gentamicin are just overwhelmed by the 
excessive amount of antibiotic. It can be theorised that there is a relationship between 
the antibiotic concentration required for destroying the biofilm and cell density. 
However, the main reason behind the resistance has to be the biofilm structure itself. 
The different cell types within the biofilm are less susceptible because of changes in 
growth rates, gene expression and protein production. If the antibiotic targets are not 
active or less active then the antibiotic just won’t have the expected activity. The 
biofilm matrix including the EPS would also have a protective effect.     
 
Development and Challenge of Mixed Species Biofilms 
 
In order to discover whether the presence of another bacterial species has any effect 
on biofilm development and resistance, an experiment was undertaken whereby 
Staph. aureus and Ps. aeruginosa G were combined in a mixed culture. These two 
species were chosen as in a clinical setting, they can be found in the same host sites 
and have been shown to cause duel infections [Hendricks et al., 2001]. 
 
Development of the Biofilms 
An equal starting inoculum of each species was combined and grown with beads for 
0.5, 1, 2, 3, 4, 6, 8, and 24 hours, to examine the development of the mixed species 
biofilm (Figure 4.5). The beads were incubated at 37°C, 150 rpm for the required time 
before being washed and placed into fresh LB containing 150 μg/ml gentamicin. The 
biofilms were challenged for 2 hours after which they were washed, dissolved, serially 
diluted and plated as described previously.  
The culture was plated on either LB-rifampicin (5 μg/ml) or LB-Linezolid (4 μg/ml) to 
select for Staph. aureus and Ps. aeruginosa G respectively. Previous experiments 
had determined the antibiotic concentration required in the agar plates to select for 
each species (data not shown).  
Development of the mixed biofilm by each species was relatively even (Figure 4.5) 
and follows the same pattern as single species biofilms (Figures 3.5 B and 4.2A). The 
125 
 
final CFU/ml counts at 24 hrs showed that neither species has a detrimental effect on 
the other in terms of forming a biofilm. However, this is without any external pressures, 
such as an antibiotic challenge, which could change how the biofilm develops and 





Figure 4.5: Development of a Mixed Species Biofilm Consisting of Staphylococcus 
aureus and Pseudomonas aeruginosa. Mean CFU/ml counts are plotted against time of 
growth with error bars of standard deviation. Cultures were set up from overnight cultures (as 
described in Materials and Methods) with triplicate beads sampled at the indicated time points. 
Starting inoculum of Staph. aureus was 4.08x103 CFU/ml and for Ps. aeruginosa 5.15x103 
CFU/ml. Beads were washed, dissolved, serially diluted and plated on to selective plates for 






Development of Resistance over 24 hours 
 
Figure 4.6 shows how the addition of an antibiotic affects biofilm viability and when 
resistance develops. The protocol used is identical to that described for Figure 4.3. 
When the mixed biofilm was challenged with 150 μg/ml gentamicin Ps. aeruginosa 
showed immediate resistance. Comparing this to Ps. aeruginosa in a single species 
biofilm which, when challenged with 75 μg/ml gentamicin (Figure 4.3c), only showed 
resistance after 1hr growth.  
A similar effect can be seen with the Staph. aureus in that the gentamicin resistance 
develops earlier than when it is growing on its own (Figure 3.6). In a single species 
biofilm antibiotic resistance develops at 6hrs (~106 CFU/ml) whereas, in a mixed 
species biofilm, resistance develops at 3hrs and at a lower cell density (~103 CFU/ml).  
Thus, a mixed biofilm appears to have a beneficial effect on both species in terms of 
antibiotic resistance in the early stages of a biofilm (Figure 4.6). However, by 24 hrs 
the Ps. aeruginosa isolated from the mixed biofilm showed a 2 log difference in 
CFU/ml to that of the unchallenged control. This suggests that the beneficial effect of 
the mixed biofilm is reducing especially as the Ps. aeruginosa single culture (Figure 
4.3c) biofilm challenged with gentamicin matches that of the unchallenged control.  
There is a difference in the survival numbers of Staph. aureus as well but it is not as 
great. There is a possibility that the gentamicin is still present within the bacterial cells 
however, the biofilms have been rinsed to remove any planktonic cells, as well as the 
surrounding gentamicin. As the culture sample was diluted, any remaining gentamicin 
would also be diluted. If this is the case any bactericidal effect would be minimal due 













Figure 4.6: Development of Resistance of a Mixed Species Biofilm Consisting of 
Staphylococcus aureus and Pseudomonas aeruginosa over 24hrs. Mean CFU/ml counts 
are plotted against time of growth with error bars of standard deviation. The biofilms were 
incubated for the indicated times before being challenged with 150 ug/ml gentamicin for 2 hrs 
(Staph/Ps Challenged). Cultures were set up from overnight cultures with triplicate beads for 
each time points. Starting inoculum of Staph. aureus was 4.08x103 and for Ps. aeruginosa 
5.15x103 which were mixed equally. Beads were washed, dissolved, serially diluted and plated 
on to selective plates for each species. No antibiotic were added to the control (Staph/Ps 





Levels of Resistance of 3 hour old Mixed Species Biofilms 
As with the single species biofilms the resistance levels of the mixed biofilm, after 
different periods of growth (3 and 24 hours), were determined and compared to the 
individual species biofilms to see how the mixed biofilm influences antibiotic 
resistance levels.  
The three cultures used for the following two experiments (Figures 4.7 and 4.8) were 
Staph. aureus, Ps. aeruginosa and the mixed culture. The experiment was set up in 
the same way as described for Figure 4.4. 
The mixed biofilm confers some protection from gentamicin for Ps. aeruginosa with 
this species surviving in higher antibiotic concentrations than in the individual culture 
which correlates with what is seen in Figure 4.6; initial faster growth and development 
of Ps. aeruginosa biofilms. There is some difference in the survival rates between the 
Staph. aureus from the mixed and individual biofilms, with 225 μg/ml gentamicin 
eradicating the individual Staph. aureus whereas, 450 μg/ml gentamicin was required 


















Figure 4.7: Antibiotic Concentrations required to Reduce Biofilm Load after 3 hours 
growth of a Mixed Species Biofilm Consisting of Staphylococcus aureus and 
Pseudomonas aeruginosa. Mean CFU/ml counts are plotted against antibiotic 
concentrations with error bars of standard deviation. The biofilms were incubated for 3 hrs 
before being challenged with gentamicin for 2 hrs. Cultures were set up from overnight cultures 
with triplicate beads for each time point as described in Materials and Methods. Beads were 
washed, dissolved, serially diluted and plated on to selective plates for each species from the 
mixed biofilms. The individual species were plated on to LB agar.  The dashed line indicates 







Levels of Resistance of 24 hour old Mixed Species Biofilms 
In order, to determine how a mature biofilm responds to increasing levels of antibiotic, 
a 24 hour old biofilm was challenged with different antibiotic concentrations. The 
protocol for this is identical to that described for Figure 4.4. As with the three hour old 
biofilms (Figure 4.7), 3 different cultures were used, an individual Staph. aureus 
culture, an individual Ps. aeruginosa culture, and a mixture of the two species. 
It is clear that an older mixed biofilm confers protection to Staph. aureus as even 
3000μg/ml gentamicin could not eradicate the biofilm. However, there is a 4 log 
reduction when challenged with gentamicin for 2 hours compared to the unchallenged 
control (Figure 4.8). 
In direct contrast, to the effects of antibiotics on a 3 hour old biofilm (Figure 4.7), which 
showed that Ps. aeruginosa survived in the higher antibiotic concentrations, a 24 hour 
old biofilm seems to have a detrimental effect on Ps. aeruginosa. However, the 
reduction in the Ps. aeruginosa CFU/ml count does correlate with Figure 4.6 showing 
that after 24 hrs Ps. aeruginosa numbers are less in a mixed biofilm situation than in 




















Figure 4.8: Antibiotic Concentrations required to Reduce Biofilm Load after 24 hours 
growth of a Mixed Species Biofilm Consisting of Staphylococcus aureus and 
Pseudomonas aeruginosa. Mean CFU/ml counts are plotted against antibiotic 
concentrations with error bars of standard deviation. The biofilms were incubated for 24 hrs 
before being challenged with gentamicin for 2 hrs. Cultures were set up from overnight cultures 
with triplicate beads for each time points. Beads were washed, dissolved, serially diluted and 
plated (as described in Materials and Methods) on to selective plates for each species from 
the mixed biofilms. The individual species were plated on to LB.  The dashed line indicates 





Novel Methods of Disruption to Biofilms may Include D-amino acids and 
Sugar Metabolites 
The antibiotic amounts required to kill or significantly reduce biofilm loads are 
extremely high. It is reasonable to assume that these levels could never be used in a 
clinical setting due to the difficultly in administration and toxic side effects of such 
antibiotic concentrations to the patient. Therefore, other approaches need to be 
identified which can be used in conjunction with conventional therapies to treat 
biofilms. 
 
Use of D-Amino Acids to Disrupt Staphylococcus aureus Biofilms 
In Bacillus subtilis cultures, D-amino acids are naturally produced during late 
stationary phase and have an effect on the structure of pellicles within the culture 
[Kolodkin-Gal et al., 2010]. The same activity has been found to affect Staph. aureus, 
Ps. aeruginosa and Staph. epidermidis [Kolodkin-Gal et al., 2010].  The D-amino acids 
which have the greatest effect on Staph. aureus are D-phenylalanine, D-proline and 
D-tyrosine [Hochbaum et al., 2011]. 
The D-amino acids have been reported to disrupt both the formation of a biofilm when 
added to the culture medium and to disrupt a fully formed biofilm when added after 
the biofilm has become established. 
In the experiments carried out by Hochbaum et al [2011] an older biofilm (over 24 
hours old) was used to examine the effect of D-amino acids on biofilm formation. It 
would be interesting to examine whether the D-amino acid inhibitory effect occurs 
immediately after biofilm formation or whether the biofilms need to be established first. 
Figure 4.10 shows the effects of D-amino acids on the growth of young Staph. aureus 
biofilms.  
Triplicate beads for each time point were inoculated with a 1/10 000 dilution from an 
overnight culture (~104 CFU/ml). D-amino acids were included in the medium either 
singularly or in combination at a concentration of 100 μM (as detailed in Hochbaum 
et al., [2011]). After incubation at 37°C, 150 rpm for the required time (2, 4, 6, or 8 
hours) the beads were washed, dissolved, serially diluted and plated. CFU/ml counts 








Figure 4.9: Effects of D-amino acids on Young Staphylococcus aureus Biofilms. Mean 
CFU/ml counts are plotted against growth time with error bars of standard deviation. Overnight 
cultures were diluted and used to incubate alginate beads for the indicated times. Triplicate 
beads were set up for each condition. Various D-amino acids were included in the inoculum: 
Phenylalanine (Phe), Proline (Pro), Tyrosine (Tyr), all of them or none (control). Beads were 







Figure 4.9 illustrations that the CFU/ml counts still increased over time even with the 
D-amino acids in the culture. This indicates that the presence of D-amino acids has 
no detectable effects on biofilm formation over the first few hours of a biofilm’s 
development, with the strain examined. 
Hochbaum et al., [2011] reported two different experiments. In the first, the biofilms 
were grown in the presence of D-amino acids at different concentrations (Figure 4.10 
A and B). The second experiment involved growing the biofilm for 24 hours then 
placing the biofilms into fresh medium and challenging with D-amino acids to disrupt 
the established biofilms (Figure 4.11). 
For the first experiment (Figure 4.10) biofilms were grown in the presence of D-amino 
acids. Triplicate beads were inoculated with a 1/10000 dilution from an overnight 
culture. D-amino acids were included in the medium either singularly or in combination 
at a concentration of 100 μM (Figure 4.10 A) or 500 μM (Figure 4.10 B). The different 
concentrations are based on the paper published by Hochbaum et al [2011], which 
reported that higher D-amino acid concentrations affected biofilm formation to a 
greater extent. After incubation at 37°C, 150 rpm for 24 hours the beads were washed, 
dissolved, serially diluted and plated. CFU/ml counts were calculated as before. 
CFU/ml counts are plotted against the different D-amino acids on the graphs with error 
bars of standard deviation. 
For the second experiment (Figure 4.11), the D-amino acid challenge, the biofilms 
were pre-grown for 24 hours at 37°C, 150 rpm after which the beads were washed 
and placed into fresh medium with the appropriate D-amino acid for a further 24 hours 




Figure 4.10: Growth of Staphylococcus aureus Biofilms with 100 μM (A) and 500 μM (B) 
D-Amino Acids. Mean CFU/ml counts are plotted against D-amino acids with error bars of 
standard deviation. Overnight cultures were diluted and used to inoculated alginate beads for 
24 hours. 100 μM (A) or 500 μM (B) of Phenylalanine (1), Proline (2), Tyrosine (3) all of them 
(4) or none (5: control) were included in the inoculum. Beads were washed, dissolved, serially 









Figure 4.11: Growth and Challenge of Staphylococcus aureus Biofilms with 100 μM D-
Amino Acids. Mean CFU/ml counts are plotted against D-amino acid with error bars of 
standard deviation. Overnight cultures were diluted and used to inoculate alginate beads for 
the 24 hours. Beads were washed and placed in fresh medium with 100 μM D-amino acids: 
Phenylalanine (1), Proline (2), Tyrosine (3) all of them (4) or none (5: control) for 24 hours. 
Beads were washed, dissolved, serially diluted and plated as described in Materials and 








Even after repeated experiments, with different D-amino acid concentrations added 
immediately or after a growth period, there was no measureable effect on the biofilm 
formation and cell viability. This contradicts the published papers.  
It can be theorised that the D-amino acid effect is strain specific, as has been reported 
with Staph. epidermidis [Ramón-Peréz et al., 2014]. A recently published paper has 
also been unable to replicate the results of the original Staph. aureus experiments 
[Sarkar and Pires, 2015] even using the same strain. Moreover, the D-amino acids 
effect observed in the original Bacillus subtilis study has been shown to be due to a 
strain specific mutation [Leiman et al., 2013].  
 
Using Sugar Metabolites to Restore Gentamicin Sensitivity to Staphylococcus 
aureus Biofilms 
A previous study by Allison et al [2011] details how the addition of sugar metabolites 
can reverse aminoglycoside resistance in biofilms by activating the proton-motive 
force (PMF) transport system. The sugar metabolites, specifically fructose, are taken 
up into the cell by the PMF transport system. This then triggers the uptake of the 
antibiotic.  
Established (24 hours old) biofilms were used for the Allison et al [2011] experiments,  
as it has previously been shown that the biofilms are firmly attached to the alginate 
beads by 4 hours (Figure 3.4) and are resistant to 15 μg/ml gentamicin (Figure 3.5). 
It would be interesting to investigate whether young biofilms have the same reaction 
to the addition of fructose and revert to a gentamicin sensitive phenotype (Figure 
4.12).  
Triplicate beads were incubated with diluted overnight culture for 2 hours before being 
transferred into stationary phase medium (see Materials and Methods) with either 15 
μg/ml gentamicin, 10 μg/ml fructose, both additives or neither and then challenged for 
the required time (1, 2, 3, or 4 hours). After the challenge time, the beads were 
dissolved, serially diluted and plated. CFU/ml counts were calculated as previously 
described. Graphs show CFU/ml counts plotted against challenge times (Figure 4.12). 
Figure 4.12 shows that, while there is no major alteration in antibiotic sensitivity, there 
is a slight dip after 2 hours’ challenge however, the effect is transient. As this 
experiment did not yield the expected result of a reversion to gentamicin sensitivity in 
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the biofilms, the original experiment from Allison et al [2011] was replicated. The 





Figure 4.12: Reversal of Antibiotic Resistance is not Achieved in Young Biofilms (<4 
hours) of Staphylococcus aureus with the Addition of Fructose. Mean CFU/ml counts are 
plotted against challenge time with error bars of standard deviation. The biofilms were 
incubated for 2 hours, washed and transferred into stationary phase medium with 15 μg/ml 
gentamicin (Gent), 10 μg/ml fructose (Fructose) or both (G and F). Control beads had no 
additions. Triplicate beads were set up for each time point. Biofilms were incubated and 
sampled at the indicated time points. Beads were washed, dissolved, serially diluted and 













Figure 4.13: Gentamicin Resistance is not Reversed with the Addition of Fructose to a 
24 hour Staphylococcus aureus Biofilm. Mean CFU/ml counts are plotted against 
challenge time with error bars of standard deviation. The biofilms were incubated for 24 hours, 
washed and transferred into stationary phase medium with 15 μg/ml gentamicin (Gent), 10 
μg/ml fructose (Fructose) or both (G and F). Control beads had no additions. Triplicate beads 
were used for each condition. Biofilms were incubated and sampled at the indicated time 






Development of Biofilms 
It is well documented that numerous bacteria and other microorganisms can form 
biofilms [Burmølle et al., 2014; Costeron et al., 1987]. Indeed biofilms are one of the 
most dominant cell states (>95%) in which bacteria are found [Whitman et al., 1998]. 
The species used in this study were Staph. epidermidis, Staph. saprophyticus, Strep. 
mutans, Strep. pneumoniae, E. coli (2 strains), E. faecalis, K. pneumoniae and Ps. 
aeruginosa. The infections caused by these species include catheter and implant 
associated infections, osteomyelitis, burns and chronic wounds, otitis media and 
pneumonia. All of these infections have a large biofilm component [Bjarnsholt, 2013]. 
Other infections and diseases caused by these bacteria are detailed in Table 1.5 
[Goering et al., 2008]. 
Figures 4.1 A and 4.2 A demonstrated that like so many other bacterial species, the 
species utilised for this study, most of which are clinical isolates, can form biofilms. 
The pattern of the biofilm formation between the species is similar with rapid non-
specific attachment followed by development of a mature biofilm with significant 
resistance to antibiotics.  
Most published studies have been conducted on biofilms which have been grown for 
24 hours or even longer [Ceri et al., 1999; Hochbaum et al., 2011]. Indeed there are 
very few papers detailing the development of young biofilms (under 24hrs old) and 
their resistance profiles. It is true, that within a clinical environment, a biofilm infection 
would only be diagnosed after various tests over a period of weeks [Stoodley et al., 
2011]. Therefore, working with older biofilms allows an appropriate comparison. 
However, it is interesting to note that biofilms are firmly established and exhibit 
substantial antibiotic resistance after such a short growth period. 
Another conclusion which can be drawn from Figures 4.1 A and 4.2 A, is that the 
alginate bead method is further validated as a viable alternative to other biofilm 
models. This relates to the work detailed in Chapter 3. Dall [2013], who initially 
developed the alginate bead method only worked with staphylococcal species. The 
inclusion of these other Gram-positive and Gram-negative bacteria in the present 
study, demonstrates the versatility of the alginate bead method. The inclusion of a 
mucoid alginate producing strain of Ps. aeruginosa was to determine if the alginate 
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composition of the beads affected the formation of biofilms. As a stable biofilm was  
formed on the beads it shows that, even with an alginate producing species (as seen 
in Figure 4.2 A), the alignate of the beads can be regarded as inactive and should 
have no effect on biofilm formation and composition.  
 
Development of Resistance  
Biofilm resistance to antibiotics developed much earlier than expected, in some cases 
within an hour of colonisation (Figure 4.3). Most published biofilm papers are based 
on older (over 24 hours) models and the resistance which develops as the biofilms 
age [Pettit et al., 2009; Yang et al., 2015]. 
The protection a biofilm affords is multifactorial [Burmølle et al., 2014] and may 
influence resistance through innate cell mechanisms, such as efflux pumps, 
sequestering of the antibiotic, and changes in the chemical microenvironment [Mah 
and O’Toole, 2001]. The biofilm matrix itself would also contribute to resistance 
through reduced diffusion rates of compounds [del Pozo and Patel, 2007], low or 
stalled growth rates [Stewart, 2002] and altered gene and protein expression patterns 
[Van Acker et al., 2014]. The associated EPS and extracellular proteins could also 
play a significant role in biofilm resistance [Davis, 2003].  Increasing bacterial 
densities, especially in older biofilms, result in more waste products which could affect 
antibiotic actions inside the biofilms [del Pozo and Patel, 2007]. 
Transport mechanisms, such as efflux pumps, which prevent the antibiotic from 
reaching their target or actively transport compounds out of the cell have been 
extensively investigated [Webber and Piddock, 2003; Piddock, 2006].  
Efflux pumps can either export a specific drug or a group of drugs out of a cell: their 
main function is thought to be the export of natural toxic substances out of the cell, 
and the transport of antibiotics and ensuing resistance is simply a by-product of this 
process [Hooper, 2005; Piddock, 2006]. Although increased expression of efflux 
pumps, especially multidrug resistance (MDR) pumps, is required for active transport 
of antibiotics some wild type bacteria have sufficient constitutive basal pump activity 
to display innate resistance to some antibiotics, for example E. coli and linezolid or 
Ps. aeruginosa and fluoroquinolones. When these pumps are inactivated the bacteria 
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demonstrate susceptibility to these antibiotics [Livermore, 2003; Lomovskaya et al., 
1999]. 
In a clinical situation gentamicin is used against Gram-negative aerobic bacilli and 
Gram-negative species, such as the strains used in this study [Ramirez and 
Tolmasky, 2010]. The known resistance mechanisms of gentamicin include 
modification of the antibiotic target site [Galimand et al., 2005], reduced membrane 
permeability [Hancock, 1981], active transport out of the cell [Aires et al., 1999], 
sequestering the antibiotic [Magnet et al., 2003] and enzymatic inactivation of the 
antibiotic [Ramirez and Tolmasky, 2010]. 
Of these mechanisms, it is probably the active transport and sequestering of the 
antibiotic which are the major cell specific resistance mechanisms in use in Figure 
4.4.  For the lower concentrations of antibiotics resistance was present thus, these 
two mechanisms are functioning effectively. As the antibiotic concentrations rise the 
mechanisms could be overwhelmed thus leading to a killing effect and a reduction in 
biofilm load (4.4b). 
Other resistance mechanisms are a consequence of the biofilm matrix itself as the 
negatively charged biofilm matrix inhibits penetration of positive aminoglycosides and 
the absence of oxygen within the biofilm reduces aminoglycoside activity [del Pozo 
and Patel, 2007]. 
Three of the strains used in the current study, were innately resistant to gentamicin 
(Staph. saprophyticus, Strep. mutans and E. faecalis), as determined by growth 
overnight on agar plates.  Therefore, vancomycin was used to test the development 
of resistance. Vancomycin is the clinical treatment of choice for invasive 
staphylococcal infections [Kiedrowski and Horswill, 2011]. Vancomycin is a slow 
acting antibiotic [Chamber and DeLeo, 2009], however, in E. faecalis resistance was 
seen to develop within 1 hour of growth (Figure 4.3b, G). When the biofilm is 
challenged after 3 hours growth only the highest vancomycin concentration destroys 
the E. faecalis biofilm (Figure 4.4b, G). The same effect can be seen with the 24 hour 
old biofilm only being reduced by ~2 log growth rather than completely eliminated like 
the strains treated with gentamicin (Figure 4.4b, G). 
Vancomycin resistance was first identified in Enterococcus species in the mid-1980s 
and though it has spread resistance remains at relatively low levels. There are two 
recognised forms of resistance. High-level resistance is due to a plasmid encoding 
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proteins which decrease the binding affinity for vancomycin [Courvalin, 2006]. The 
second form of resistance is termed intermediate and is due to mutations which 
increase cell wall thickness and teichoic acid D-alanylation resulting in reduced 
penetration of the antibiotic into the bacterial cell [Howden et al., 2010]. 
The three strains treated with vancomycin all showed the same resistance pattern of 
incomplete biofilm clearance even with higher antibiotic concentrations (Figure 4.4). 
It may be that as vancomycin is slow acting [Chambers and DeLeo, 2009] the biofilm 
is able to establish itself and become resistant before the antibiotic can take effect. A 
significant limitation to the use of vancomycin for biofilm treatment is that vancomycin 
only effectively acts on actively growing cells which only make up a small percentage 
of a biofilm [Chamber and DeLeo, 2009]. Although, vancomycin has been shown to 
be able to penetrate and damage biofilms, cells remain viable. Thus it is rarely used 
as monotherapy in a clinical environment [Dunne et al., 1993]. 
Whilst some innate cell mechanisms such as efflux pumps play a role in biofilm 
resistance, the main reason behind the resistance must be due to the biofilm itself. 
Biofilms resistance mechanisms have been discussed previously but to summarise 
heterogeneous gene and protein expression, reduced diffusion into the biofilm matrix, 
EPS, formation of persister cells, and different growth rates all contribute to biofilm 
resistance to antibiotics, disinfectants, antiseptics and other environmental stresses.  
Antibiotic sensitivity is restored when the bacteria re-enter a planktonic state, this 
indicates that biofilm resistance is an adaptive mechanism rather than one which 
requires genetic modification [Stewart, 2002]. 
 
Development and Challenge of Mixed Species Biofilms  
Mixed species biofilms develop in much the same way as a single species biofilm. 
However, the presence of more than one species may generate a more complex 
structure and different functions and mechanisms need to be considered [Sanchez-
Vizuete et al., 2015]. Multispecies biofilms are common in nature and can be found in 
many geochemical cycles, human health and homeostasis, industrial and clinical 
settings [Davey and O’Toole, 2000].  
Bacteria forming multispecies biofilms have been shown to have a protective effect 
on each other and to produce a higher biofilm load when compared to the individual 
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species [Burmølle et al., 2006]. These mixed biofilms are more resistant to chemical 
stress, antimicrobials and host immune defence mechanisms [Bridier et al., 2012; 
Harriott and Noverr, 2009; Stewart, 2002]. Multispecies biofilms can be composed of 
bacteria, yeast or a combination of these two microorganisms [Harriott and Noverr, 
2009].  
The mixed biofilm investigated in this study was constructed of Staph. aureus and Ps. 
aeruginosa. These two species are serious HCAIs and cause a variety of diseases, 
infections, and problems within healthcare environments as detailed in Chapter 1. The 
combination of these two species was chosen as, in a clinical environment, they are 
found in the same host sites and associated with similar types of infections and 
diseases and thus could form biofilms together [Hendricks et al., 2001]. 
Staph. aureus and Ps. aeruginosa are among the most frequently isolated organisms 
from HCAIs [ECDC, 2011]. The ability of these two organisms to form a mixed biofilm 
which can delay wound healing and alter the production of virulence factors [DeLeon 
et al., 2014]. Dual infections by Ps. aeruginosa and Staph. aureus result in worse 
patient outcomes than individual infections [Rosenbluth et al., 2004]. 
Synergistic effects have been reported in mixed biofilms of Staph. aureus and Ps. 
aeruginosa, and Figure 4.6 correlates with the published results [DeLeon et al., 2014]. 
The resistance of the biofilm is immediate, and was developed at a lower cell density 
than the biofilms formed by the individual species. Higher antibiotic concentrations 
were also withstood (Figure 4.7). 
However, it is interesting to note that for the 24 hour old biofilm (Figure 4.8) there 
seems to be a reduction in the Ps. aeruginosa cell numbers from the mixed biofilm 
compared to the individually formed biofilm. It may be by the 24 hour time point that 
the culture medium is exhausted so the cells are becoming competitive against the 
second species.  
The Staph. aureus quorum sensing system, unlike that in Ps. aeruginosa [O’Loughlin 
et al., 2013] actually encourages biofilm detachment by the activation of the agr 
system and release of extracellular proteases [Kiedrowski and Horswill, 2011; 
Thoendel et al., 2011]. It is possible that the Staph. aureus cells are dissociating from 
the biofilm and this and the resulting proteases are damaging the Ps. aeruginosa cells 
and causing their detachment allowing the antibiotics to once again penetrate the 
biofilm and have an effect. This could account for the difference in colony numbers 
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between the challenged and unchallenged cultures of Figure 4.6, and the fact that a 
lower antibiotic concentration is required to kill the Ps. aeruginosa from the mixed 
culture than that of the individual culture (Figure 4.8). 
 
Use of D-Amino Acids to Disrupt Staphylococcus aureus Biofilms 
The antibiotic concentrations required to reduce the biofilm load in both single and 
mixed species biofilms are immense and not necessarily practical in a clinical setting 
therefore, alternative approaches are needed to disrupt biofilms and act in conjunction 
with conventional therapies. 
The ability of D-amino acids to disrupt biofilms is controversial. It was originally 
suggested that the D-amino acids inhibit and disrupt biofilm formation and was first 
observed for B. subtilis, although it was then reported for various other species 
including Staph. aureus and Staph. epidermidis [Kolodkin-Gal et al., 2010; Hochbaum 
et al., 2011; Ramón-Peréz et al., 2014].  
The theory behind the disruptive effect is that the D-amino acids are incorporated into 
the cell wall affecting peptidoglycan synthesis and preventing major biofilm matrix 
proteins from attaching to the cell wall. This might lead to decreased intracellular 
adhesion and poor formation of biofilms [Lister and Horswill, 2014]. 
Different D-amino acids have been reported to be effective against different species. 
It was reported that D-Phenylalanine, D-Proline and D-Tyrosine were most effective 
against Staph. aureus. D-methionine and D-alanine were reported to affect Staph. 
epidermidis whereas apparently D-Tryptophan, D-Tyrosine, D-leucine and D-
methionine were most effectual against B. subtilis biofilms [Hochbaum et al., 2011; 
Kolodkin-Gal et al., 2010; Ramón-Peréz et al., 2014]. 
The initial experiments carried out in the current study examined the effect of D-amino 
acids on young biofilms (Figure 4.9). When no effect was observed one of the 
Hochbaum et al [2011] experiments was replicated as closely as possible (Figure 4.10 
A). Once again no effect was seen even with the higher D-amino acid concentrations. 
A combination of the three D-amino acids, which had been reported as being more 
effective than them individually, did not produce any significant disruption to the 
biofilms (Figure 4.10 B).  
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The second experiment detailed in the Hochbaum et al [2011] paper reported that if 
biofilms were allowed to develop normally for a period (24 hours), the addition of D-
amino acids extensively damaged the biofilms. However, once again no reduction in 
biofilm load or damage to the biofilm was seen when the experiment was replicated, 
using this Staph. aureus strain (Figure 4.11). 
An explanation for these results could be that the original reports of the D-amino acids 
effects were incorrect or exaggerated. In fact, there have been recently published 
papers which have found that the original experimental results were not reproducible, 
even when using the same Staph. aureus strain. Sankar and Pires [2015] 
demonstrated that none of the three reported effective D-amino acids inhibited biofilm 
formation or enhanced disruption of biofilms in Staph. aureus, Staph. epidermidis or 
B. subtilis. Sankar and Pires [2015] also screened 96 unnatural D-amino acids, none 
of which had any inhibitory effect on Staph. aureus biofilms.  
The B. subtilis strain used in the original experiments [Kolodkin-Gal et al., 2010] was 
found to have a strain specific mutation in the dtd gene [Leiman et al., 2013]. This 
gene encodes D-tyrosyl-tRNA deacylase which prevents misincorporation of D-amino 
acids into proteins. When this mutation was repaired the strain was no longer 
susceptible to the D-amino acids effects and was able to correctly develop and 
maintain biofilms. 
When the use of D-amino acids to inhibit biofilms was first proposed it seemed like a 
promising addition to the arsenal of alternative biofilm treatments. However, the 
recent publications and the results gathered from this study, have proven that the D-
amino acids have little to no effect on biofilm formation and disruption. Thus the use 
of D-amino acids is not a viable adjunctive therapy to antibiotic treatment of biofilms.   
 
Using Sugar Metabolites to Restore Gentamicin Sensitivity to Staphylococcus 
aureus Biofilms 
The possible use of sugar metabolites in returning persister cells and biofilms to an 
aminoglycoside sensitive state was first reported by Allison et al [2011]. This paper 
reported that various sugar metabolites are transported by PMF into the cell’s 
cytoplasm where they enter glycolysis. The catabolism of the sugars produces NADH 
which is oxidised by electron transport chain enzymes contributing to subsequent 
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generation of PMF. The increase in PMF facilitates entry of aminoglycosides into the 
cell where the antibiotics are able to act upon their target and induce cell death.  
Both E. coli and Staph. aureus were used in the Allison et al [2011] experiments. 
Interestingly, only fructose was reported to aid gentamicin activity in Staph. aureus 
whereas in E. coli mannitol, glucose and pyruvate also had an effect. When the sugar 
metabolites were tested with other antibiotic classes, it was demonstrated that the 
sugar assisted eradication of biofilms was aminoglycoside specific. It was suggested 
that as aminoglycoside uptake into cells is based on PMF [Taber et al., 1987] this is 
only this class of antibiotics whose transport and activity is affected by the sugar 
metabolites and that the cells did not revert back to a normal growing state – as 
evidenced by the lack of renewed activity of the β-lactams and quinolones antibiotic 
classes. 
Based on the Allison et al [2011] paper, this study attempted to disrupt young (>4hrs 
old) Staph. aureus biofilms with the addition of fructose. As can be seen from Figure 
4.12 a slight dip was observed in the CFU/ml count after 2 hours challenge with 
gentamicin and fructose. However, this decrease is present in all conditions, even the 
control and thus should not be considered significant. The results indicated that 
fructose does not disrupt biofilm formation in young biofilms  
In the Allison et al [2011] experiment, the biofilms were incubated for 24 hours before 
been challenged with fructose and gentamicin. As no inhibition was detected in Figure 
4.12, this experiment was replicated (Figure 4.13). However, there were no 
observable differences in the biofilms when challenged with gentamicin alone, 
fructose alone, gentamicin and fructose combined or when nothing was added to the 
culture.  
Possible explanations for these results are that, although the experimental protocol 
was followed as closely as possible there is always variation in personal and 
laboratory techniques and equipment. A different Staph. aureus strain was used in 
this study compared to the Allison et al [2011] study which may suggest that the effect 
of sugar metabolites is strain specific. However, this seems unlikely as the PMF 
system is universal between bacteria [Kashket, 1985]. 
The use of sugar metabolites to disrupt biofilms is worth further investigation although, 
the effects published in Allison et al., [2011] were not able to be reproduced. Other 
papers have demonstrated that sugar metabolites have a detrimental effect on biofilm 
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formation. In the study, conducted by Durmus et al [2012], Staph. aureus bacterial 
growth on endotracheal tubes (ETTs) was reduced when the tubes were coated with 
fructose.  
Bucior et al [2013] reported a sugar mixture of mannitol, fucose and galactose 
inhibited bacterial adhesion to bronchial epithelial cells in vitro in a murine model of 
acute Ps. aeruginosa pneumonia. Synergistic activity was also demonstrated when 
the sugars were administered with conventional antibiotics reducing bacterial lung 
colonization and damage.  
From these papers it appears that a mixture of sugars are required for Gram-negative 
bacteria whereas a single sugar (usually fructose) is able to produce an effect in 
Gram-positive bacteria. However, further work is required to clarify this and further 























The Bacterial Binding Proteins; CPGRP and 
SP-D, and their expression in Pichia pastoris 












As has been described previously in Chapters 3 and 4, biofilms are a major issue in 
the health care environment and can form on catheters, prosthetic valves, artificial 
joints and other devices [Goering et al., 2008]. Successful eradication of biofilms is 
difficult due to the nature of where the biofilms form and the antibiotic resistance that 
they develop. Treatment is commonly long term, high dose antibiotics combined with 
removal and replacement of the affected device. However, in some cases, such as 
prosthetic joints, replacement is not an option. Therefore confirmation of existing 
biofilm presence and/or the successful eradication of biofilms would be a huge 
advantage. 
This chapter details experiments in which a fusion protein consisting of a bacterial 
binding protein and a fluorescent detector molecule were explored. Potential uses of 
such a fusion protein, in a clinical setting could include the imaging of prosthetic 
devices such as catheters which are commonly colonised but difficult to image and 
treat [Leevy et al., 2008; White et al., 2010]. 
If bacterial biofilms were found at a site treatment could be tailored specifically thereby 
reducing the investigation cost and time, the antibiotic usage and improving the 
patient’s quality of life. 
The two potential bacterial binding proteins examined are Camel Peptidoglycan 
Recognition Protein (CPGRP) and Surfactant Protein-D (SP-D) from both yeast 










Camel Peptidoglycan Recognition Protein (CPGRP) 
 
Discovery of Peptidoglycan Recognition Proteins (PGRPs) 
The term Peptidoglycan Recognition Protein was first used by Yoshida, Kinoshita and 
Ashida [1996] in reference to the protein purified from the hemolymph of the silkworm 
Bombyx mori. The discovery of this protein was related to the hemolymph prophenol 
oxidase cascade which is one of the silkworm’s defence pathways against infection. 
PGRP is triggered by recognition of non-self molecules including lipopolysaccharide 
(LPS), lipoteichoic acid (LTA), peptidoglycan (PGN), flagella of Gram-negative and 
Gram-positive bacteria, as well as elements of the fungal cell wall [Yoshida et al., 
1996; Swaminathan et al., 2006]. 
Since then, PGRPs have been identified in many species including cows, camels, 
humans, pigs, moths and mosquitoes [Dziarski, 2004], showing that this group of 
proteins is highly conserved between insects and mammals [Kang et al., 1998; Guan 
and Mariuzza, 2007]. There have been nearly 100 PGRPs identified to date [Guan 
and Mariuzza, 2007]. Cysteine residues in mammalian PGRPs are considered to be 
especially important as they form disulphide bonds (Cys6-Cys130, Cys22-Cys67 and 
Cys43-Cys49, see Figure 5.1) [Sharma et al., 2011a] which assist in stabilising the 
protein in the extracellular or leukocyte granule environments [Dziarski, 2004]. 
Within insects, PGRPs and other similar molecules provide the main defence against 
infecting pathogens as invertebrates lack an adaptive immune system, instead relying 
on their innate immunity [Kang et al., 1998]. The basic function of a PGRP is the 
recognition of conserved molecular patterns found on the surfaces of bacterial cells, 
which are not native to the host. [Swaminathan et al., 2006; Medzhitov and Janeway, 
1998]. This recognition function triggers various innate immune system cascades and 









1   10     20        30    40   50 
CPGRP-S ----EDPPACGSIVPRREWRALASECRERLTRPVRYVVVSHTAGSHCDTPASCAQQAQNV 56 
BPGRP-S -------QDCGSIVSRGKWGALASKCSQRLRQPVRYVVVSHTAGSVCNTPASCQRQAQNV 53 
HPGRP-S -QETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNV 59 
MPGRP-S -----------FIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNV 49 
RPGRP-S ---------CCFVVPRSEWKALPSECSKGLKKPVRYVVISHTAGSFCSSPDSCEQQARNV 51 
DPGRP-S KSRQRSPANCPTIKLKRQWGGKPSLGLHYQVRPIRYVVIHHTVTGECSGLLKCAEILQNM 60 
     60   70     80         90     100  110 
CPGRP-S QSYHVRNLGWCDVGYNFLIGEDGLVYEGRGWNIKGAHAGPTWNPISIGISFMGNYMNRVP 116 
BPGRP-S QYYHVRERGWCDVGYNFLIGEDGLVYEGRGWNTLGAHSGPTWNPIAIGISFMGNYMHRVP 113 
HPGRP-S QHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNPMSIGISFMGNYMDRVP 119 
MPGRP-S QHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVP 109 
RPGRP-S QLYQMKQLGWCDVAYNFLIGEDGHVYEGRGWTIKGDHTGPIWNPMSIGITFMGDYSHRVP 111 
DPGRP-S QAYHQNELDFNDISYNFLIGNDGIVYEGTGWGLRGAHT-YGYNAIGTGIAFIGNFVDKLP 119 
   120   130     140  150     160  170 
CPGRP-S PPRALRAAQNLLACGVALGALRSNYEVKGHRDVQPTLSPGDRLYEIIQTWSHYRA-- 171 
BPGRP-S PASALRAAQSLLACGAARGYLTPNYEVKGHRDVQQTLSPGDELYKIIQQWPHYRRV- 169 
HPGRP-S TPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP- 175 
MPGRP-S AKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE-- 164 
RPGRP-S AKRALRAALNLLKCGVSEGFLRSNYEVKGHRDVQSTLSPGDQLYEIIQSWDHYRE-- 166 
DPGRP-S SDAALQAAKDLLACGVQQGELSEDYALIAGSQVISTQSPGLTLYNEIQEWPHWLSNP 176 
 (C: Camel, B: Bovine, H: Human, M: Mouse, R: Rat, D: Drosophila) 
 
Figure 5.1: Alignment Diagram showing the Conserved Amino Acid Sequences from 
Various Species [Adapted from Sharma et al, 2011b]. CPGRP-S is the molecule of interest 
for this study (pink). Yellow highlighted portions denote cysteine residues. The important 
amino acids which favour dimerisation in CPGRP are shown in green. Subsite I consists of 







Peptidoglycan is the most common component which is recognised as part of a 
Pathogen Associated Molecular Pattern (PAMP), with the components N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) making up this 
polymeric molecule in a series of repeating units. [Swaminathan et al., 2006; Sharma 
et al., 2012b]. 
Peptidoglycan activates the mammalian immune system through two pattern 
recognition receptors; Toll like receptor 2 (TLR-2) and CD14 [Weidemann et al., 1994; 
Weidemann et al., 1997]. These receptors are found on the surface of macrophages 
and induce cytokine and chemokine production in response to invasion by foreign and 
unrecognised molecules. If the cytokine and chemokine reactions are too excessive, 
symptoms of infection such as inflammation, fever, hypotension and in severe cases, 
circulatory shock and multiple organ failure may be caused [Swaminathan et al., 2006; 
Lie et al., 2000]. 
 
Classifications of PGRPs Types  
Approximately 100 different PGRPs have been identified, all of which contain a 
peptidoglycan binding site of ~165 amino acids in length [Guan and Mariuzza, 2007]. 
Those found in insects can be divided into two groups; short PGRPs (PGRP-S) which 
are no more than 20kDa and long PGRPs (PGRP-L) which are no more than 90kDa 
[Dziarski 2004]. These are extracellular (PGRP-S only), intracellular or 
transmembrane proteins, found in the insect’s immune organs (fat body, gut and 
haemocytes), some of whose expression may be up-regulated upon exposure to 
either bacteria or peptidoglycan [Dziarski, 2004; Guan and Mariuzza, 2007]. There 
are two possible roles within the immune system which these proteins can fulfil, either 
activating proteolytic cascades and signalling pathways (non-catalytic PGRPs), or 
hydrolysing peptidoglycan (catalytic PGRPs) [Dziarski, 2004]. 
Four classes of mammalian PGRPs: short (PGRP-S), intermediate, of which there are 
two sub-groups (PGRP-Iα and PGRP-Iβ), and long (PGRP-L) have been identified 
[Sharma, 2008]. All are soluble intracellular or secreted proteins [Guan and Mariuzza, 
2007] with immune defence roles [Liu et al., 2000]. One of the effects that a 
mammalian PGRP has within a system is the reduction of the immune cascade 
activation, in effect reducing the consequences of recognition of peptidoglycan and 
other PAMPs, within the immune system [Sharma, et al., 2008; Liu, et al., 2000]. 
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Camel Peptidoglycan Recognition Protein  
CPGRP-S is a soluble conserved pattern recognition molecule of the innate immune 
systems of camels [Kappeler et al., 2004; Medzhitov and Janeway, 1998; Sharma et 
al., 2008; Sharma et al., 2011a; Sharma et al., 2011b]. CPGRP has a more 
pronounced role than in other mammals because of the camel’s unusual immune 
system [Sharma et al., 2008; Sharma et al., 2011b]. Molecules which are common in 
other mammalian immune systems including lysozyme C, lactoferrin and 
lactoperoxidase are only found at low concentrations within the camel. This may 
explain the prominence of CPGRP [Sharma et al., 2008; Sharma et al., 2011a] as it 
provides a first line of defence against infecting pathogens. When the molecule was 
originally discovered it was isolated from camels’ milk, [Kappeler et al, 2004] with the 
highest concentration produced during mastitis. Mastitis is rarely reported in camels 
in comparison to cattle and other mammals used for milking due to the presence of 
CPGRP [Sharma et al., 2011b].  
CPGRP has a similar specificity, but higher affinity, for peptidoglycan than another 
molecule of the immune system, lysozyme C. Lysozyme C antimicrobial properties 
include hydrolysing peptidoglycan, as well as immunomodulation and anti-
inflammatory functions [Kappeler et al., 2004]. CPGRP acts by inhibiting bacterial 
infections through interaction with peptidoglycan and other PAMP components, 
including LTA, LPS and their moieties [Sharma et al., 2011b; Sharma et al., 2012a]. 
The binding of CPGRP to these molecules occurs with varying affinities, specificities 
and potencies for each one [Sharma et al., 2011a; Sharma et al., 2012a].  
A subsequent effect of this interaction is the reduction in LTA/LPS induced expression 
of the pro-inflammatory cytokines (Tumour Necrosis Factor-α and Interleukin-6). This 
results from the blocking of available LTA/LPS to the PAMP receptors (CD14, Toll 
and CD6) expressed on T-cells. Studies have shown that a reduction of these 
potentially excessive immune responses may prevent severe inflammatory reactions 
and sepsis [de Kimpe et al., 1995]. 
CPGRP is made up of four polypeptide chains (Figure 5.2) each consisting of 171 
amino acids [Sharma et al., 2011b]. Of all the known PGRPs, CPGRP is the only 
tetrameric complex structure which has been identified, that gives rise to a versatile 







Figure 5.2: Representation of Camel Peptidoglycan Recognition Protein Showing the 
Channel and Binding Region [Sharma et al., 2011b]. Major α-helices are represented by 
the long cylinders, the central β-sheet by the arrows, the remaining cylinders show minor α-
helices. MDP: muramyl dipeptide is a moiety of peptidoglycan. Subsite I is located along the 
boundary of molecular C and D with some extension into the interface of molecular A and C.  







Comparisons with PGRPs from other species e.g. human PGRP binding sites, show 
that their amino acid residues do not favour dimerisation as in CPGRP. The amino 
acids which impart this multimerisation property onto CPGRP include an Alanine 
residue at position 94 and Proline moieties at positions 96 and 151(highlighted in 
green on Figure 5.1) [Sharma et al., 2011a].  
The basic architecture of a CPGRP monomer is a central β sheet surrounded by 3 
major α helices, stabilized by 3 disulphide linkages [Sharma et al., 2011a]. A CPGRP 
monomer is ~20kDa [Sharma et al., 2008] and, therefore, is considered a short PGPR. 
The tetramer itself is constructed of non-covalent associations between the four 
molecules leading to the formation of a binding site which is located inside the 
asymmetric homotetramer [Sharma, 2008]. The four monomers naturally assemble 
into a multimer when expressed [Sharma et al., 2011b]. 
The CPGRP binding channel is formed from the lack of intermolecular interactions 
between monomers B and D, with the final binding region residing at the interface of 
monomers C and D with some extension into the boundary between monomers A and 
C. Binding of ligands does not disrupt the structural formation of the binding site or 
molecule, however, the orientations of some of the side chains are slightly altered 
[Sharma et al., 2011b].  
The shape of the channel is similar to a funnel in that it has a wider opening at the 
exterior of the molecule than the internal end in the middle of the molecule; this may 
help in capturing PAMPs more effectively. Another factor which may influence PAMP 
recognition is the flexible N termini of monomers B and D which may filter out non-
PAMP molecules lacking stereo-chemical complementarity [Sharma et al., 2011b]. 
The binding channel contains multiple subsites therefore, it is able to detect different 
PAMPs with specificity through direct interaction [Sharma et al., 2012b]. Different 
compounds bind to different subregions of the binding site. Two different subsites 
have been identified (residues highlighted in Figure 5.1). Subsite I (S I) recognises 
the glycan moieties of peptidoglycan more readily than Subsite II (S ll) [Sharma et al., 






Sharma et al., [2011a] compared the binding of LPS (from E. coli serotype O55:B5) 
and LTA (from Staph. aureus) and found that there are common amino acid residues 
but also some which are polymer specific. LPS connects with the amino acids Lys-
C90, Ala-C92, Asn-C99 and Arg-A170 (mainly from monomer C) whereas LTA 
interacts with Thr-D27, Asn-C99, Gln-D150 and Asn-A140 residues (primarily from 
monomer D) [Sharma et al., 2011a].  
CPGRP targets cell wall molecular patterns rather than cell membranes and as such 
could possibly be developed as a protein antibiotic, with a bacteriostatic action 
[Kappeler et al., 2004], which would be unlikely to encounter bacterial resistance 
[Sharma et al., 2011a]. Whole bacterial cells (Staph. aureus) were used to determine 
the effect of CPGRP on growth inhibition [Sharma et al., 2011b]. The binding channel 
interacts directly with the molecules of the bacterial cell wall, thereby, inhibiting further 
cell growth. Activation of immune cells is also reduced, thus there is less amplification 
of immune system reactions [Sharma et al., 2011b].  
CPGRP is capable of detecting a wide range of microorganisms including many 
Gram-positive and some Gram-negative bacteria [Sharma et al., 2011b]. 
Enterobacter agglomerans, E. coli, Staph. aureus, Micrococcus species and lactic 
acid bacteria including Lactobacillus delbrueckii spp. bulgaricus (whole cells) have 
been used in studies examining the binding of CPGRP to bacteria [Kappeler et al., 
2004]. Binding was found to be strong against the Gram-positive bacteria with weak 
binding against the Gram-negative bacteria [Kappeler et al., 2004]. However, 
subsequent studies have found that CPGRP does in fact bind to Gram-negative 
bacteria mainly through the LPS component of the bacterial cell membrane [Sharma 
et al., 2008; Sharma et al., 2011a]. 
When the 3D structure of CPGRP is examined closely (Figure 5.2) it can be seen that 
the N termini are more accessible than the C termini, with slight ‘tails’ reaching out 
from the main structure of the protein. Consequently the addition of a detector 
molecule, such as a fluorescent protein, onto these ends should not interfere with 
protein folding and function. This would prove advantageous in the potential 






Surfactant Protein D (SP-D) 
 
Discovery and History 
Pulmonary surfactant is composed of a mixture of phospholipids (90%) and proteins 
and is found at the interface of alveolar gas and liquid hypophase in the airways and 
alveoli [Wright, 1997], maintaining the surface tension in the lungs to prevent the lungs 
from collapsing during respiration [Head et al., 2003; Kishore et al., 2006]. Surfactant 
deficiency can lead to a range of problems such as laboured breathing and 
inadequate oxygenation, this is most commonly seen in premature infants unable to 
produce enough surfactant [Wright, 1997]. 
There are four surfactant proteins which are synthesised by the alveolar type II cells 
and secreted into the airspaces of the lung [Crouch et al., 1994]. They were first 
detected in amniotic fluid in 1975; production begins between 30 and 37 weeks 
gestation [Lu et al., 1992]. The surfactant protein’s role in this environment is thought 
to be the clearance of pathogens from the foetal membranes and amniotic fluid via 
amnion cells or decidual membranes [Malhotra et al., 1994]. 
The four surfactant proteins SP-A, SP-B, SP-C and SP-D are present at different 
distributions within the lungs, found at 5.3%, 0.7%, 0.4%, and 0.6% of the pulmonary 
surfactant respectively [Weaver and Whitsett, 1991]. SP-B (14kDa) and SP-C (6kDa) 
are small, hydrophobic proteins whereas SP-A and SP-D are large hydrophilic 
proteins. The functions of SP-B and SP-C include organisation of the surfactant, 
adsorption to the air-liquid interface, phospholipid packaging, and stabilisation of the 
phospholipid monolayer ensuring the stability of the surfactant layer [Kishore et al., 
2006; Lu, et al., 1992]. 
It is interesting to note that even though SP-A and SP-D have similar structures they 
have very different binding patterns and modes of action. SP-D binds to the heptoses 
on the inner oligosaccharide core or the mannose rich O-polysaccharide of LPS while 
SP-A prefers the lipid A domain of LPS [Head et al., 2003; Seaton et al., 2010]. These 
differences in binding potentials could be attributed to the structural variances of the 
binding region’s shape and orientation [Seaton et al., 2010].  
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The placement of these two proteins within the alveolar compartment will enable them 
to immediately intercept any inhaled microbes coming into the lungs. Estimations of 
SP-A and SP-D concentrations in the lungs are 300-1800µg/ml and 36-216µg/ml 
respectively [Wu et al., 2003]. Even though SP-D is mainly associated with the lung it 
is also found in other tissues including the intestinal mucosa, thymus, prostate gland 
and paranasal sinuses [Wang et al., 2008b].  
SP-A and SP-D, along with serum mannose-binding protein (MBP), are members of 
the collectins, a family of innate immune defence proteins named for the collagen-like 
and lectin domains within their structure [Gupta and Surolia, 2007]. Collectins are 
known for enhancing clearance of microorganisms through agglutination, 
opsonisation and reduction of epithelial adherence via binding to glycoconjugates on 
a microorganism’s surface [Head et al., 2003].  
The main roles of SP-A and SP-D are controlling infection by having a bacteriostatic 
effect on microbial growth, inducing phagocytosis though activating neutrophils and 
macrophages, and influencing cytokine and chemokine pathways during inflammation 
bought about by infection, necrotic/apoptotic cells and allergen challenges [Gupta and 
Surolia, 2007; Kishore et al., 2006]. 
SP-D, and SP-A, can act as immunomodulators which may assist in regulating the 
inflammatory response [Wu et al., 2003]. This is done primarily by enhancing 
production of cytokines such as TNF-α, IL-1α, IL-1β [Wright, 2005] and regulation of 
LPS induced inflammation by endotoxin clearance [Quintero et al., 2002].  
There is ~70% identity in the amino acid sequences of human SP-D to rat and bovine 
SP-D [Lu et al., 1992]. However, binding affinities of the proteins differ, for example 
rat and mouse SP-D bind more efficiently to Influenza A virus than human SP-D. 
Human SP-D interactions with viruses are based on binding to asparagine-linked 
glycans which are expressed on viral envelope proteins [Hartshorn et al., 2000; Leth-
Larsen et al., 2007]. Human SP-D also demonstrates a different saccharide inhibition 







Protein sequence analysis has shown that each SP-D chain is made up of a short N- 
terminal domain, a triple-helical collagen like sequence, a short α-helical neck domain 
and a non-collagenous COOH- terminal domain, [Crouch et al., 1994; Seaton et al., 
2010] which is known as the Carbohydrate Recognition Domain (CRD), as can be 
seen in Figure 5.3 [Kishore et al., 2006]. 
 
Figure 5.3: Linear Representation (A) and Crystal Structure (B) of Surfactant Protein-D 
bound with Maltose [Adapted from Kishore et al., 2006]. A) Linear Representation of the 
SP-D structure. UTR: Untranslated region, N: N-terminal region, CLR: Collagen like region, 
Neck: Neck domain, and CRD: Carbohydrate recognition domain. B) Neck-CRD trimeric 
recombinant fragments of SP-D viewed perpendicular to the molecular three-fold axis. Maltose 
and three calcium ions are bound. Each of the three monomers is a different colour. The CRD, 




The protein is secreted as monomers of trimeric subunits [Crouch, 2000] which self-
assemble to form trimers [Crouch et al., 1994]. Each monomer is ~43 kDa. These 
monomers form the collagen-like triple helix (Figure 5.3) [Lu et al., 1992]. The shape 
of the trimer presents a broad surface which connects with the microbial or membrane 
surface of interest to assist in recognition and binding [Seaton et al., 2010]. 
 
Binding characteristics 
Peptidoglycan has been suggested to be the generic ligand for SP-D recognition of 
microorganisms as it has a conserved structure between species [Gupta and Surolia, 
2007].  It is the CRD of SP-D which is responsible for the binding of the molecule to 
LPS of bacteria specially the core oligosaccharide and/or polysaccharide chains. 
There seems to be a preference for ‘rough’ LPS though ‘smooth’ LPS can also be 
bound [Wang et al., 2008a]. 
Ligand recognition occurs at three structural levels; the CRD, the trimeric CRD and 
multimers of trimeric subunits [Seaton et al., 2010]. The minimal recognition unit is 
the CRD; fragments of this molecule which include the neck-CRD show the same 
binding capabilities as the entire molecule [Wang et al., 2008b]. However, multiple 
trimers bound together may amplify the strength of ligand binding [Gupta and Surolia, 
2007]. The shape of the SP-D molecule with a bound ligand is slightly different from 
that of the molecule without a ligand bound, in that the tilt angle of the neck region is 
reduced and the perpendicular orientation of the CRD region is absent [Wang et al., 
2008b]. 
As suggested by the name CRD, carbohydrate ligands such as glucose, fucose, 
GlcNAc and ManNAc can be bound. However, interactions with hydrophobic 
molecules, such as fatty acids have also been reported [Seaton et al., 2010]. 
Bacterial species to which SP-D binding has been recorded include P. aeruginosa, 
acapsular K. pneumoniae, E. coli, Bordetella pertussis, Haemophilus influenzae, 
Mycobacterium tuberculosis and Helicobacter pylori [Wang et al., 2008a]. Fungal and 
viral species include Saccharomyces cerevisiae, Candida albicans, Aspergillus 
fumigatus, rotavirus, Influenza A Virus (IAV) and Respiratory Syncytial Virus, SARS 
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coronavirus and HIV [Crouch et al., 2009]. It is the polysaccharides and highly 
glycosylated proteins found on fungal cell surfaces which act as ligands for SP-D and 
SP-A [Gupta and Surolia, 2007]. SP-D activity against viruses is facilitated by 
interactions with viral envelope proteins. For example IAV, consists of recognition of 
the oligomannose sugars on the viral hemagglutinin [Crouch et al., 2005; Crouch et 
al., 2009]. Binding and opsonising pathogens augment their uptake by macrophages 
and neutrophils [Crouch et al., 2009]. 
The activity of SP-D can be inhibited by supplying the experimental system with 
excess free LPS vesicles, which compete with bacterial surfaces for binding leading 
to a reduction in aggregation and growth inhibition [Wu et al., 2003]. 
Both Gram-positive and Gram-negative species are bound to and aggregated by SP-
D in a calcium dependent manner enhancing microbial phagocytosis by alveolar 
macrophages. Agglutination of bacterial species would also have a negative impact 
upon the microbe’s physiology and access to nutrients thereby further inhibiting its 
growth [Crouch et al., 1994; Wu et al., 2003]. SP-D also enhances neutrophil uptake 
of bacteria including E. coli, Strep. pneumoniae and Staph. aureus [LeVine and 
Whitsett, 2001].  
 
In vivo Imaging 
 
Approaches to investigating diseases and cellular processes used to be limited to 
broad spectrum techniques such as ex vivo methods & assays, imaging procedures 
including magnetic resonance imaging (MRI) and computerised tomography (CT) 
scans and monitoring phenotypical changes of cell cultures and animal models 
[Dorthager et al., 2009]. However, animal studies are often destructive requiring 
defined end point analysis involving host sacrifice and enumeration of infected organs 
[Dorthager et al., 2009]. Such approaches only provide information for specific, pre-
designed criteria and as the animal has been destroyed, a sequence showing 
unforeseen disease effects and possible immune reactions generally cannot be 
constructed [Pribaz et al., 2011]. Therefore, when in vivo imaging technologies, such 
as fluorescent proteins, were developed their value quickly became apparent. The 
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ability to image cell and disease processes vastly improved and is now a promising 
and powerful method of detection [Leevy et al., 2008]. 
Near-Infrared Fluorescent Protein (NirFP)  
Currently available fluorescent proteins include a red-GFP like fluorescent protein, 
[Matz et al., 1999] which has been derived from a GFP isolated from Aequorea victoria 
[Tsien, 1998]. Included in this near-infrared fluorescent protein group are mCherry, 
Katushka, mKate, Katushka-9-5 and one of the variants recently developed from 
Katushka-9-5; eqFP670 [Shcherbo et al., 2007; Shcherbo et al., 2010; Shu et al., 
1999].  
The eqFP670 variant has since been developed by Evrogen, renamed NirFP, and is 
available on a mammalian expression vector [Evrogen, 2012]. eqFP670/ NirFP has 
been proposed to be the first GFP-like fluorescent protein which has such a long 
wavelength emission, half of which is in the infrared range of the spectrum [Shcherbo 
et al., 2010]. 
NIR light can penetrate through two or more centimetres of most tissues; this is the 
area of the spectrum in which light scattering and absorbance by lipids, water and 
biological molecules is minimal [Shu et al., 2009]. The autofluorescence issues of 
biological molecules such as haemoglobin does not affect NIR imaging, as the NIR 
region has the lowest absorption coefficient for these molecules [Weissleder and 
Ntziachristos, 2003]. 
The properties of NirFP include an excitation peak of 605nm with an emission peak 
of 670nm leading to a strong bathochromic shift [Shcherbo et al., 2010]. The 
extremely high photostability and high pH stability of the protein may be the 
consequence of two specific amino acid mutations (Asn148 and Asn165). These two 
mutations are thought to result in tight packaging of the chromophore [Shcherbo et 
al., 2010]; and consequently the proteins do not show the wavelength fluorescence of 
alternative chromophore forms [Evrogen, 2012].  
Comparing the NirFP to its original form, Katushka, there is a fourfold increase in 
infrared brightness, and no observed cell toxicity or protein aggregation when utilized 
for imaging purposes, especially in animal models [Evrogen, 2012]. The NirFP 
fluorescence signal is easy to differentiate from background fluorescence (which 
should be minimal) and studies have shown that it can be detected for up to 48 hours 
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after transfection into mammalian cells [Evrogen, 2012]. The use of this protein, as 
the detector molecule in a fusion protein, would thus be advantageous.  
 
Protein Expression Systems 
 
Pichia pastoris Expression System 
In order to utilise the fusion proteins they must first be overexpressed and purified. 
The expression system which has been selected for use is the yeast P. pastoris.  This 
was first developed in the 1970s as a means to produce high protein animal feed 
[Cereghino and Cregg, 1999]. However, this was not a viable option economically so 
the yeast’s process of expression was developed as a system for heterogeneous 
protein production [Celik and Celik, 2011; Wegner, 1990]. Since that time P. pastoris 
has become an important host organism and is a well-accepted and standard tool for 
the production of proteins from many species [Cereghino et al., 1999; Cregg et al., 
2000]. In the present study P. pastoris is the ideal choice for protein expression 
because of the following key factors: 
The fusion protein produced is a bacterial binding protein. Thus, there is a strong 
possibility that a bacterial expression system would not be able to produce the protein 
without inflicting toxicity on itself.  
P. pastoris plasmids contain a bacterial origin of replication for maintenance and 
propagation in E. coli. This is vital for ease of cloning and for the extraction of DNA 
for sequencing purposes. However, no bacterial promoter or Shine-Dalgarno 
sequence is present upstream of the gene encoding the fusion protein, essentially 
excluding protein transcription and translation in E. coli [Invitrogen, 2010c].  
The P. pastoris expression system is capable of performing functions such as 
eukaryotic protein processing, protein folding and disulphide-bond formation [Celik 
and Calik, 2011; Cereghino and Cregg, 2000]. Many polypeptides which require post-
translational modifications are expressed as functional active proteins in the P. 
pastoris system. In bacterial expression systems, such proteins may not be correctly 
formed or contain the glycosylation necessary to make them functional [Cereghino 
and Cregg, 1999].  
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P. pastoris is a methylotrophic yeast capable of metabolising methanol as its sole 
carbon source, though it is also capable of growing on glucose, glycerol or a 
combination of the aforementioned. This metabolic process involves the oxidation of 
methanol to formaldehyde, using molecular oxygen, by the enzyme alcohol oxidase 
(encoded by genes AOX1 and AOX2). As this reaction generates formaldehyde and 
hydrogen peroxide it is carried out within a peroxisome, sequestering the toxic by-
products away from the rest of the cell. The main promoter for expression within P. 
pastoris is the AOX1 gene, therefore induction only occurs within the cells in the 
presence of methanol [Cereghino and Cregg, 1999; Invitrogen 2010b; Weider et al., 
2010]. Of the eukaryotic promoters used in expression systems, the AOX1 promoter 
is regarded as especially strong and tightly regulated [Celik and Calik, 2011; Ellis et 
al., 1987]. 
A second control mechanism regulating AOX1 transcription is a repression/ 
derepression system concerning growth on glucose and glycerol. Growth on glucose 
represses transcription even in the presence of methanol. Only when the yeast is 
grown on glycerol (and methanol) will there be optimal induction of the AOX1 promoter 
and the best possible expression levels of the fusion protein [Cereghino and Cregg, 
2000; Cereghino et al., 2002].   
P. pastoris can express high levels of both extracellular and intracellular proteins 
[Celik and Calik, 2000]. For the purposes of this project a vector (pPICZαB) was 
selected that contains a α-factor signal sequence (derived from Saccharomyces 
cerevisiae), which triggers extracellular secretion. Thus the fusion protein should be 
expressed into the surrounding medium [Cereghino and Cregg, 2000]. As P. pastoris 
has very few native proteins which are secreted via the extracellular route [Celik and 
Calik, 2011], the majority of protein found in the medium should be the fusion protein. 
This can be considered as a first step in the purification process. Figure 5.4 shows 
these and other features of the plasmid [Invitrogen, 2010c].  
The expression vector will be integrated into P. pastoris genome at the AOX1 locus 
upon transformation and only those transformants which have incorporated the 




Figure 5.4:  pPICZα Vector Map [Invitrogen, 2010c]. Features of the vector include the α-
factor signal sequence which triggers secretion into the surrounding medium. Zeocin 
resistance with promoters for use in P. pastoris (TEF1) and E. coli (EM7), bacterial origin of 
replication (pUC ori), AOX1 promoter which tightly regulates protein expression via methanol 
induction, native transcription termination and polyadenylation signal (AOX1 TT) from AOX1 
gene that permits efficient 3’ mRNA processing and multiple cloning site. The vector is 
produced in three different reading frames (A, B, and C).  
 
Bacterial Expression Systems 
A common bacterial expression system that is widely used is based around the pBAD 
vector. This vector, when transformed into E. coli and induced with arabinose, 
generally gives reliable and consistent protein production [Guzman et al., 1995]. 
The pBAD/His vector (Figure 5.5) used for this study includes a polyhistidine tag which 
will fuse to the inserted protein, for easier detection and purification. The vector also 
includes a multiple cloning site, ampicillin resistance gene, araBAD promoter (AraC) 
and three different reading frames (A. B and C) [Invitrogen 2010a]. 
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The induction of proteins is triggered in the presence of arabinose. Varying the 
concentration of this sugar will produce tight dose-dependent gene expression 
[Miyada et al., 1984]. An advantage of the tight regulation by the AraC protein is 
allowing bacterial growth to an optimal density before protein production by not 
inducing the gene. This would prove beneficial in expression experiments producing 




Figure 5.5: pBAD/His Vector Map [Invitrogen, 2010a]. Features of the vector include a 
polyhistidine tag (6x His), arabinose induced promoter (pBAD) for tight, dose dependent 
protein expression, ampicillin resistance for selection and maintenance, and multiple cloning 





Aims of this Chapter 
 
 To construct a CPGRP-NirFP fusion hybrid gene encoding a fusion protein. 
 To insert the bacterial binding gene encoding CPGRP-NirFP into the P. 
pastoris chromosome for extracellular secretable expression. 
 To express and purify secreted CPGRP-NirFP from P. pastoris. 
 To investigate CPGRP-NirFP binding specificity and characteristics. 
 To construct two plasmids containing the genes encoding CPGRP and a 
second bacterial binding protein SP-D for expression in E. coli. 
 To express and purify CPGRP and SP-D from E. coli. 























CPGRP Gene Synthesis for Insertion into Pichia pastoris 
This was a two stage process which involved inserting the gene encoding CPGRP 
into a P. pastoris plasmid and then constructing a hybrid between this and the gene 
encoding the NirFP. 
As the first stage, the bacterial binding gene was synthesised by GeneArt (Invitrogen). 
CPGRP was codon optimised for P. pastoris and cloned into pPICZαB to give the 
following arrangement: 
 
EcoR1 – [His8 – Kpn1 – Xho1 – SacII – Not1 – CPGRP] – Xba1 
 
Codon optimisation is necessary to ensure good translation rates and accuracy for 
ideal protein expression. The signal sequence which allows for secretable protein 
production is already present within the pPICZαB plasmid. The Kozak sequence is 
located before the α-factor signal sequence.  
This plasmid does not contain a yeast origin of replication thus transformants can only 
be isolated if recombination occurs between the plasmid and the P. pastoris 
chromosome. 
The plasmid was digested with SacII to verify the plasmid size of 4172bp by gel 
electrophoresis (Figure 5.6). DNA Sequencing was also carried out to validate the 







Figure 5.6: Verification of pCPGRP size. Samples of plasmid CPGRP digested with SacII 
separated by agarose gel (0.8 w/v) electrophoresis in TAE buffer at 90 V for approximately 1 
hour. Lanes (from LHS) are: 1 kb DNA ladder and pCGPRP. The linearised 4172 bp band is 
indicated (dashed line with arrowhead). 
 
Construction of a Sequence Encoding a His8-CPGRP-NirFP Fusion Protein 
In order to discover and image bacterial infections the bacterial binding protein has to 
be detectable. The best way in which this can be done is through the use of a 
fluorescent protein. A Near Infrared Fluorescent Protein (NirFP) was selected 
because of its long wavelength emission range, high photostability and high pH 
stability. After extraction from its parent plasmid the NirFP gene sequence was 
inserted into the pCPGRP plasmid to create pCPGRP-NirFP which when inserted into 
P. pastoris KM71wt and expressed should yield a fluorescently tagged bacterial 





Figure 5.7: Order of Experiments from pCPGRP Gene Synthesis to Protein Expression.
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PCR, with primers J and K, (Table 2.3) was used to amplify the NirFP gene sequence 
from its parent plasmid and incorporate KpnI and SacII sites onto the 5’ and 3’ ends 
respectively. Colony PCR, using primers J and K (see Table 2.3) was used to screen 
for transformants (Figure 5.8). Once possible pCPGRP-NirFP clones had been 
identified, they were grown overnight and DNA was extracted via Qiagen Miniprep 





Figure 5.8: Results of Colony PCR of pCPGRP-NirFP transformants. Samples of possible 
NirFP clones from patch plates were separated by agarose gel (0.8 w/v) electrophoresis in 
TAE buffer at 120 V for approximately 1½ hours. Lanes 1 to 16 (from LHS) are as follows. 
Lanes 1 and 16: 100 bp Ladder. Lane 2 contains a NirFP positive control (PCR template was 
parent plasmid) Lanes 4, 7, 10, 12 and 13 (as indicated by the boxes) contain the correct NirFP 












Figure 5.9:  Results of PCR of Possible pCPGRP-NirFP Clones with Different Primer 
Combinations. Possible pCPGRP-NirFP clone DNA was extracted with Qiagan miniprep kits 
used according to the manufacturer’s instructions. PCR was carried out with different primer 
combinations and was then separated by agarose gel (0.8 w/v) electrophoresis in TAE at 90V 
for approximately 1 hour. Lanes 1 to 4 (from LHS) are as follows. Lane 1: 1 kb Ladder. Lane 
2: NirFP Forward (primer J) and CPGRP Reverse (primer H). Lane 3: NirFP Forward (Primer 
J) and CPGRP sequence middle reverse (primer G). Lane 4: NirFP Forward (Primer J) and 
NirFP Reverse (Primer K). 
PCR was carried out with various primer combinations, the different sized bands 
which can be seen in Figure 5.9 show that both the CPGRP and NirFP gene 
sequences are present within the plasmid. The largest band size (lane 2) is the 
complete fusion protein gene sequence (1420 bp) and the smallest (lane 4) is the 
NirFP gene sequence (788 bp). Sequencing was used to confirm the presence of 
these gene sequences (data not shown). Figure 5.10 shows the final vector construct. 





Figure 5.10: Final Vector Construct of pCPGRP-NirFP. Vector features which should be 
noted are α-factor secretion signal, AOX1 which permits methanol inducible, high level gene 
expression and the His8 tag which allows easier protein purification. Zeocin is used for 
selection and maintenance in E. coli (25 μg/ml in low salt LB) and selection in P. pastorius 
(100 μg/ml in YPD).  
 
Once the correct construct had been confirmed it was transformed into P. pastoris, as 
was pCPGRP (Figure 5.7). Once P. pastoris transformants were obtained, DNA was 
extracted using the Promega Wizard Genomic DNA Purification Kit from overnight 




TTC GAA ACG ATG AGA TTT CCT TCA ATT TTT ACT GCT GTT TTA TTC GCA GCA TCC TCC 
-F – E – T – M – R – F – P – S – I - F – T – A – V – L – F – A – A – S - S 
GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA CAA ATT CCG GCT 
-A – L – A – A – P – V – N – T – T – T - E – D – E – T – A – Q – I – P - A 
GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA GGG GAT TTC GAT GTT GCT GTT TTG CCA 
-E - A – V – I – G – Y – S – D – L – E – G – D – F – D – V – A – V – L - P 
TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT GCC AGC ATT 
-F – S – N – S – T – N – N – G – L – L – F – I – N – T – T – I – A – S - I 
GCT GCT AAA GAA GAA GGG GTA TCT CTC GAG AAA AGA GAG GCT GAA GCT GCA GGA ATT 
-A – A – K - E – E – G – V – S – L – E – K – R – E - A – E – A – A - G – I 
CAA CAT CAC CAT CAC CAC CAT CAT CAT GGT ACC ATG GGA GAG GAT AGC GAG CTG ATC 
–Q – H – H – H – H – H – H – H – H – G – T – M – G – E – D – S – E - L – I 
TCC GAG AAC ATG CAC ACG AAA CTG TAC ATG GAG GGC ACC GTG AAC GGC CAC CAC TTC 
– S – E – N – M – H – T - K - L – Y – M – E – G – T – V – N – G - H-H – F 
AAG TGC ACA TCC GAG GGC GAA GGC AAG CCC TAC GAG GGC ACC CAG ACC TGT AAG ATC 
–K - C – T – S – E – G – E – G – K – P – Y – E – G – T – Q – T – C - K – I 
AAG GTG GTC GAG GGC GGC CCT CTC CCC TTC GCC TTC GAC ATC CTG GCT ACC AGC TTC 
–K – V – V – E – G – G – P – L – P – F - A  - F –D – I – L – A - T - S – F 
ATG TAC GGC AGC AAA ACC TTT ATC AAC CAC ACC CAG GGC ATC CCC GAC TTC TTT AAG 
–M – Y – G – S – K – T – F – I – N – H – T – Q – G – I – P – D – F - F – K 
CAG TCC TTC CCT GAG GGC TTC ACA TGG GAG AGG ATC ACC ACA TAC GAA GAC GGG GGC 
–Q – S – F – P – E – G – F – T – W – E – R – I – T – T – Y – E – D - G – G 
GTG CTG ACC GCT ACC CAG GAC ACC AGC CTC CAG AAC GGC TGC CTC ATC TAC AAC GTC 
–V – L – T – A – T – Q – D – T – S – L – Q – N – G – C – L – I – Y -N – V 
AAG ATC AAC GGG GTG AAC TTC CCA TCC AAC GGC CCT GTG ATG CAG AAG AAA ACA CTC 
–K – I – N – G – V – N – F – P – S – N – G – P – V – M – Q – K – K - T – L 
GGC TGG GAG GCC AAC ACC GAG ATG CTG TAC CCC GCT GAC AGC GGT CTG AGA GGC CAT 
–G – W – E – A – N – T – E – M – L - Y – P – A – D – S – G – L – R - G – H 
AAT CAG ATG GCC CTG AAG CTC GTG GGC GGG GGC TAC CTG CAC TGC TCC CTC AAG ACC 
–N – Q – M – A – L – K – L – V - G – G – G – Y – L – H – C – S – L - K – T 
ACA TAC AGA TCC AAG AAA CCC GCT AAG AAC CTC AAG ATG CCC GGC TTC TAC TTC GTG 
–T – Y – R – S – K – K – P – A – K – N – L – K – M – P – G – F – Y - F – V 
GAC CGT AAA CTG GAA AGA ATC AAG GAG GCC GAC AAA GAG ACC TAC GTC GAG CAG CAC 
–D – R – K – L – E – R – I – K – E – A – D – K – E – T – Y – V – E - Q – H 
GAG ATG GCT GTG GCC AGG TAC TGC GAC CTG CCT AGC AAA CTG GGG CAC AGC GGC CGC 
–E – M – A – V – A – R – Y - C – D – L – P – S – K – L – G – H – S - G – R 
GGC GGC CGC ATG ACT AGA CAT TGT GTT TTG TTG GTT TGG GCT TTG TTG GCT TTG TTG 
–G – G – R – M – T – R – H – C – V – L – L – V – W – A – L – L – A - L – L 
TCC TTG GGT GCT GCT AGA GAA GAT CCA CCA GCT TGT GGT TCT ATC GTT CCT AGA AGA 
–S – L – G – A – A – R – E – D – P – P – A - C – G – S – I – V – P - R – R 
GAG TGG AGA GCT TTG GCT TCT GAG TGT AGA GAG AGA TTG ACT AGA CCA GTT AGA TAC 
–E – W – R – A – L – A – S – E – C – R – E – R – L – T – R – P – V - R – Y 
GTT GTT GTT TCC CAC ACT GCT GGT TCC CAC TGT GAT ACT CCA GCT TCA TGT GCT CAA 
–V – V – V – S – H – T – A – G – S – H – C – D – T – P – A – S – C – A – Q 
CAG GCT CAA AAC GTT CAG TCC TAC CAC GTT AGA AAC TTG GGT TGG TGT GAC GTT GGT 
–Q – A – Q – N – V – Q – S – Y – H – V – R – N – L – G - W – C – D - V – G 
TAC AAC TTC TTG ATT GGT GAG GAC GGT TTG GTT TAC GAG GGT AGA GGT TGG AAC ATT 
–Y – N – F – L – I - G – E – D – G – L – V – Y – E – G – R – G – W - N – I 
AAG GGT GCT CAT GCT GGT CCA ACT TGG AAC CCA ATT TCC ATC GGT ATT TCT TTC ATG 
–K – G – A – H – A – G – P – T – W – N – P – I – S – I – G – I – S - F – M 
GGT AAC TAC ATG AAC AGA GTT CCA CCA CCA AGA GCT TTG AGA GCT GCT CAG AAC TTG 
–G – N – Y – M – N – R – V – P – P - P - R – A – L – R – A – A - Q - N – L 
TTG GCT TGT GGT GTT GCT TTG GGT GCT TTG AGA TCC AAC TAC GAG GTT AAG GGT CAC 
–L – A – C – G – V – A – L – G – A – L – R – S – N – Y – E – V – K - G – H 
AGA GAT GTT CAG CCA ACT TTG TCT CCA GGT GAC AGA TTG TAC GAG ATC ATC CAA ACT 
–R – D – V – Q – P – T – L – S – P – G – D – R – L – Y – E – I – I - Q – T 
     TGG TCC CAC TAC AGA GCT TAA TCT AGA 
     –W – S – H – Y – R – A -STOP 
 
Figure 5.11: Gene Sequence of CPGRP-NirFP. CPGRP was inserted into pPICZαB using 
EcoRI and XbaI (indicated in yellow). KpnI and SacII (indicated in pink) were used to clone 
the NirFP gene into pCPGRP. The region encoding the poly-His tag is shown in blue. The start 
and stop codons are indicated in green. The purple text represents the α-factor secretion 
signal, the grey highlighted region directly before is the Kozak sequence. The corresponding 




Expression and Detection of CPGRP-NirFP Fusion Protein in Pichia pastoris 
The first Pichia pastoris expression protocol used consisted of inoculating 25 ml 
BMGY (See Chapter 2) with a single colony and growing at 30°C until OD600 was 
between 2 and 6. Once the correct OD has been achieved the cells were harvested 
by spinning at 1500 xg for 5 minutes and then re-suspended in 100ml BMMY (see 
Chapter 2) medium to induce expression. 100% methanol was added to a final 
concentration of 0.5% (v/v) every 24 hours to maintain expression. A more detailed 
protocol can be found in the manual [Invitrogen, 2010c]. 
Samples were taken at 0, 6, 12, 24, 36, 48, 60, 72, 84, and 96 hours, spun down 
(14000 rpm, 2 minutes) to separate the supernatant and pellet and frozen at -80°C 
until required.  Three strains, (KM71, and the two cultures containing the CPGRP and 
CPGRP-NirFP genes) were set up to run concurrently. KM71 is the wild type strain 
which was included as a negative control. CPGRP was included to investigate 
whether the inclusion of the NirFP would affect the expression and characteristics of 
the binding protein.   
The growth, expression and sample times of the cultures were altered to attempt to 
produce and detect the bacterial binding proteins. Expression was induced between 
a wide range of culture density (OD600 0.5 to 6), and the cultures were sampled more 
regularly (every hour for the first 12, then every 6 hours for 96). Both the cell pellet 
(after lysis) and the supernatant were tested for the bacterial binding protein though 
the nature of expression should have been extracellular (data not shown). 
When this did not work the method of the Barlow Lab (who supplied the original strains 
and plasmids) was adopted. This involved taking a single colony, inoculating 5ml 
BMGY, and growing the culture at 30°C, 150 rpm for 24 hrs. 95 ml BMGY was added 
and the culture was grown for a further 60 hours. The cells were harvested by spinning 
at 1500xg for 5 minutes and resuspended in 25 ml BMMY. The culture was incubated 
at a reduced temperature of 18°C for 5 days. 125 ml methanol was added once on 
the second and third days, then twice on the fourth day (in the morning and evening). 
The culture was harvested on the fifth day by spinning down at 1500xg for 5 minutes, 
both the supernatant and pellets were stored separately at -80°C until required.  
A positive control G1107C, supplied by the Barlow lab, was incorporated into the 
experiment. When testing for the binding protein through SDS-PAGE gels there was 
no detectable protein. Cell pellets and supernatants were boiled for 10 minutes and 
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visualised by SDS-PAGE gels as described in Chapter 2. In other experiments 125 
ml sorbitol was added to the culture alongside the methanol. This approach also did 
not prove to be successful (Figure 5.12).  
Figure 5.12: SDS-PAGE Gel showing Pichia pastoris Expression of Proteins in both Cell 
Pellets and Supernatants. Expression was carried out according to the Barlow method. After 
lysis the cell pellet and supernatant were run on SDS-PAGE gels. Lanes 1-4 contain G1107C, 
KM71 (wt), CPGRP and CPGRP-NirFP whole cell pellets. Lanes 5 and 10 contain the 
prestained broad range protein marker (7-175kDa) and lanes 6-9 contain G1107C, KM71 (wt), 
CPGRP and CPGRP-NirFP supernatant samples. The arrow indicates the positive control 
band from G1107C supernatant. 
 
In further approaches, similar samples of 50ml supernatant were concentrated 
through Centricon Centrifugal Filter Devices Plus-70 (10K) to test if the protein was 
produced at a low level. The Barlow protocol was used twice and the harvested 
supernatant was combined to give the required amount for the filter devices. The 50 
ml supernatant was concentrated down to 400 μl though the filters in a swinging 
bucket centrifuge at 3500xg for 30 minutes. However, still no secreted protein was 
detected (data not shown). 
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As an additional tactic, the expression supernatant was purified on Ni-NTA Magnetic 
Agarose Beads using the poly-His tag on the plasmid. This process did not return any 
results (Figure 5.13). 
After harvesting the expression supernatant on the fifth day, 5ml was incubated at 
4°C with 50 μl bead resin for 4 hours with rotation. A magnetic rack was used to bind 
the beads allowing the supernatant to be removed. The beads were resuspended and 
washed in buffers (See Chapter 2) containing NaCl which reduces non-specific 
binding, as well as Tween and β-mercaptoethanol which prevents the beads and 
proteins sticking. 50 μl of elution buffer containing high levels of imidazole was used 




Figure 5.13: Pichia pastoris CPGRP and CPGRP-NirFP Supernatant Purified on Ni-NTA 
Magnetic Beads. CPGRP and CPGRP-NirFP expression was carried out according to the 
Barlow method, and purified on Ni-NTA beads before been run on a SDS-PAGE gel. Lane 1: 






Inclusion into the Study of a Second Bacterial Binding Protein: Surfactant 
Protein D 
With no detectable expression of either CPGRP or CPGRP-NirFP using the P.  
pastoris system the decision was taken to explore whether the CPGRP protein could 
be produced using a bacterial expression system.  
The gene encoding a bacterial binding second protein, SP-D, was also synthesised 
for expression, to provide a comparison with CPGRP. SP-D was selected for use as 
there is a lot of available knowledge surrounding SP-D and its structure and function. 
The shape and orientation of the molecule is known, the amino acid sequence is 
available and it has been expressed previously by another group [Crouch et al., 2005; 
Crouch et al., 2006; Crouch et al., 2009].  
pBAD/His A [Invitrogen, 2010a] was used for the vector in both cases. This is an 
arabinose inducible vector with a built in His-tag (indicated in blue in Figure 5.14A and 
B). SacI and EcoRI (Figure 5.14A and B, yellow) were used to insert the gene 
sequences into the vector. A ribosome binding site (highlighted in grey in Figure 5.14A 
and B) is present in the vector. Both CPGRP and SP-D were codon optimised for 
expression in E.coli and synthesised by GeneArt (Invitrogen) The NirFP was not 
included in these experiments. After transformation into E. coli the genes were 















CAG GAG GAA TTA ACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC 
-Q – E – E – L – T - M – G – G – S - H – H – H – H – H – H – G – M – A – S 
ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CGA 
-M – T – G – G – Q - Q – M – G – R – D – L – Y – D – D – D – D – K – D – R 
TGG GGA TCC GAG CTC ATG ACC CGG CAC TGC GTG CTT CTC GTC TGG GCT CTC CTC GCC 
–W – G – S – E – L - M – T – R – H – C – V – L – L – V – W – A – L – L – A 
CTC CTC AGC CTC GGA GCG GCT CGA GAA GAC CCG CCG GCC TGC GGC TCC ATC GTG CCC 
–L – L – S – L – G - A – A - R – E – D – P – P – A – C – G – S – I – V – P 
CGC CGA GAG TGG AGG GCC CTG GCG TCC GAG TGC AGA GAA AGG CTA ACA CGG CCG GTG 
–R – R – E – W - R - A – L – A – S – E – C – R – E - R – L – T – R – P – V 
CGC TAC GTG GTG GTG TCG CAC ACT GCG GGC AGC CAC TGC GAC ACC CCG GCT TCG TGC 
–R – Y – V – V – V - S – H – T – A – G – S – H – C – D - T – P – A – S – C 
GCG CAG CAG GCC CAG AAC GTG CAA AGC TAC CAT GTG CGG AAC CTG GGC TGG TGC GAC 
–A – Q – Q – A – Q - N - V – Q – S – Y – H – V – R – N – L - G  - W – C – D 
GTG GGC TAC AAC TTC CTG ATC GGA GAA GAT GGG CTC GTG TAC GAA GGC CGA GGC TGG 
–V – G – Y – N – F - L - I – G – E – D – G – L – V – Y – E – G - R – G – W 
AAC ATC AAG GGC GCC CAC GCA GGT CCC ACC TGG AAC CCC ATA TCC ATA GGC ATC TCC 
–N – I – K – G – A - H – A - G – P – T – W – N – P – I – S – I – G - I – S 
TTC ATG GGC AAC TAT ATG AAT CGA GTG CCC CCG CCC CGC GCC CTC CGG GCA GCC CAG 
–F – M – G – N – Y - M – N – R - V – P – P – P – R – A – L – R – A – A - Q 
AAT CTG CTG GCT TGT GGT GTG GCT CTG GGA GCC CTG AGA TCC AAC TAC GAG GTC AAA 
–N – L – L – A – C - G – V – A – L - G – A – L – R – S – N – Y – E – V – K 
GGA CAC CGG GAT GTG CAG CCG ACC CTC TCT CCA GGT GAC CGG CTC TAC GAA ATC ATC 
–G – H – R – D – V - Q – P – T – L – S - P – G – D – R - L – Y – E – I – I 
     CAG ACT TGG TCA CAC TAC CGC GCA TGA GAATTC 
     –Q – T – W – S – H - Y – R - A –STOP 
 
Figure 5.14a: CPGRP Gene Sequence Optimised for Expression in Escherichia coli. The 
codon optimised gene encoding CPGRP was synthesised by GeneArt (Invitrogen) and then 
sequenced. The poly-His tag, is shown in blue. The restriction sites, SacI and EcoRI, used for 
insertion are indicated in yellow. The start and stop codons are indicated in green. The grey 
highlighted region represents the ribosome binding site. The corresponding protein sequence 




























CAG GAG GAA TTA ACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC 
-Q – E – E – L – T - M – G – G – S – H – H – H – H – H - H – G – M – A – S 
ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CGA 
-M – T – G – G – Q - Q – M – G – R – D – L – Y – D – D – D – D – K – D – R 
TGG GGA TCC GAG CTC ATG CTG CTG TTT CTG CTG AGC GCA CTG GTT CTG CTG ACC CAG 
–W – G – S – E – L - M – L – L – F – L – L – S – A – L – V – L – L – T – Q 
CCG CTG GGC TAT CTG GAA GCA GAA ATG AAA ACC TAT AGC CAT CGT ACC ATG CCG AGC 
–P – L – G – Y – L - E – A – E – M – K – T – Y – S – H – R – T – M – P – S 
GCA TGT ACC CTG GTT ATG TGT AGC AGC GTT GAA AGC GGT CTG CCT GGT CGT GAT GGC 
–A – C – T – L - V - M – C – S - S – V – E – S – G – L – P – G – R – D – G 
CGT GAT GGT CGC GAA GGT CCG CGT GGT GAA AAA GGT GAT CCG GGT CTG CCA GGT GCA 
-R – D – G – R – E - G – P – R – G - E – K – G – D – P – G – L – P – G – A 
GCA GGT CAG GCA GGT ATG CCT GGA CAG GCA GGT CCG GTT GGT CCG AAA GGT GAT AAT 
–A – G – Q – A - G - M – P – G – Q – A - G – P – V – G – P – K – G – D – N 
GGT AGC GTT GGT GAA CCG GGT CCT AAA GGC GAT ACC GGT CCG AGC GGT CCT CCG GGT 
-G – S – V – G – E - P – G – P – K – G – D - T – G – P – S – G – P – P – G 
CCT CCT GGT GTT CCT GGT CCG GCA GGT CGT GAA GGA CCG CTG GGT AAA CAG GGT AAT 
–P – P – G – V – P - G – P – A – G – R – E – G - P – L – G – K – Q – G – N 
ATT GGT CCG CAG GGT AAA CCG GGA CCA AAA GGT GAA GCC GGA CCG AAA GGC GAA GTG 
–I – G – P – Q – G - K – P – G – P – K – G – E – A – G – P – K – G – E – V 
GGT GCA CCG GGT ATG CAG GGT AGT GCC GGT GCA CGT GGT CTG GCA GGC CCT AAA GGT 
–G – A – P – G - M - Q – G – S – A – G – A – R – G – L - A - G – P – K – G 
GAA CGT GGC GTT CCG GGT GAA CGC GGT GTT CCA GGT AAT ACC GGT GCA GCC GGT TCA 
–E – R – G – V – P - G – E – R – G – V – P – G – N – T – G - A - A – G – S 
GCG GGT GCA ATG GGT CCT CAG GGC TCA CCG GGT GCT CGT GGT CCG CCT GGT CTG AAA 
–A – G – A – M – G - P - Q - G – S – P – G – A – R – G – P – P - G - L – K 
GGC GAC AAA GGT ATT CCT GGT GAT AAA GGC GCA AAA GGC GAA TCA GGT CTG CCG GAT 
–G – D – K – G – I - P – G - D – K – G – A – K – G – E – S – G – L – P – D 
GTT GCA AGC CTG CGT CAG CAG GTT GAA GCA CTG CAG GGT CAG GTT CAG CAT CTG CAG 
–V – A – S – L - R - Q – Q – V – E – A – L – Q – G – Q – V – Q – H – L – Q 
GCA GCA TTT AGC CAG TAC AAA AAA GTT GAA CTG TTT CCG AAT GGT CAG AGC GTT GGC 
–A – A – F – S – Q - Y – K – K – V - E – L – F – P – N – G – Q – S – V – G 
GAA AAA ATC TTT AAA ACC GCA GGT TTT GTG AAA CCG TTT ACC GAA GCA CAG CTG CTG 
–E – K – I – F – K - T – A – G – F – V - K – P – F – T – E – A – Q – L – L 
TGT ACC CAG GCA GGC GGT CAG CTG GCA AGT CCG CGT AGC GCA GCA GAA AAT GCA GCC 
–C – T – Q – A – G - G – Q – L – A – S – P - R – S – A – A – E – N – A – A 
CTG CAG CAG CTG GTT GTT GCA AAA AAT GAA GCA GCA TTT CTG AGC ATG ACC GAT AGC 
–L – Q – Q – L – V - V – A – K – N – E – A – A - F – L – S – M – T – D – S 
AAA ACC GAA GGC AAA TTT ACC TAT CCG ACC GGT GAA AGC CTG GTT TAT AGC AAT TGG 
–K – T – E – G – K - F – T – Y – P – T – G – E – S – L – V – Y – S – N – W 
GCA CCA GGT GAA CCG AAT GAT GAT GGT GGT AGC GAA GAT TGT GTT GAA ATC TTT ACC 
-A – P – G – E - P - N – D – D – G – G – S – E – D – C - V - E – I – F – T 
AAT GGC AAA TGG AAT GAT CGT GCA TGC GGT GAA AAA CGT CTG GTT GTT TGT GAA TTC 
-N – G – K – W - N - D – R – A – C – G – E – K - R – L – V – V – C – E – F 
     TAA GAA TTC 
     -STOP 
Figure 5.14b: SP-D Gene Sequence Optimised for Expression in Escherichia coli. The 
codon optimised gene encoding SP-D was synthesised by GeneArt (Invitrogen) and then 
sequenced. The poly-His tag, is shown in blue. The restriction sites used for insertion, SacI 
and EcoRI, are indicated in yellow. The start and stop codons are indicated in green. The grey 
highlighted region represents the ribosome binding site. The corresponding protein sequence 







Protein Expression in Escherichia coli  
Four bacterial strains were used for the expression of the bacterial binding proteins, 
DH5α, Top10, BL21 and Rosetta-gami 2. Genotypes are detailed in Chapter 2. This 
was done to optimise the chances of protein expression. EHPT1, which is a His-
tagged protein was used as a positive control. This is an arabinose induced protein 
which was constructed by a previous Gallagher lab Ph.D. student. 
For expression, a single colony was used to inoculate 5 ml LB supplemented with 50 
μg/ml ampicillin, and grown overnight at 37°C until OD600 was between 1 and 2. 10 ml 
LB-amp was then inoculated with 0.1ml of the overnight culture and grown at 37°C, 
200rpm, until OD600 =0.5. Arabinose was added to the cultures to induce expression. 
Samples were taken at 0 and 4 hours. Samples were centrifuged at top speed in a 
table top centrifuge for 1 minute to remove the supernatant, and the pellets were 
stored at -20°C until required. The bacterial binding proteins were tested for using 
SDS-PAGE gels and Western Blots. Cell pellets and supernatants were boiled for 10 
minutes and visualised by SDS-PAGE gels. Separated proteins were transferred onto 
nitrocellulose membranes for the Western Blot through a semi-wet transfer (BioRad). 
The antibody used was an anti-His-HRP at a 1:500 dilution in blocking solution.  
Initial arabinose concentrations suggested by Invitrogen [2010a] for induction are 
0.2% (v/v), 0.02% (v/v), 0.002% (v/v), 0.0002% (v/v) and 0.00002% (v/v). After 
preliminary experiments arabinose concentrations for induction and sampling times 
were optimised through testing various concentrations and sampling more often 
(Figure 5.15). The final arabinose concentration used was 0.4% with induction at 
OD600 0.3. Experiments revealed that DH5α, BL21 and Top10 did not produce 
detectable protein. Representative examples of SDS-PAGE gels are illustrated 
(Figure 5.15). Samples were also transferred to nitrocellulose membrane and except 
for the positive control the corresponding western blots did not shown any 
fluorescence indicating that the proteins were not produced (data not shown). Thus 
efforts were concentrated on the Rosetta-gami 2 strain (Figure 5.16). 
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Figure 5.15: A) CPGRP Expression in TOP10 with Different Arabinose Concentrations. 
The culture containing pCPGRP in TOP10 was grown to an OD600 of 0.4 (37°C, 200 rpm) 
before being induced at different arabinose concentrations. Samples were taken 4 hours after 
induction and run on a SDS-PAGE gel. Lane 1 contains the protein marker. Lane 2 the 0 hour 
sample (before arabinose addition). Lanes 3-7 are samples induced at 0.0002% (v/v), 
0.0002% (v/v), 0.002% (v/v), 0.02% (v/v) and 0.2% (v/v) arabinose.  
B) CPGRP expression in DH5α. The culture containing pCPGRP in DH5α was grown to an 
OD600 of 0.4 at 37°C, 200 rpm, before being induced to a final concentration of 0.2% (v/v) 
arabinose. Samples were then taken at different time points and run on a SDS-PAGE gel. 
Lane 1 contains the protein marker, lane 2 is empty. Lane 3 is 0hrs (before arabinose addition). 
Lanes 4-8 are samples taken at 1, 2, 3, 4, and 6 hours. The positive control of EHPT1 is shown 




Figure 5.16: SDS-PAGE gel (A) and Western Blot (B) of Expression of CPGRP and SP-D 
from Rosetta-gami 2. The cultures were grown to an OD600 of 0.4 (37°C, 200 rpm) before 
being induced to a final concentration of 0.2% (v/v) arabinose. Samples were taken at specific 
time points and run on a SDS-PAGE gel. The positive control of EHPT1 is shown in lane 1. 
Lane 2 contains the protein marker. Lanes 3-6 contain CPGRP cultures, sampled at 0, 1, 2, 
and 4 hours. Lanes 7-10 contain SP-D samples taken at 0, 1, 2, and 4hrs after induction. For 
the Western Blot (B) the His-tagged positive control is indicated (1) and slight expression of 
SP-D can be seen (2). The proteins were transferred to a nitrocellulose membrane through a 
semi-wet transfer system (Biorad). A peroxidase-conjugated anti-His6 antibody, (1:500 dilution 
in blocking buffer) was used and images were recorded with an Epi Chem II Darkroom under 







Figure 5.17: SDS-PAGE gel (A) and Western blot (B) of SP-D expression in Rosetta-
Gami 2. The culture containing SP-D was grown to an OD600 of 0.3 (37°C, 200 rpm) before 
being induced to a final concentration of 0.4% (v/v) arabinose. Samples were then taken at 
specific time points and run on a SDS-PAGE gel (A) as well as being transferred onto a 
nitrocellulose membrane (B). The His-tagged positive control of EHPT1 is shown in Lane 1. 
Lane 2 contains the protein marker and lane 3 the 0hr sample. Lanes 4-8 are samples taken 
2, 4, 6, 8, 24 hrs after induction. A peroxidase-conjugated anti-His6 antibody, (1:500 dilution) 
was used for the Western Blot and images were recorded with an Epi Chem II Darkroom under 





At no point during the experiments was CPGRP visible or detected. SP-D was 
observed to be expressed by the Rosetta-Gami 2 strain. However, the amount 
produced was extremely low, all the bands were only visible when the display range 
was adjusted after the photograph was captured. Thus the Western Blot (Figure 5.17) 
can be considered to be overexposed in order to detect the bands. It was decided that 




The yeast P. pastoris is well documented for use as a yeast expression system since 
its development in the 1970s [Cereghino and Cregg, 1999]. A wide variety of proteins 
have been expressed including C. difficile neurotoxin [Byrne et al., 1998], human 
interleukin-17 [Eldin et al., 1998], equine lactoferrrin [Paramasivam et al., 2002], large 
T antigen from Polyomoavirus [Peng and Acheson, 1997] and glucoamylase from 
Aspergillus awamori [Fierobe et al., 1997].  
Advantages of using P. pastoris of an expression system include the ability to perform 
eukaryotic protein modifications including proteolytic processing, glycosylation, 
protein folding and disulphide bond formation [Macauley-Patrick et al., 2005]. The 
system is also tightly regulated by the promoter AOX1 which only induces protein 
production in the presence of methanol [Celik and Calik, 2011]. A secondary control 
mechanism also exists regarding growth on glucose and glycerol. Growth on glucose 
represses transcription even in the presence on methanol. Only when the yeast is 
growth in glycerol (and methanol) will there be optimal induction of the AOX1 promoter 
and best possible expression levels of the fusion protein [Cereghino et al., 2002]. 
CPGRP was originally discovered by Kappeler et al., [2004] in camels’ lactating 
mammary glands. Crystallization of the protein by Sharma et al [2008] revealed its 
structure and provided details about its binding properties and characteristics. All 
previous work characterising this protein was carried out after purification from 
camel’s milk [Sharma et al., 2008; Sharma et al., 2011a] and has in fact never been 
artificially synthesised and expressed. 
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P. pastoris is considered a first-rate expression system for production of proteins from 
multiple sources. However, it has been suggested that the feasibility of production 
appears to be target-protein dependent [Liu et al., 2013]. Codon optimization is an 
important step to improve translational fidelity to ensure optimal expression of proteins 
[Hutterer et al., 2012]. This was carried out on CPGRP for this study. Reducing the 
expression temperature has also been shown to improve protein production [Yang et 
al., 2013]. However, this was not successful in this study. 
Even with the use of different expression systems CPGRP was never visibly 
expressed or detected. Possible explanations for this could be the size of the protein, 
the complexity of the molecule, and the fact that it was a multimer. Proteolysis could 
also play a role in degrading or truncating the product [Macauley-Patrick et al., 2005]. 
It was most likely an accumulation of factors which contributed to the non-expression 
of CPGRP.  
When CPGRP was unable to be produced using the yeast expression system, a 
second bacterial binding protein, SP-D, was included in the study to provide a 
comparison to CPGRP. The decision was also made to move both proteins into a 
bacterial expression system. 
E. coli physiology is well documented as this species has long been used in many 
aspects of molecular biology and biotechnology and is considered a reliable 
‘workhorse’ [Berlec and Štrukelj, 2013]. The arabinose inducible expression vector, 
pBAD, is well characterised and considered a reliable regulator of protein production 
with a strong promoter and normally high levels of expression [Guzmann et al., 1995].  
The E. coli expression system is easier to use than the P. pastoris expression system 
and does not require as much incubation and expression time to produce proteins.  
SP-D expression has been described in multiple papers from the same research 
group in both bacterial and mammalian cell expression systems [Crouch et al., 2005; 
Crouch et al., 2006; Hartshorn et al., 19996; Wang et al., 2008]. 
Once again both proteins, CPGRP and SP-D, were codon optimised for use in E. coli 
as certain condons especially for arginine are rare which causes mis-translational 
errors and lower protein expression [Calderone et al., 1996]. However, this did not 
make a difference in the production of CPGRP which was never visibly detected. SP-
D was produced but only at very low levels.  
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Production of high protein yields is vital in order to characterise and utilise a protein. 
The reasons behind the extremely low protein yields of SP-D are multifactorial. High-
level gene expression has been shown to stress cells and adversely influence cellular 
physiology [Berlec and Štrukelj, 2013]. Intracellular and extracellular factors can also 
produce unwanted physiological consequences which may affect protein production 
[Chou, 2007]. Another contributing factor could be that the proteins are bacterial 
binding so they could be damaging the bacterial expression system when they are 
first produced. This may account for the non-detectable and very low levels of protein 
production.  
Ultimately, it was decided that this project was not suitable to pursue and efforts were 




Even though the production of these bacterial binding proteins was not successful, 
the idea behind the project is still sound. The possible use of a bacterial binding and 
fluorescent fusion proteins to detect and image bacterial infections has merit. This is 
especially true for difficult cases in which clinical presentation of infection and 
traditional laboratory tests produce unclear results leading to an unconfirmed 
diagnosis, as is often the case with prosthetic joint infections. However, before this 





























The use of multiple different bacterial species has shown that the alginate bead 
method is valid for use to investigate biofilm development. Formation of biofilms by 
the different species appears similar, with rapid non-specific attachment followed by 
the development of a mature biofilm with significant resistance to different antibiotics. 
One of the main advantages of the alginate bead method over the Calgary Biofilm 
Device is the cost. The reagents and equipment required for the alginate bead method 
are readily available and inexpensive. However, the alginate bead method is more 
labour intensive compared to the Calgary Biofilm Device. Even considering these 
factors, the alginate bead method is a suitable alternative to the Calgary Biofilm 
Device. Moreover, it lends itself to more flexible assay development, for example, 
exploring mixed community interactions and abiotic antimicrobials.   
Stable biofilms formed on the alginate beads within four hours of inoculation, though 
they continued to develop after this time, presumably with planktonic cells still 
attaching and additional replication of the biofilm based cells. This indicates that 
infections in clinical environments need to be identified quickly in order to have an 
effective treatment regimen. As the biofilms became established, antibiotic resistance 
developed. The time this took depended on the specific antibiotic and its mode of 
action as well as the bacterial species forming the biofilm. However, after eight hours 
incubation all species’ biofilms showed significant resistance to antibiotics.  
The antibiotic resistance is likely to be due to multiple reasons. Specific resistance 
mechanisms, such as selection of genetic mutations against the antibiotics probably 
only played a small role in the overall resistance over the timescale examined. 
Resistance may rely on factors including a certain cell density, innate cell 
mechanisms, such as active export and drug sequestering which prevent the 
antibiotic from reaching its target, and most importantly, the biofilm structure and its 
properties. The aspects of a biofilm which provide resistance include heterogeneous 
gene and protein expression, reduced diffusion into the biofilm matrix, EPS, presence 
of persister cells, reduced metabolism and different growth rates [Archer et al., 2011; 
Hogan et al., 2015]. 
Some of the most serious biofilm based HCAIs are prosthetic joint infections. These 
types of infections often require surgical intervention and long term, high dose 
antibiotics. When examining treatment regimens for prosthetic joint infections, 
gentamicin is the most common and is incorporated in the bone cement used in the 
joint replacement surgery [Neut et al., 2005]. Due to increasing resistance a second 
191 
 
antibiotic is often combined with the gentamicin in the bone cement. The presence of 
the antibiotic pre-colonisation is thought to reduce infection rates. However, the 
results gathered in this thesis indicate that gentamicin might not be a suitable 
antibiotic to use in this manner.  
The effect of gentamicin on biofilms, of not just Staph. aureus but also other clinically 
relevant bacteria (both Gram-positive and Gram-negative species) is minimal 
especially with established biofilms. Even a concentration of 1024μg/ml only reduced 
the Staph. aureus biofilm load by 3 log orders. While this is a significant reduction the 
end point of any clinical treatment would be the complete eradication of a biofilm, as 
any remaining cells would be able to reseed the site and reactivate the infection.  
The clinical treatment dosage of gentamicin is recommended at 5mg/kg per day, 
whereas prophylaxis is 3 mg/kg per day for adults. Ideally administrated once a day, 
gentamicin should not be used in cases of myasthenia gravis or in patients with renal 
impairment [NHS, 2010]. Ideally when administered into a patient, antibiotics would 
be present at inhibitory concentrations. However, over time and with inactivation, 
chemical decay and elimination from the host, the concentrations would fall. At this 
stage, the antibiotics may promote the development of antibiotic resistant strains and 
even further biofilm formation. 
Indeed aminoglycosides, especially at subinhibitory concentrations, have been shown 
to stimulate biofilm formation in both Gram-positive species (Staph. aureus) and 
Gram-negative species (Ps. aeruginosa/ E. coli) [Hess et al., 2011; Hoffman et al., 
2005]. This raises the question about whether gentamicin is an appropriate antibiotic 
for use. However, until a replacement antibiotic which has an equal or better activity 
and range, and is heat stable, is developed, the use of gentamicin persists. 
It is usual in a clinical situation, especially with severe infections, to combine different 
classes of antibiotics to enhance their activity range and effects and to prevent to 
emergence of resistant mutants. The effects of different antibiotics on the activity of 







Figure 6.1: Antibiotic Targets within the Bacterial Cell. There are four main target areas 
within the bacterial cell which antibiotics can target. 1) DNA, 2) RNA, 3) Cell wall and 
membrane and 4) Protein synthesis.  
 
As can be seen from Figure 6.1, most of the antibiotics target processes upstream of 
the gentamicin target. While cell wall and membrane inhibition is not directly upstream 
of protein synthesis, if these processes are disrupted the cell dies and there is no 
protein synthesis. The other two antibiotics (clindamycin and linezolid) which target 
protein synthesis do so at different sites (as explained in Chapter 1) and are 
bacteriostatic rather than bactericidal. The only antibiotic to show enhanced inhibitory 
effect was daptomycin, this may be due to the completely different target sites acted 
on in the cell simultaneously by the two antibiotics. 
All the tested combinations delayed the emergence of gentamicin resistance. The 
main reason behind this may be that the target on which the gentamicin acts is 
downstream of the second antibiotic target. Thus, gentamicin activity and possible 
resistance cannot develop until resistance to the second antibiotic has developed 
giving the gentamicin a target.  
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Within a clinical environment, biofilm infections may be caused by multiple species 
from the same host site, acting synergistically [Burmølle et al., 2014].  Staph. aureus 
and Ps. aeruginosa duel infections have been shown to delay wound healing resulting 
in worse patient outcomes [DeLeon et al., 2014; Rosenbluth et al., 2004]. In the 
alginate bead model, a mixed species biofilm consisting of Staph. aureus and Ps. 
aeruginosa developed evenly (Figure 4.6) and conferred substantial protection 
against antibiotics upon the component species. Antibiotic resistance developed 
earlier and lasted longer than the individual biofilms formed by each species (Figures 
4.7-4.9). 
In both single and mixed species biofilms, antibiotic resistance is due to a multitude 
of factors. The discussions of Chapters 3 and 4 detail these aspects and propose that 
the resistance should not be considered permanent as there is no genetic basis for it, 
as when the cells return to a planktonic state the antibiotics are once again effective.  
The antibiotic concentrations required to reduce biofilm loads in both single and mixed 
species biofilms are immense and not practical in a clinical setting due to the difficulty 
in administration and the possible side effects on the patients. Therefore, alternative 
approaches are required to disrupt the biofilms and act in conjunction with 
conventional therapies.  
Many alternative approaches to disrupt biofilms, especially those caused by 
staphylococcal species, have been proposed (Table 1.7) including sugar metabolites, 
bacteriophage therapy, D-amino acids and activation of the quorum sensing system 
[Kiedrowski and Horswill, 2011]. Some of these approaches show more promise than 
others, but a recurring concern with many of the therapies is that they are strain 
specific which would make development of a universal treatment difficult [Pincus et 
al., 2015]. Nevertheless, due to the nature of the treatments acting on a certain target 
or species, there may be diminished side effects compared with antibiotics [Wu et al., 
2003].   
A potential alternative approach that was explored involved the use of D-amino acids 
to prevent stable biofilm formation (Figure 4.11) or to disrupt an established biofilm 
(Figure 4.12). The effects of D-amino acids was first reported in B. subtilis [Kolodkin-
Gal et al., 2010] and then in Staph. aureus [Hochbaum et al., 2011]. Disruptive effects 
were also reported for Ps. aeruginosa and some Staph. epidermidis strains [Kolodkin-
Gal et al., 2010; Ramón-Peréz et al., 2014]. However, it has since been discovered 
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that the original experiments were not reproducible [Leiman et al., 2013; Sankar and 
Pires 2015]. Experimental results from this thesis supported that conclusion (Chapter 
4). Consequently, the use of D-amino acids as an alternative therapy is unlikely.  
The use of sugar metabolites, especially fructose, is worth further investigation though 
the effects published by Allison et al [2011] were not reproduced in this thesis (Figures 
4.13 and 4.14). Other publications have reported that different sugar combinations 
have a detrimental effect on biofilm formations, not just in Staph. aureus but also in 
other species [Bucior et al., 2013, Durmus et al., 2012]. The administration of sugars 
should have minimal or no side effects as they are naturally occurring molecules 
which can be found in the human system. Another advantage connected to this would 
be the lack of any immune response, as could be the case with lysostaphin for 
example, as the sugar metabolites would not be recognised as foreign. Furthermore, 
as the cells do not revert back to a metabolically active (pathogenic) state there is not 
a risk of seeding other sites and systemic infection.  
As the sugar metabolites are not strain specific, immediate treatment could begin 
upon clinical diagnosis. However, they are primarily aminoglycoside specific so could 
not be used for infections caused by certain bacteria. Such species would include 
anaerobes, upon which the gentamicin cannot act as the antibiotic requires oxygen to 
function. The issue of innate, genetic antibiotic resistance would also have to be 
considered and lack of such verified, before treatment could begin.  
As biofilms are such a huge issue within the clinical environment, especially in regards 
to promoting antibiotic resistance and inducing treatment failure, the current therapy 
protocols need to be revisited. Current use of gentamicin, especially in bone cements 
is an excellent example of this, as the antibiotic is not very effectual and no longer fit 
for the purpose. Alternative approaches, including the promising use of sugar 
metabolites, urgently need to be developed and introduced in order to counteract 
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